

THE UNIVERSITY OF BRITISH COLUMBIA

**Curriculum Vitae for Faculty Members**

**Date:** August 10, 2022      **Initials:** VDL

**1. SURNAME:** Lima

**FIRST NAME:** Viviane  
**MIDDLE NAME(S):** Dias

**2. DEPARTMENT/SCHOOL:** Division of Infectious Diseases

**3. FACULTY:** Medicine

**4. PRESENT RANK:** Associate Professor (Partner Track)

**SINCE:** July 1<sup>st</sup>, 2016

**5. POST-SECONDARY EDUCATION**

**(a) Degrees**

University or Institution	Degree	Subject Area	Dates
Escola Nacional de Ciências Estatísticas Rio de Janeiro, Brazil	BSc Honours, with thesis	Statistics	08/1992-06/1996
Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil	MSc, with thesis	Statistics	03/1996 - 07/1997
University of British Columbia Vancouver, British Columbia, Canada	PhD	Epidemiology	09/2000 - 11/2005

**Note 1.** From 08/1997 to 08/1998, I was taking courses in Brazil to prepare for the TOEFL and Graduate Record Examination (GRE) exams. These exams were required for admission into the PhD program at the University of British Columbia.

**Note 2.** From 09/1998 to 05/2000, I was admitted into the PhD program in the Statistics Department at the University of British Columbia. I did not complete this program because I decided to change my degree to the Department of Health Care and Epidemiology (now the School of Population and Public Health).

**(b) Title of Dissertation and Name of Supervisor**

- PhD: Small-Area Disability-Adjusted Life Years: A New Approach to the Spatio-Temporal Analysis of Public Health Surveillance Data. Supervisors Drs. Stephen Marion and Ying MacNab. Received highest grade.
- MSc: Obtenção das Constantes Reguladoras de Várias Classes de CM-Estimadores • English: Obtaining Regulatory Constants of Several Classes of Constrained M-Estimators. Supervisors: Dr. Beatriz Vaz de Melo Mendes. Received highest grade.
- BSc: Métodos de Hedge Robusto Aplicados ao Mercado de Ações Brasileiro • English: Robust Hedging to Analyze Brazilian Stock Market Data. Supervisors: Drs. Beatriz Vaz de Melo Mendes and Antonio Marcos Duarte Junior. Received highest grade.

**(c) Continuing Education or Training**

**Training with certificate**

- Introduction to Infectious Disease Modelling and Its Applications. The London School of Hygiene and Tropical Medicine, London, United Kingdom. 07/2008.

- MITACS Summer School on Mathematical Modeling of Infectious Diseases. York University, Toronto, Canada. 06/2006.
- National HIV Estimates for Canada Technical Meeting. Public Health Agency of Canada. 05/2006.
- Faculty Instructional Skills Workshop. University of British Columbia's Centre for Teaching, Learning and Technology. 07/2015.
- Case-Based Learning Training. University of British Columbia's Centre for Teaching, Learning and Technology. 11/2016.
- Training in the Fundamentals of OCAP® by the First Nations Information Governance Centre (FNIGC). 08/2021.

**(d) Continuing Medical Education**

*Not applicable*

**(e) Special Professional Qualifications**

*Not applicable*

**6. EMPLOYMENT RECORD**

**(a) Prior to coming to UBC**

**During BSc and MSc in Brazil**

- Junior Statistician
  - \* Responsibilities: To conduct different statistical analyses.
  - \* Instituto Brasileiro de Geografia e Estatística • English: Brazilian Institute of Geography and Statistics; 08/1993 - 12/1993
  - \* Empresa Brasileira de Correios e Telégrafos • English: Brazilian Post Office; 01/1994 - 01/1995
  - \* Furnas Centrais Elétricas • English: Furnas - Hydroelectric Company of Brazil; 03/1995 - 07/1995
  - \* Banco da Bahia Investimentos (BBM) • English: Bahia's Investment Bank; 07/1995 - 01/1996

**(b) At UBC**

**During PhD in Canada**

- Consultant in Statistics
  - \* Responsibilities: To provide statistical support to all UBC faculties and departments, as well as to off-campus clients.
  - \* Department of Statistics; University of British Columbia; 09/1999 - 09/2000
- Graduate Researcher in Statistics
  - \* Responsibilities: To conduct different statistical analyses and assist in the preparation of manuscripts, presentations, abstracts and grant proposals.
  - \* Department of Statistics; University of British Columbia; 01/2000 - 04/2000
  - \* Centre for Healthcare Innovation and Improvement; British Columbia Research Institute for Children's and Women's Health; 11/2002 – 04/2005
- Junior Researcher in Statistics
  - \* Responsibilities: To conduct different statistical analyses and assist in the preparation of manuscripts, presentations, abstracts and grant proposals.
  - \* Arthritis Research Centre of Canada; 10/2001 - 10/2002
  - \* Arthritis Research Centre of Canada; 05/2005 - 07/2005
- Graduate Student Teaching Assistant
  - \* Responsibilities: To conduct tutorial sessions, computer labs and mark assignments and exams.
  - \* University of British Columbia - Faculty of Graduate Students - Health Care and Epidemiology; 09/2002 - 12/2002
  - \* University of British Columbia - Faculty of Graduate Students - Occupational & Environmental Hygiene; 09/2003 - 12/2003

\* University of British Columbia - Faculty of Graduate Students - Health Care and Epidemiology; 09/2004 - 12/2004

### **(c) Date of granting of tenure at UBC**

*Not applicable.* I have a Partner Track Faculty Appointment.

- \* Brief Description: This category is identical to the grant tenure track faculty appointment with the sole distinction that the salary and benefits do not flow through the University, but rather through a partner institution (in my case the British Columbia Centre for Excellence in HIV/AIDS).
- \* Expectations: As per my contract with UBC and the British Columbia Centre for Excellence in HIV/AIDS, I need to dedicate 75% of my time to research activities. The remaining 20% should be spent teaching, with at least 40 scheduled hours per year teaching undergraduate medical students. The remaining 5% of my time should be spent fulfilling my hospital and university obligations, such as memberships on committees.

- Assistant Professor (Partner): 01/2011 – 06/2016
- Associate Professor (Partner): 07/2016 – present

### **(d) Other Affiliations**

- Scientist and Senior Methodologist - British Columbia Centre for Excellence in HIV/AIDS (03/2006 – present)
- Member - Experimental Medicine Program (02/2014 – present)
- Associate Member - School of Population and Public Health (03/2014 - present)

## **7. LEAVES OF ABSENCE**

## **8. TEACHING**

### **(a) Areas of special interest and accomplishments**

The goal of my teaching, and focus of my teaching philosophy, is active learning. I believe that the teaching of epidemiology and biostatistics should focus on training students to apply the techniques they learn in a lecture-based environment to “real world” problems. I use different teaching techniques in my courses, including in-class activities and discussions, presentations, take-home assignments, and in some cases, manuscript preparation for submission to peer-reviewed journals. In this process, I view my role as a facilitator by actively engaging with students in their learning activities and being accessible. I also seek improvement of my teaching skills based on students’ evaluations and by taking teaching development courses. My teaching goal also includes the development of skills that students will use in their future careers. These include encouraging students to develop their independence, play an active role in their learning experience, think creatively and critically, and improve their writing and communication skills.

### **(b) Courses Taught**

- Elective Teaching<sup>96</sup> - Once, I was invited to teach at Dr. David Moore’s elective Public Health & Preventive Medicine. My role was to teach basic concepts in epidemiology.
- Elective Teaching<sup>5</sup> - In a few instances, I was invited to teach at Dr. Art Poon’s elective Translational Bioinformatics. My role was to teach basic concepts in epidemiology.
- INDE440: Clinical and Population Health Research for 3<sup>rd</sup> and 4<sup>th</sup> year medical students; University of British Columbia - Faculty of Medicine - Medicine - Division of Infectious Diseases; Preceptor: Dr. Viviane D. Lima (Syllabus at the end of the CV)
- MEDI 548: Clinical, Patient Oriented and Translational Research for graduate students (this old version of the course is now MEDI 503); University of British Columbia - Faculty of Medicine – Medicine – Experimental Medicine Program
- MEDI 503: Introduction to Clinical, Patient Oriented and Translational Research; University of British Columbia - Faculty of Medicine – Medicine – Experimental Medicine Program
- MEDI 548 (starting in 2021) – Directed Study, 3 credits, summer course; University of British Columbia - Faculty of Medicine – Medicine – Experimental Medicine Program (Syllabus at the end of the CV)
- MEDD 422A: Case-Base Learning Tutoring for 2<sup>nd</sup> year medical students; University of British Columbia - Faculty of Medicine – Medicine

- MEDD 419, 429 & 449 FLEX: Aging with HIV for 1<sup>st</sup> year medical students; University of British Columbia – Faculty of Medicine – Medicine (Syllabus at the end of the CV)

**Undergraduate level**

Year	Course #	Sched. Hrs	Class Size	Contact Hrs	Hours Taught			
					Lectures	Tutorials	Labs	Other (Manuscript Writing)
09/2013	Elective <sup>8</sup>	4 weeks	1	10	3			7
10/2013	Elective <sup>5</sup>	4 weeks	1	1 ½	1 ½			
03/2014	Elective <sup>5</sup>	4 weeks	1	5 ½	2			3 ½
11/2014 -12/2014	INDE440	2 weeks	1	39 ½	5			34 ½
01/2015	INDE440	2 weeks	1	24 ½	6			18 ½
02/2015 - 03/2015	INDE440	4 weeks	1	27 ½	27 ½			
03/2015	INDE440	2 weeks	1	15	3			12
03/2015 - 04/2015	INDE440	2 weeks	1	11	11			
05/2015 – 06/2015	INDE440	4 weeks	1	30	19			11
09/2015	INDE440	2 weeks	1	13 ½	13 ½			
01/2016	INDE440	2 weeks	1	10 ½	10 ½			
03/2016 – 04/2016	INDE440	4 weeks	1	18 ½	18 ½			
09/2016 – 10/2016	INDE440	2 weeks	1	17	17			
10/2016 – 11/2016	INDE440	4 weeks	1	23	14			9
(01/2017)	MEDD 422A	4 weeks - total 28h 17min	8	18h 50 min				Preparation for class – Week 1 (3h 50 min), Week 2 (2h), Week 3 (2h 17min), Week 4 (1h 20min) – Total: 9h 27min
03/2017	INDE440	2 weeks	1	13	13			
04/2017	INDE440	4 weeks	1	12	12	After the first week, Dr. Marjorie Robbins needed teaching hours and the student was interested in working in her lab. Thus, the remaining of time the student was under the supervision of Dr. Robbins.		

(1/2018)	MEDD 422A	4 weeks	8	1590 min which is 26h 30min	880 min which is 14h 40 min	Tutor meetings 4 h		Total time spent preparing class: 470 min, which is ~ 7h 50 min
01/2018	INDE440	2 weeks	1	10 h 20 min	10 h 20 min			
02/2018	INDE440	4 weeks	1	49	22			27 h she worked with my research team on a manuscript and abstract
10/2018 (student took 1 day of sick leave)	INDE440	2 weeks	1	13	13			
10/2018	INDE440	2 weeks	1	12 ½	12 ½			
11/2018 (student took 1 day of sick leave)	INDE440	3 weeks	1	20 ½	20 ½			
01/2019	MEDD422 A	4 weeks	8	26 h 20min	14 h 40 min	4 h (tutor meetings)		Total time spent preparing class: 459 min, which is ~ 7h 40 min
05/2019 – 06/2019	MEDD419 FLEX	6 weeks	1	24½	9 ½		15h (research group meeting)	The rest of the time the student conducted a literature review.
05/2019 – 06/2019	MEDD419 FLEX	6 weeks	1	30	15		15h (research group meeting)	The rest of the time the student conducted a literature review, and assisted in writing a manuscript.
06/2019	INDE440	4 weeks	1	18½	10½		8h (research group meeting)	The rest of the time the student read the chapters from <i>Gordis 2013</i> , and helped with various projects.

09/2019 – 05/2020	MEDD429 FLEX	60hrs	1	29	23		6h (research group meeting)	Student is helping write a manuscript.
01/2020	MEDD422 A	4 weeks	8	21 h 30 min	14 h 40 min	4 h (tutor meetings)		Total time spent preparing class: 170 minutes
04/2020 – 05/2020	MEDD 419 FLEX	6 weeks	1	28	10		18h (research group meeting)	The rest of the time the student conducted a literature review.
09/2020 – 05/2021	MEDD429 FLEX	60hrs	1	26	12 1/2		10 h (research group meeting)	Student produced a report, a literature review, the introduction and methods of a manuscript.  I read all the material and spent 3 ½ reading and providing feedback
01/2021	MEDD422 A	4 weeks	8	24 h 20min	14 h 40 min			The time I spent to train to use Zoom (web resources), writing the WBA, mid-term evaluation and tutor meetings: 9h 40 min
01/2022	MEDD422 A	4 weeks	8	23 h 58 min	14 h 40 min			Tutor meetings: 3h Mid-term evaluations & WBI: 1.5 h Class preparation: 4.83 h

07/2022	INDE440	2 weeks	1	11h 41min	7h 41min		4h (research group meeting)	The rest of the time the student read the chapters from <i>Gordis</i> , worked on a concept sheet to incorporate all that she learned in the course.
---------	---------	---------	---	-----------	----------	--	-----------------------------	--

### Graduate-level

Year	Course #	Sched. Hrs	Class Size	Contact Hrs
04/2016	MEDI 548	1 ½ h	12	1h 30 min
09/2020	MEDI 503	1 ½ h	18	1h 30 min
06-08/2021	MEDI 548 – directed studies	36 h	1	30h
09/2021	MEDI 503	1 ½ h	20	1h 30 min

### (c) Other Teaching of Undergraduates, Graduates and Postgraduates

#### Scheduled Hours

Combined structured teaching (CST) Rounds for Medical Fellows at St. Paul's Hospital - University of British Columbia - Faculty of Medicine - Medicine - Division of Infectious Diseases.

Year	Course #	Sched. Hrs	Class Size	Contact Hrs
04/2015	CST Rounds – Basic Concepts in Clinical Epidemiology	1h	5	1h
07/2015	CST Rounds – Basic Concepts in Clinical Epidemiology	1h	9	1h

#### Unscheduled Hours

Another Teaching – Clinical Epidemiology Summer Studentship; University of British Columbia - Faculty of Medicine - Medicine - Division of AIDS (Description – 8(h)).

Year	Student	Duration (hours)	Peer-Reviewed Paper Accepted	Current Placement
06/2012 - 08/2012	David Nguyen 4 <sup>th</sup> year UBC medical student	3 months (65 h)	<u>Nguyen D</u> , Stanek V, Guillemi S, Ding E, Colley G, Montaner J, Lima V, Bondy G. (2014) High prevalence of Carotid Plaque identified using standard Carotid Ultrasound Techniques in HIV-Positive Patients with Low To Moderate Vascular Risk. <i>J AIDS Clin Res</i> , 5(9):338	Physician, Canada

06/2013 - 08/2013	Adrian Le 4 <sup>th</sup> year UBC medical student	3 months (130 h)	Lima VD, <u>Le A</u> , Nosyk B, Barrios R, Yip B, Hogg RS, Harrigan PR, Montaner JS. (2012) Development and validation of a composite programmatic assessment tool for HIV therapy. PloS One, 7(11): e47859.	Sports Medicine Physician in Toronto, Canada
-------------------	---	---------------------	--	--

### Other Teaching

<sup>§</sup>Journal Club for the medical staff of the John Ruedy Immunodeficiency Clinic (IDC); St. Paul's Hospital

<sup>⌘</sup>Journal Club for the medical/non-medical staff of BC Centre for Excellence in HIV/AIDS; St. Paul's Hospital

<sup>@</sup>Journal Club - University of British Columbia, Department of Medicine, Infectious Diseases Division

<sup>⊖</sup>See Appendix 4 for better description of this annual summer course.

Year	Journal Club & Summer Course	Class Size	Contact Hrs
09/2008 <sup>§</sup>	Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy	5-10	1
06/2009 <sup>§</sup>	Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay	5-10	1
12/2009 <sup>§</sup>	The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time	5-10	1
03/2011 <sup>§</sup>	Pre-exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men	5-10	1
10/2018 <sup>⌘</sup>	Design of Epidemiological Studies and Statistical Analyses	>20	1
08/2021 <sup>⊖</sup>	Principles of STI/HIV Research and Public Health Practice Course. University of Washington, US. July 19-August 6, 2021	>100	1
02/2022	The Impact of COVID-19 on People Living with HIV	>10	1
TBD <sup>⊖</sup>	Principles of STI/HIV Research and Public Health Practice Course. University of Washington, US. July 19-July 29, 2022	>100	1

### (d) Students Supervised

To fulfill my supervision duties, I am currently receiving MPH-level students from UBC's School of Population and Public Health, and MSc-level students from UBC's Co-op program, UBC's School of Population and Public Health and from UBC's Department of Statistics. Additionally, I have accepted both MSc- and PhD-level students from UBC's Experimental Medicine and Interdisciplinary Programs.

#### (d.1) Undergraduate Students

#### (d.2) Graduate Students Supervised

MSc Total = 6; 2 current; 4 completed

MPH Total = 1; 1 completed

PhD Total = 4; 2 current; 2 completed

### Present

#### PhD

Student Name	Program Type	Year Start	Year Finish	Supervisory Role	Current Position
Ni Gusti Ayu Nanditha	PhD Candidate in Experimental Medicine Thesis: "Burden of chronic comorbidities among people living with and without HIV in	09/2017	08/2022	Primary	Working at British Columbia Centre for Excellence in HIV/AIDS



	British Columbia, Canada: A look into aging with HIV.” <i>*Passed the comprehensive exam</i> <i>* Sent thesis to External Examiner</i>				as a Graduate Research Assistant  CIHR Doctoral Award & UBC 4-year fellowship Awardee
Nance Cunningham	<b>PhD Candidate in Experimental Medicine</b> Thesis: “Centring patient experience in supporting greater healthcare engagement between members of two hepatitis C priority populations and primary care providers of BC” <i>*Passed the comprehensive exam</i>	09/2019	Present	Primary	Working at British Columbia Centre for Excellence in HIV/AIDS as a Graduate Research Assistant  UBC Public Scholar Initiative Awardee
Monica Ye	<b>PhD Student in Statistics</b> Thesis: “Robust non-linear mixed effect model to study virologic dynamics in naïve individual starting ART in BC”	09/2020	Present	Co-supervisor (Primary Dr. Lang Wu)	Working at British Columbia Centre for Excellence in HIV/AIDS as a Statistician under my supervision

### MSc

Student Name	Program Type	Year Start	Year Finish	Supervisory Role	Current Position
Felipe Duailibe	<b>MSc in Experimental Medicine</b> Thesis: “The Application of Syndemic Theory to Compare Risk Profiles of Younger and Older Gay, Bisexual, and Other Men Who Have Sex With Men Engaged in High-Risk Sexual Behaviour in Four Major Provinces in Canada”	05/2020	Present	Primary	Working at the British Columbia Centre for Excellence in HIV/AIDS as a Graduate Research Assistant
Sara Shayegi-Nik	<b>MSc in Experimental Medicine</b> Thesis: “Gaps within the Mental Health Continuum of Care for people living with HIV and Mood and Anxiety disorders in British Columbia”	09/2020	Present	Primary	Working at the British Columbia Centre for Excellence in HIV/AIDS as a Graduate Research Assistant

### MPH

Student Name	Program Type	Year Start	Year Finish	Supervisory Role	Current Position
Bronhilda Takeh	<b>MPH in the School of Population and Public Health</b> Bronhilda’s practicum will focus on writing a paper for publication. Title: “What Will It Take to Control the Syphilis Epidemic among Gay, Bisexual and Other Men Who Have Sex	01/2022	05/2022	Primary	Working at the British Columbia Centre for Excellence in HIV/AIDS as a Graduate Research Assistant

	with Men (MSM) in British Columbia, Canada?”				
--	--	--	--	--	--

## Completed

Student Name	Program Type	Year Start	Year Finish	Supervisory Role	Current Position
Zishan Cui	<p><b>MSc in Statistics (Co-op Program)</b> Project Description: Zishan learnt how to do statistical modeling in HIV research.</p> <p>Published Peer-Reviewed Paper: 1. Cui Z , Grafstein E , Yip B , Hogg R , Montaner J , Lima V , "Modelling clinical progression and health care utilization of HIV-positive patients in British Columbia prior to death." HIV Medicine 2014. 15(9):557-64</p>	09/2011	05/2013	Primary	Statistician at the British Columbia Centre for Substance Use
Huiting Ma	<p><b>MSc in Statistics (Co-op Program)</b> Project Description: Huiting learned how to do statistical modeling in HIV research. She participated in different projects at the British Columbia Centre for Excellence in HIV/AIDS.</p> <p>Published Peer-Reviewed Paper: 1. Lima VD, Eyawo O, <u>Ma H</u>, Lourenço L, Chau W, Hogg RS, Montaner JS. The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada. J Int AIDS Soc. 2015; 18(1): 20261.</p>	05/2014	12/2014	Primary	Working at St-Michael’s Hospital in Toronto, Canada
Huiting Ma	<p><b>MSc in Statistics (Thesis-based)</b> Thesis: The Impact of HCV Co-Infection on Healthcare-Related Utilization among HIV Patients in British Columbia, Canada</p>	12/2014	08/2015	Co-supervisor: Lang Wu	Working at St-Michael’s Hospital in Toronto, Canada
Hiwot Tafessu	<p><b>MSc in Statistics (Co-op Program)</b> Project Description: Hiwot learnt how to work on “big data” and analyze healthcare utilization data applied to HIV research.</p> <p>Published Peer-Reviewed Paper: Nanditha NGA, St-Jean M, <u>Tafessu H</u>, Guillemi SA, Hull MW, Lu M, Henry B, Barrios R, Montaner JSG, Lima VD. (2019) Missed</p>	05/2017	09/2018	Primary	Working for an American tech company

	opportunities for earlier diagnosis of HIV in British Columbia, Canada: A retrospective cohort study. <i>PLoS One</i> , 14(3): e0214012.				
Samuel Antoine	<b>PhD in Epidemiology</b> Thesis Description: Samuel is running statistical analysis to understand the burden of osteoarthritis in BC	01/2017	2018	Co-supervisor: Jacek Kopec	Due to personal issues, Samuel withdrew from the program.
Jummy David	<b>PhD in Interdisciplinary Studies</b> Thesis: "The Study of Epidemic and Endemic Diseases using Mathematical Models"	09/2017	01/2020	Co-supervisor (Primary Prof. Fred Brauer)	Completing post-doctoral fellowship at York's University.
Doreen Nehumba	<b>MSc in Experimental Medicine</b> Thesis: "Psychosocial Factors, Mental Health Disorders and Health Satisfaction in Canada."	09/2017	04/2020	Primary	

### (d.3) Graduate Student Supervisory Committees

Total = 5; 3 completed; 1 changed role; 1 present

PhD Total = 3; 2 completed; 1 changed role

MSc Total = 2; 1 completed; 1 present

#### Present

##### MSc

Year	Student
11/2021 - present PhD Thesis Committee Member	Mr. Hanwei Sudderuddin Supervisor: Dr. Chanson Brumme Experimental Medicine Program University of British Columbia
	<b>My Duties</b>   I am advising Hanwei on the statistical analyses for his thesis.

#### Completed

Year	Student
09/2011 - 02/2015 PhD Thesis Committee Member	Mrs. Yanink Neried Caro Vega Supervisor: Dr. Juan Sierra-Madero Dictamen Subcomité Académico Ciencias de la Salud Posgrado Universidad Nacional Autónoma de México
	<b>My Duties</b>   I am advising Yanink on the mathematical model she is developing for her thesis.
03/2010 – 08/2015 PhD Thesis Committee Member	Mr. Chanson Brumme Supervisor: Dr. Richard Harrigan Experimental Medicine Program University of British Columbia
	<b>My Duties</b>   I am advising Chanson on the statistical analyses for his thesis.
06/2014 – 12/2015 MSc Thesis Committee Member	Mr. Brent James Gali Supervisor: Dr. David Moore School of Population and Public Health University of British Columbia

	<b>My Duties</b>	I am advising Brent on the statistical analyses that he is performing to address the objectives in his thesis.
--	------------------	--

#### Changed Roles (see section d.2)

Year	Student
09/2013 – 01/2017	Mr. Samuel Antoine Supervisors: Dr. Jacek Kopec and Viviane Lima School of Population and Public Health University of British Columbia
	<b>My Duties</b> I am advising Samuel on the microsimulation model that he is using to address the objectives in his thesis.

#### (d.4) Postgraduate Students Supervised

09/2015 – 11/2016	Mr. Ofer Amram Supervisor: Dr. Viviane Lima Co-Supervisor: Dr. Julio Montaner Division of AIDS, Department of Medicine, Faculty of Medicine University of British Columbia
	<b>Project Title</b> The main objective of his fellowship is to use GIS technology to improve the health and well-being of people living with HIV/AIDS and to reduce the rate of HIV/AIDS transmission through better care access and improved monitoring
	<b>Current Position</b> Assistant Professor University of Washington, US

#### (e) Continuing Education Activities

##### Invited Presentations - Main Audience: Researchers and Physicians

- Lima VD. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. Forefront Series. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. September 3rd, 2008.
- Lima VD. Evidence from the iPrEx Study: Should it be considered in BC? AIDS Care Rounds. St. Paul's Hospital, Vancouver, Canada. May 19, 2011.
- Lima VD. Exporting the Success of the "HIV Treatment as Prevention" Strategy to Control the HCV Epidemic. University of British Columbia (UBC) Department of Medicine Grand Rounds. St. Paul's Hospital, Vancouver, Canada. October 10, 2013.
- Lima VD. Oak Tree Clinic Educational Sessions. Exporting the Success of the "HIV Treatment as Prevention" Strategy to Control the HCV Epidemic. Vancouver, Canada. February 3, 2014.
- Lima VD. When to start cART? Recent results from the START Trial and cohort studies. HIV Care Rounds. St. Paul's Hospital, Vancouver, Canada. September 24, 2015.
- Lima VD. Determinants of ART Outcomes in BC. Fall HIV/ARV Update. Sheraton Hotel, Vancouver, Canada. November 23, 2015.
- Lima VD. Potential Impact of Generic Antiretrovirals in British Columbia: A work in progress. Fall HIV/ARV Update. Sheraton Hotel, Vancouver, Canada. November 6, 2017.
- Lima VD. Introduction of Generic Antiretrovirals in British Columbia: A Counterfactual Analysis. HIV Care Rounds. St. Paul's Hospital, Vancouver, Canada. April 25, 2018.
- Lima VD. New PrEP Program in BC - Projections. Fall HIV/ARV Update. Sheraton Hotel, Vancouver, Canada. May 7, 2018.
- Lima VD. The Use of Healthcare Claims Data in Research: What Are the Pitfalls? Infectious Diseases Plenary. University of British Columbia, Department of Medicine, Infectious Diseases Division. February 15, 2022

- Lima VD. The Use of Mathematical Modelling to Inform Public Health Interventions. University of British Columbia (UBC) Department of Medicine Grand Rounds. St. Paul’s Hospital, Vancouver, Canada. May 12, 2022.

**(f) Visiting Lecturer (indicate university/organization and dates)**

**Invited Presentations - Main Audience: Students**

- Lima VD. Sample Size Calculation in Longitudinal Observational Studies. Visiting Lecture for Graduate Students. Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada. September 26th, 2006.
- Lima VD. Introduction to Mathematical Modeling in Infectious Diseases. Visiting Lecture for Undergraduate Students. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. March 2, 2009.
- Lima VD. Exporting the Success of the “HIV Treatment as Prevention” Strategy to Control the HCV Epidemic. Visiting Lecture for Undergraduate Students. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. October 11, 2013.

**Invited Presentations - Main Audience: Researchers, Decision Makers and Physicians**

- Lima VD. Recent clinical and modelling studies from the BC Centre for Excellence in HIV/AIDS. Visiting Lecture for Researchers. The South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch, South Africa. April 15, 2011.
- Lima VD. HIV Treatment as Prevention in US Correctional Facilities: A Mathematical Model. Visiting Lecture for Researchers. Emory University, Atlanta, USA. June 26, 2012.
- Lima VD. Exporting the Success of the “HIV Treatment as Prevention” Strategy to Control the HCV Epidemic. Visiting Lecture for Physicians. Academia Nacional de Medicina • English: Brazilian Medical Academy, Rio de Janeiro, Brazil. August 7, 2014.
- Lima VD. The “HIV Treatment as Prevention” Strategy to Control the HIV Epidemic. Visiting Lecture for Researchers and Decision Makers. Brazilian Ministry of Health Department of STD, AIDS and Viral Hepatitis, Brasília, Brazil. August 26, 2014.
- Lima VD. Introduction to Mathematical Modelling. Principles of STI/HIV Research and Public Health Practice Course. University of Washington, US. August 5, 2021
- Lima VD. The use of mathematical models to address the global HIV response. IAPAC-Lancet HIV Commission on the Future of Urban HIV Responses. November 2, 2021
- Lima VD. Introduction to Mathematical Modelling. Principles of STI/HIV Research and Public Health Practice Course. University of Washington, US. August 27, 2022

**(g) Educational Leadership**

**Mentorship**

Year	Description	
August 25- 29, 2014 (40 hours)	<b>Mentee</b>	Dr. Ana Roberta Pati Pascom
	<b>Place</b>	Brasília, Brazil
July 8-22, 2015 (48 hours)	<b>Memorandum of understanding (MoU)</b>	I recently developed a collaboration between the British Columbia Centre for Excellence in HIV/AIDS and the Brazilian Ministry of Health Department of STD, AIDS and Viral Hepatitis. The MoU was formally signed on July 22, 2015
May 9-13, 2016 (40 hours)	<b>Goals</b>	<ul style="list-style-type: none"> <li>• To compare patient prognosis between two contrasting settings with universal access to HIV treatment (Brazil and BC) after the expansion of Treatment as Prevention;</li> <li>• To create research training opportunities for post-doctoral fellows and graduate students.</li> </ul>
	<b>My Duties</b>	<ul style="list-style-type: none"> <li>• To provide mentorship to visiting scientists on statistical and mathematical modeling techniques to analyze clinical and epidemiological data obtained from different interventions to control the spread of HIV in Brazil.</li> </ul>

		<ul style="list-style-type: none"> <li>To train scientists on the writing of manuscripts for peer-reviewed publication</li> </ul>
May 4, 2015 (4 hours)	<b>Mentee</b>	Dr. Yi Lyu from the Chinese Center for Disease Control
	<b>Place</b>	Vancouver, British Columbia, Canada
	<b>Memorandum of understanding (MoU)</b>	This MoU was signed by the British Columbia Government, the British Columbia Centre for Excellence in HIV/AIDS, the Chinese Center for Disease Control and the National Centre for AIDS/STD Control and Prevention in China.
	<b>Goals</b>	<ul style="list-style-type: none"> <li>To improve the health of British Columbians and Chinese citizens through the enhancement of the capacity to deliver HIV/AIDS education and training to health professionals in British Columbia and China.</li> <li>To establish a three-year HIV fellowship program that will allow top Chinese scientists to come to Vancouver to work with researchers and clinicians at the British Columbia Centre for Excellence in HIV/AIDS.</li> </ul>
	<b>My Duties</b>	<ul style="list-style-type: none"> <li>To provide mentorship to visiting scientists on statistical and mathematical modeling techniques to analyze clinical and epidemiological data obtained from different interventions to control the spread of HIV and Hepatitis C in China.</li> </ul>
October 27-29, 2018  Ongoing	<b>Mentee</b>	Dr. Zunyou Wu and his team from the Chinese Center for Disease Control
	<b>Place</b>	Beijing, China
	<b>Memorandum of understanding (MoU)</b>	This MoU was signed by the British Columbia Government, the British Columbia Centre for Excellence in HIV/AIDS, the Chinese Center for Disease Control and the National Centre for AIDS/STD Control and Prevention in China.
	<b>Goals</b>	<ul style="list-style-type: none"> <li>To improve the health of Chinese citizens through the enhancement of the capacity to deliver HIV/AIDS education and training to health professionals in British Columbia and China.</li> <li>To establish a two-year HIV fellowship program that will allow top Chinese scientists to come to Vancouver to work with researchers and clinicians at the British Columbia Centre for Excellence in HIV/AIDS.</li> </ul>
	<b>My Duties</b>	<ul style="list-style-type: none"> <li>Since 2018, I have provided mentorship to visiting scientists and those in China on statistical and mathematical modeling techniques to analyze clinical and epidemiological data obtained from different interventions to control the spread of HIV and Hepatitis C in China. I have also assisted Dr. Wu with his NIH grant application that was submitted in 2019.</li> </ul>

### Organization of Workshop

Year	Workshop Description	
April 1, 2011 - May 3, 2011	US Criminal Justice Meeting. Pre-workshop prior to the International Treatment as Prevention Conference. Vancouver, British Columbia, Canada	
	<b>My Duties (Main Host)</b>	<ul style="list-style-type: none"> <li>Organize content and logistics for workshop</li> <li>Set goals for the collaboration of various research groups, including: National Institute of Drug Abuse (USA), Emory University (USA), Browns University (USA), North Carolina University (USA), Yale University (USA) and the University of British Columbia (CA)</li> </ul>
	<b>Outcomes</b>	<b>Conference Abstract:</b> <a href="#">Lima V</a> , Spaulding A, Kim B, Stein M, Messina L, Beckwith CG, Wong J, Bazeman L, Montaner J, Graf I, Issaei A, Coombs D, Altice F, Springer S, Winn T, Herma M, Powers K, Wohl D, Erinoff L, Normand J, Seek Test Treat and Retain Corrections (STTaR Corr) Modeling Group. Modeling the impact of implementing a seek, test, treat and retain (STTR) strategy to halt the HIV epidemic within the criminal justice

		<p>system (CJS) in different regions in the U.S. XIX International AIDS Conference (AIDS 2012). Washington, USA. July 22-27, 2012. Abstract THPE105.</p> <p><b>Peer-Reviewed Publication:</b> Lima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JS, Spaulding A. The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLoS One. 2015;10(4):e0123482.</p>
<b>Year</b>	<b>Satellite Description</b>	
February 5, 2015 – July 21, 2015	<p>Computational models of HIV/AIDS: sharing new tools and ideas. Satellite prior to the 2015 International AIDS Conference, Vancouver, British Columbia, Canada</p> <p>Co-hosts: Anna Bershteyn (Intellectual Ventures Laboratory, USA), Ruanne Barnabas (University of Washington, USA), Jeffrey Eaton (Imperial College London, UK) and John Stover (Avenir Health, USA)</p>	
	<b>My Duties (Co-Host)</b>	<ul style="list-style-type: none"> <li>• Help organize content for satellite</li> <li>• Give a presentation highlighting other HIV prevention mathematical models in the literature</li> </ul>
<b>Year</b>	<b>Webinar Description</b>	
2019	PrEP and STOP HIV/AIDS Indicators Webinars	
	<b>Duties (Main Host)</b>	<p><b>Objective:</b> In these webinars, I presented the proposed new indicators to monitor the progress of the Pre- Exposure Prophylaxis (PrEP) and the Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) programs in British Columbia.</p> <p><b>Target Audience:</b> BC Health Authorities, Ministry of Health and Researchers.</p>
	<b>Outcomes</b>	<p><b>Final Product:</b> Design a report for each of these programs. These two reports will be available online on a quarterly basis for different stakeholders monitor the progress of these two programs. Each list of indicators will be published in peer-reviewed journals.</p> <p><b>PrEP report:</b> <a href="http://bccfe.ca/hiv-pre-exposure-prophylaxis-prep/prep-reports">http://bccfe.ca/hiv-pre-exposure-prophylaxis-prep/prep-reports</a></p> <p><b>STOP HIV/AIDS report:</b> <a href="http://bccfe.ca/stop-hiv-aids/documents">http://bccfe.ca/stop-hiv-aids/documents</a></p>

#### (h) Curriculum Development & Innovation

<b>Year</b>	<b>Course</b>	
06/2012 - present	<p>Clinical Epidemiology Summer Studentship</p> <p>University of British Columbia - Faculty of Medicine - Medicine - Division of Infectious Diseases</p>	
	<b>Course Description:</b>	I created this studentship to provide an opportunity to 4 <sup>th</sup> year medical students, registered at UBC, to be exposed to clinical research in the area of HIV/AIDS and to gain experience in writing abstracts and scientific papers. For published papers see section 8(c).
06/2012 - present	<p>INDE440: Elective - Clinical and Population Health Research for 3<sup>rd</sup> and 4<sup>th</sup> year medical students</p> <p>University of British Columbia - Faculty of Medicine - Medicine - Division of Infectious Diseases</p>	
	<b>Course Description:</b>	I created this elective for 3 <sup>rd</sup> and 4 <sup>th</sup> year medical students from UBC and from other universities. In this elective, I go over the course material and the STROBE guidelines, I teach students to critically appraise and discuss peer-reviewed articles, and if time permits, involve students in the writing of manuscripts for peer-review publication. <i>For more detail, please see Appendix 1.</i>
06/2018 - present	<p>MEDD 419, 429 and 449: FLEX - Aging with HIV</p> <p>University of British Columbia – Faculty of Medicine – Medicine – Division of Infectious Diseases</p>	
	<b>Course Description:</b>	I created this FLEX activity for medical students from UBC. In this course, I guide students as they conduct a literature review and prepare an abstract, manuscript or presentation. This provides the student experience in the interpretation of biostatistical analysis, the

		composition of manuscripts/scientific papers, and insight into health research. <i>For more detail, please see Appendix 2.</i>
05/2021 - present	MEDI 548 – Directed Study, 3 credits, summer course University of British Columbia - Faculty of Medicine – Medicine – Experimental Medicine Program	
	<b>Course Description:</b>	In this course, students will explore working knowledge of the basic concepts and methods of epidemiology, with a focus on approaches for the acquisition, analysis and interpretation of information about disease. The knowledge provides the basis for describing and explaining disease occurrence, and introduces methods for developing, prioritizing and evaluating public health programs. <i>For more detail, please see Appendix 3.</i>

**(i) Other Teaching & Learning Activities**

**9. SCHOLARLY AND PROFESSIONAL ACTIVITIES**

**COVID-19 impact on my research:** This pandemic has significantly impacted my research. Initially, my research was suspended for three months until the BC Centre for Excellence in HIV/AIDS (BCCfE) granted virtual access to workstations for my staff and trainees. I also use data from Statistics Canada, and accessing it has been challenging because of the long wait times for approval and limited access to the University’s approved facilities to analyze the data. The workload has also increased dramatically due to all work being done virtually. I must both take and provide a considerable amount of new training. Because we are working remotely, I have had to obtain further approval for every project that I was already working on to ensure we follow the standard operating procedures to guarantee the data’s privacy. Projects that rely on updated data from BC’s linked administrative health datasets are still on hold since the delivery of these datasets has been delayed since 2020. Journals have been slow in providing reviews, especially if the paper is not related to COVID-19. In some cases, I have waited for 6-9 months to hear back from a journal. Some conferences that I was invited to present at were cancelled, and others moved to a virtual format which hindered my ability to network and find new collaborators. Since my team is working remotely, I use Zoom© for my weekly research team communication, video conferencing, and interactions with other personnel. I have established a WhatsApp© team group for quick non-confidential communication. I also hold weekly private meetings with each staff member and trainee to address any emerging issue, to provide feedback on their progress and work, and to support their general and mental health during this pandemic. Although my research and training workload increased significantly, I developed new processes that enabled me to perform as efficiently as possible, continuing to publish papers, mentoring staff/students, teaching at the University of British Columbia, managing my grants and supporting other research activities at the BCCfE.

**(a) Areas of special interest and accomplishments**

I am a Scientist and the Senior Methodologist at the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) with 16 years of experience conducting research on vulnerable populations living with or at high risk of HIV/AIDS. The focus of my research career has been on the epidemiology and control of HIV. Based on my extensive training in statistics, epidemiology and mathematical modelling, I have developed innovative disease progression and transmission models to understand the potential impact of behavioural, biomedical and programmatic interventions on the HIV epidemic. For example, one of my papers provided empirical evidence of the effect of ‘Treatment as Prevention’ (TasP) on reducing HIV incident cases (901 citations); this paper has been cited in international antiretroviral therapy (ART) guidelines and used as key evidence by UNAIDS and several countries implementing TasP programs. This work was also instrumental in obtaining a multimillion-dollar government fund to support the provincial ART expansion program.

Recently, I have focused my research on the impact of aging on the population living with HIV. Given that PLWH are living longer, my research interest has focused on assessing the impact of age-associated comorbidities on patient outcomes and BC’s healthcare system. My published papers have provided evidence of the epidemiological transition of the HIV epidemic since 1996 and insight into how the morbidity and mortality burden of age-associated comorbidities differ in PLWH compared to the general population. My work has demonstrated that non-AIDS-related cancers, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) represent the highest burden of illness in PLWH in BC. In addition, through this work, my research team has developed new methods to minimize bias when using administrative data in health research.

I believe that I have demonstrated my abilities as a skilled researcher and epidemiologist and that my research has had a significant impact in improving the lives of individuals living with HIV, and in averting healthcare system costs in BC, Canada and abroad. I have also been able to build networks of national and international collaborators, and I have an outstanding level and quality of research output: >200 peer-reviewed papers in high-impact journals (Web of Science h-index 51; Google Scholar i10-index 137;



average 12 papers/year); >5 years as an academic editor for PLoS One; several invitations to serve as a reviewer for peer-reviewed journals; various presentations at national and international meetings; and numerous advisory appointments to influential national/international organizations. Over the years, I have secured continuous research funds to support my research staff and trainees through my research lab (<https://embarc.med.ubc.ca>). I completed my salary support through prestigious career awards by the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research. Currently, I am the principal applicant or a co-applicant on several national grants (>\$10M in funding).

**(b) Research or equivalent grants**

In the grants I served as co-applicant, my role is to advise on the design of the different studies (e.g., research questions, epidemiological models, development of surveys) and provide statistical support to all analyses. The statistical support is done by either performing the analyses myself or by supervising my team of statisticians. Additionally, I provide mentorship on the writing of abstracts and papers lead by students, project coordinators or other staff recruited through these grants.

**Current Funding**

Year & Role	Description
2022/11-2024/10 Co-applicant	<b>Providing insight into and mitigating the impact of the COVID-19 pandemic on the occurrence, severity, complications, and long-term health effects of drug overdoses in people living with and without HIV in British Columbia, Canada.</b> <b>Principal Applicant: Robert Hogg</b>
	<b>Funding Source</b>   Addressing the Wider Health Impacts of COVID-19 Canadian Institutes of Health Research (CIHR) Total Funding: 480,992 (Canadian dollar) Period: 2 years Funding Competitive? Yes
2022/04-2023/03 Co-applicant	<b>Imaging, Molecular, and Clinical Biomarkers of Accelerated Lung Aging in People Living with Human Immunodeficiency Virus (AGE- HIV)</b> <b>Principal Applicant: Janice Leung</b>
	<b>Funding Source</b>   Project Scheme Program - Priority Announcement: HIV/AIDS and STBBI Canadian Institutes of Health Research (CIHR) Total Funding: 100,000 (Canadian dollar) Period: 1 years Funding Competitive? Yes
2021/08-2024/07 Co-applicant	<b>Uptake and gaps in HIV pre-exposure prophylaxis (PrEP) use among HIV-negative gay, bisexual, and other men who have sex with men (gbMSM) in Metro Vancouver, Canada before, during and following COVID-19</b> <b>Principal Applicant: David Moore</b>
	<b>Funding Source</b>   Project Scheme Program Canadian Institutes of Health Research (CIHR) Total Funding: 230,000 (Canadian dollar) Period: 3 years Funding Competitive? Yes
2020/11-2022/10 Principal Applicant	<b>Assessing the Burden of Chronic Comorbidities Focused on the Aging Population Living with HIV in British Columbia</b>
	<b>Funding Source</b>   Canadian Foundation for AIDS Research (CANFAR) 2020 Innovation Grant Cycle 30 Total Funding: 40,000 (Canadian dollar) Period: 2 years Funding Competitive? Yes

2020/10-2025/09 Co-applicant	<b>Engaging and retaining marginalized populations in primary health care in the downtown east side of Vancouver</b> <b>Principal Applicant: David Moore</b>	
	<b>Funding Source</b>	Project Scheme Program Canadian Institutes of Health Research (CIHR) Total Funding: 994,500 (Canadian dollar) Period: 5 years Funding Competitive? Yes
2018/05-2024/04 <b>Principal Applicant</b> Due to COVID-19 it was extended for 1 year, but no extra funds for the last year	<b>What will it take to decrease the burden of the HIV and STI epidemics among MSM in British Columbia, Canada? A sexual network modeling analysis, combining syndemic theory, to evaluate the impact of behavioural and biomedical interventions for HIV and STI prevention</b>	
	<b>Funding Source</b>	Project Scheme Program Canadian Institutes of Health Research (CIHR) Total Funding: 810,900 (Canadian dollar) Period: 5 years Funding Competitive? Yes
2017/11-2023/10 Co-Applicant Due to COVID-19 it was extended for 1 year, but no extra funds for the last year	<b>Scaling up PrEP for HIV Prevention: Optimizing strategies for targeting and delivering PrEP to MSM in British Columbia and Ontario</b> <b>Principal Applicant: Darrell Tan</b>	
	<b>Funding Source</b>	Team Grant: HIV Implementation Science Canadian Institutes of Health Research (CIHR) Total Funding: 1,994,000 (Canadian dollar) Period: 6 years Funding Competitive? Yes
2016/07-2022/06 <b>Principal Applicant</b> Due to COVID-19 it was extended for 1 year, but no extra funds for the last year	<b>The Health and Economic Forecasting Micro-Simulation Model: A tool to evaluate future health policies and programmatic interventions targeting the aging population living with HIV in British Columbia</b>	
	<b>Funding Source</b>	Project Scheme Program Canadian Institutes of Health Research (CIHR) Total Funding: 558,085 (Canadian dollar) Period: 6 years Funding Competitive? Yes
2015/08 - 2023/07 Co-Applicant Due to COVID-19 it was extended for 1 year, but no extra funds for the last year	<b>Expansion of Antiretroviral Therapy and its Impact on Vulnerable Populations in Canada and Global Settings</b> <b>Principal Applicant: Robert Hogg</b>	
	<b>Funding Source</b>	Foundation Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 6,500,000 (Canadian dollar) Funding Competitive? Yes
Since 2010 and no end date Co-Applicant	<b>STOP HIV/AIDS Initiative in BC</b> <b>Principal Applicant: Julio Montaner</b>	
	<b>Funding Source</b>	British Columbia Ministry of Health Yearly Funding: 1,400,000 (Canadian dollar) Funding Competitive? No

### Submitted Funding

Year & Role	Description
-------------	-------------

<b>Spring 2022</b> Principal Applicant	<b>Addressing the Burden of Chronic Obstructive Pulmonary Disease and Cardiovascular Disease among the Ageing Population Living with HIV in British Columbia</b>	
	<b>Funding Source</b>	Project Scheme Program Canadian Institutes of Health Research (CIHR) Total Funding: 995,000 (Canadian dollar) Period: 5 years Funding Competitive? Yes
<b>Spring 2022</b> Principal Applicant	<b>Addressing the Burden of Chronic Obstructive Pulmonary Disease among the Ageing Population Living with HIV in British Columbia</b>	
	<b>Funding Source</b>	Health Innovation Funding Investment (HIFI) Awards University of British Columbia Total Funding: 25,000 (Canadian dollar) Period: 1 years Funding Competitive? Yes

## Completed Funding

Year & Role	Description	
2017/10-2021/09 Co-Applicant Due to COVID-19 it was extended for 1 year, but no extra funds for the last year	<b>Thrive Project: A community-driven investigation of the home and community care needs of older adults living with HIV</b> <b>Principal Applicants: Surita Parashar &amp; Kate Salters</b>	
	<b>Funding Source</b>	Operating Grant - HIV/AIDS CBR Program – General Canadian Institutes of Health Research (CIHR) Total Funding: 449,688 (Canadian dollar) Period: 3 years Funding Competitive? Yes
2014/06 - 2019/05 Co-Applicant	<b>Canadian HIV Observational Cohort (CANOC) Collaborative Research Centre.</b> <b>Principal Applicant: Robert Hogg</b>	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 2,272,460 (Canadian dollar) Funding Competitive? Yes
2013- 2018 Co-Applicant	<b>Seek and Treatment for Optimal Prevention of HIV &amp; AIDS (STOP HIV/AIDS) in BC</b> <b>Principal Applicant: Julio Montaner</b>	
	<b>Funding Source</b>	NIH Research Project Grant Program (R01) National Institute on Drug Abuse (NIDA) Total Funding: 2,651,655 (Canadian dollar) Funding Competitive? Yes
2015- 2018 Co-Applicant	<b>Seek and Treatment for Optimal Prevention of HIV &amp; AIDS (STOP HIV/AIDS) in BC - Supplement</b> <b>Principal Applicant: Julio Montaner</b>	
	<b>Funding Source</b>	NIH Research Project Grant Program (R01) - Supplement National Institute on Drug Abuse (NIDA) Total Funding: 108,008 (Canadian dollar) Funding Competitive? Yes
2014/04 - 2017/03 Co-applicant	<b>Impact of HIV on aging-related comorbidities among key affected populations across Canada.</b> <b>Principal Applicant: Robert Hogg</b>	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 450,000 (Canadian dollar) Funding Competitive? Yes
2013/04 - 2017/03 Co-applicant	Viral & Human Genetic Predictors of Response to HIV Therapies. Principal Applicant: Richard Harrigan	
	<b>Funding Source</b>	2012 Large-Scale Applied Research Project Competition in Genomics and Personalized Health Genome Canada Total Funding: 6,000,000 (Canadian dollar) Funding Competitive? Yes
2013/04 - 2017/03 <b>Principal Applicant</b>	HCV Treatment as Prevention among HIV Co-Infected Individuals: Great Promise and Big Challenges.	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 278,088 (Canadian dollar) Funding Competitive: Yes

2013/09 - 2016/08 Co-applicant	Cost-effective integration of HIV care in opioid substitution treatment. Principal Applicant: Bohdan Nosyk	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 207,525 Funding Competitive? Yes
2011/04 - 2016/03 Co-applicant	Canadian HIV Women's Sexual and Reproductive Health Cohort Study, a Canadian Observational Cohort (CANOC) Affiliated Study. Principal Applicant: Robert Hogg	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 1,400,000 (Canadian dollar) Funding Competitive? Yes
2012/04 - 2015/07 Principal Applicant	Modeling different strategies to reduce the public health impact of the HCV/HIV epidemic.	
	<b>Funding Source</b>	AIDS-Science Track Award for Research Transition (R03) National Institute on Drug Abuse (NIDA) Total Funding: 125,798 (Canadian dollar) Funding Competitive? Yes
2012/03 - 2015/02 Co-applicant	Emphysema and inflamm-aging in HIV-seropositive patients. Principal Applicant: Paul Man	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 374,683 (Canadian dollar) Funding Competitive? Yes
2010/06 - 2013/12 Co-applicant	Effect of HAART expansion on community levels of HIV viral load and HIV risk behaviours among MSM in British Columbia. Principal Applicant: Robert Hogg	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 432,672 (Canadian dollar) Funding Competitive? Yes
2009/06 - 2013/12 Co-applicant	Scaling up treatment to reduce population HIV incidence Principal Applicant: Edward Mills	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 855,614 (Canadian dollar) Funding Competitive? Yes
2009/06 - 2013/12 Co-applicant	Development of an observational database of clinical characteristics and outcomes among HIV+ adults and children in Uganda. Principal Applicant: Edward Mills	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 293,606 (Canadian dollar) Funding Competitive? Yes
2008/10 - 2013/09 Co-applicant	Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDU. Principal Applicant: Julio Montaner	
	<b>Funding Source</b>	NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1)

		National Institute on Drug Abuse (NIDA) Total Funding: 2,500,000 (Canadian dollar) Funding Competitive? Yes
2007/05 - 2012/04 Co-applicant	Canadian Observational Cohort (CANOC) Collaboration. Principal Applicant: Robert Hogg	
	<b>Funding Source</b>	Emerging Team Grant - HIV/AIDS Research Initiative Canadian Institutes of Health Research (CIHR) Total Funding: 2,500,000 (Canadian dollar) Funding Competitive? Yes
2008/06 - 2011/12 Co-applicant	Improved Screening Methods for CCR5-Antagonists Use by Ultra Deep Sequencing and Quantitative Population-Based Sequencing Techniques: Analyzes of the Phase III Human Clinical Trials of Maraviroc. Principal Applicant: Richard Harrigan	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 690,659 (Canadian dollar) Funding Competitive? Yes
2010/01 - 2011/05 Principal Applicant	HAART as a Complementary Prevention Strategy to curb the HIV Epidemic in the Correctional System.	
	<b>Funding Source</b>	Operating Grant (R01 supplement) National Institute on Drug Abuse (NIDA) Total Funding: 104,552 (Canadian dollar) Funding Competitive? Yes
2007/04 - 2009/05 Co-applicant	An investigation based on viral envelope V3 sequence, syncytium formation and coreceptor usage in a large population of therapy-naive individuals as predictors of clinical prognosis for HIV-1 infected. Principal Applicant: Richard Harrigan	
	<b>Funding Source</b>	Open Operating Grant Program Canadian Institutes of Health Research (CIHR) Total Funding: 81,450 (Canadian dollar) Funding Competitive? Yes
2007/03 - 2008/10 Co-applicant	British Columbia's HIV Patient Safety Initiative: Population-based Surveillance System to Monitor Antiretroviral-related Adverse Events. Principal Applicant: Julio Montaner	
	<b>Funding Source</b>	Operating Grant Canadian Patient Safety Institute (CPSI) Total Funding: 237,277 (Canadian dollar) Funding Competitive? Yes

**(c) Research or equivalent contracts, including funding for clinical trials**

**Clinical Trials**

I have helped design this clinical trial by providing input on its grant writing and on the sample size calculation. My role was to advise on how to address the different goals of the trial (e.g., epidemiological models) and provide statistical support to all analyses. The statistical support is done by either performing the analyses myself or by supervising my team of statisticians. Additionally, I provide mentorship on the writing of abstracts and papers lead by project coordinators recruited through this grant.

Year & Role	Description
2011/06 - 2016/12 Co-applicant	STOP HIV in DU's: randomized clinical trial of contingency management for engagement and retention in care (CTN 248).

	Principal Applicant: Mark Hull and Julio Montaner	
	<b>Funding Source</b>	Epidemiology of Drug Abuse (R01) National Institute on Drug Abuse (NIDA) Total Funding: 620,080 (Canadian dollar) Funding Competitive? Yes

### Industry Funding

I was responsible for analyzing the data that GSK needed to use as input in their economic model to predict the natural history of HIV infection under different treatment scenarios. The deliverable was a final report, which included the data tables described in the proposal and statistical analysis plan.

Year & Role	Description	
06/2013 – 05/2014 Principal Investigator	Cohort Characteristics and Mortality in HIV+ Patients	
	<b>Funding Source</b>	GlaxoSmithKline Inc. Total Funding: 97,875 (Canadian dollar) Funding Competitive? No

### (d) Invited Presentations

#### International

##### *Main Audience: General*

- Lima VD *et al.* The combined impact of male circumcision, condom use and HAART coverage on the HIV HIV-1 epidemic in South Africa: A mathematical model. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa. July 19-22, 2009.
- Lima VD. Modeling HIV incidence: advantages and limitations for different epidemic settings. XIX International AIDS Conference (AIDS 2012). Washington, USA. July 24, 2012.
- Lima VD. Cascade of Care: Heterogeneity. 3<sup>rd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 22-25, 2013.
- Lima VD. Can the Combination of TasP<sup>®</sup> and PrEP Eliminate HIV among Gay, Bisexual and Other Men Who Have Sex with Men (MSM) in British Columbia, Canada? 22<sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases. Fuengirola, Spain. March 22-24, 2018.
- Lima VD. Can Unrestricted Access to Direct-Acting Antivirals (DAAs) Reach HCV Elimination WHO Targets in Key Populations in British Columbia (BC), Canada? 23<sup>rd</sup> International Workshop on HIV and Hepatitis Observational Databases. March 28-30, 2019. Athens, Greece.

#### International

##### *Main Audience: Decision Makers, Researchers and Physicians*

- Lima VD, Montaner JSG. What can we learn from the impact of dramatically scaling-up treatment on future costs and prevention efforts? The International AIDS Society (IAS), in partnership with the International Center for AIDS Care and Treatment Programs (ICAP) and The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund): Accelerating the Impact of HIV Programming on Health Systems Strengthening. Cape Town, South Africa. July 17-18, 2009.
- Lima VD, Montaner JSG. HAART as a Complementary Prevention Strategy to curb the HIV Epidemic in the US Correctional System. National Institutes of Health. Washington, DC, USA. January 11-13, 2010.
- Lima VD, Montaner JSG. The potential impact of PrEP and HAART roll-out programs in British Columbia, Canada. World Health Organization (WHO) & The Joint United Nations Programme on HIV/AIDS (UNAIDS): Preparing for PrEP: bridging from science to implementation. Geneva, Switzerland. March 8-9, 2010.

- Lima VD. Discussant: PANEL 3: Epidemiology and Economics - Modeling Scenarios for the End of AIDS. TasP PrEP EVIDENCE SUMMIT 2013. Controlling the HIV Epidemic with Antiretrovirals: From Consensus to Implementation. Queen Elizabeth II Conference Centre, London, UK. 22-24 September 2013.
- Lima VD. Modelling the Impact of TasP for HIV. Chinese Center for Disease Control visit. Beijing, China. November 25-27, 2013.
- Lima VD. Exporting the Success of the “HIV Treatment as Prevention” Strategy to Control the HCV Epidemic. Chinese Center for Disease Control visit. Beijing, China. November 25-27, 2013.
- Modeling the Cost of Pediatric HIV Treatment Scale-Up: Focus on Pediatric Mortality”, UNAIDS/EGPAF/WHO/UNICEF consultation Moving to the Final Chapter of AIDS: A Final Set of Global Paediatric Treatment Targets. Geneva, Switzerland. June 10, 2014.
- Lima VD. Statistics and Modeling. Satellite Computational Models of HIV/AIDS: Sharing New Tools and Ideas. 8<sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, British Columbia, Canada. July 21, 2015.
- Lima VD. Mathematical Modeling in HIV and HCV. Chinese Center for Disease Control visit. Beijing, China. October 28, 2018.

## **National**

### **Main Audience: Decision Makers, Researchers and Physicians**

- Lima VD. Predicting the future of the HIV epidemic: The dynamic between high HAART usage and prevalence of drug-resistant strains of HIV. British Columbia Centre for Disease Control (BC-CDC). Vancouver, British Columbia, Canada. January 14, 2007.
- Lima VD. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. Forefront Series. British Columbia Centre for Excellence in HIV/AIDS. Vancouver, British Columbia, Canada. September 3, 2008.
- Lima VD. Mathematical Models for CDC in China. British Columbia Centre for Excellence in HIV/AIDS. Vancouver, British Columbia, Canada. October 28, 2010.
- Lima VD. HIV Modeling. University College of London & UBC Workshop. British Columbia Centre for Excellence in HIV/AIDS. Vancouver, British Columbia, Canada. February 23, 2011.
- Lima VD. Presentation to Dr. Marc Ouellette Scientific Director of the Canadian Institutes of Health Research’s Institute of Infection and Immunity. Modeling the Impact of TasP. British Columbia Centre for Excellence in HIV/AIDS. Vancouver, British Columbia, Canada. March 15, 2011.
- Lima VD. Presentation to Dr. Diane Finegood President and CEO of the Michael Smith Foundation of Health Research. Modelling the Impact of TasP for HIV/HCV. Vancouver, British Columbia, Canada. March 10, 2014.
- Lima VD. Presentation to Dr. John Ward Director of the Division of Viral Hepatitis at the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, US Centers for Disease Control. Exporting the Success of the “HIV Treatment as Prevention” Strategy to Control the HCV Epidemic. Vancouver, British Columbia, Canada. March 2, 2014.
- Lima VD. "Mathematical Modeling and Epidemiological Studies", UNAIDS Consultation. Vancouver, British Columbia, Canada. May 27, 2014.
- Lima VD. Mathematical Modeling. Presentation to researchers and health representatives of Queensland, Australia. Vancouver, British Columbia, Canada. March 6, 2015.
- Lima VD. Statistics and Modeling. Presentation to Saskatchewan Health Representatives. British Columbia Centre for Excellence in HIV/AIDS. Vancouver, British Columbia, Canada. July 19, 2015.
- Lima VD. Presentation to Dr. Martha Piper, UBC Interim President. Modeling the Impact of TasP on the HIV and HCV epidemics. Vancouver, BC. February 18, 2016.
- Lima VD. Mathematical Modeling in HIV. Presentation to the Public Health Agency of Canada. Mathematical Modeling in HIV. Vancouver, BC. March 1, 2016.
- Lima VD. Presentation to the Public Health Agency of Canada. Modeling the Impact of TasP on the HIV and HCV epidemics. Vancouver, BC. May 2, 2016.
- Lima VD. Presentation to British Columbia Centre for Excellence in HIV/AIDS’s Committee for Drug Evaluation and Therapy. Patterns of ARV drug utilization, forecasting and guidelines. Vancouver, BC. June 22, 2016.
- Lima VD. Presentation to BC’s PharmaCare. PrEP in Men Who Have Sex with Men. Vancouver, BC. July 11, 2016.
- Lima VD. Presentation to BC’s PharmaCare. 90-90-90 End of AIDS Scenarios for BC. Vancouver, BC. July 11, 2016.



- Lima VD. Presentation to BC's PharmaCare. PharmaCare Analysis for Generics. Vancouver, BC. July 11, 2016.
- Lima VD. Presentation to Saskatoon Tribal Council. Modeling the Impact of TasP on the HIV and HCV epidemics. Vancouver, BC. September 30, 2016.
- Lima VD. STOP HIV/AIDS Steering Committee. The "Situation Room": an interactive web-based mapping application. Victoria, BC. October 7, 2016.
- Lima VD. Presentation to STOP HIV/AIDS Collaborative Implementation Committee. The "Situation Room": an interactive web-based mapping application. Vancouver, BC. October 18, 2016.
- Lima VD. BC Northern Health Lead authority. Title: The "Situation Room": an interactive web-based mapping application. Victoria, BC. December 6, 2016.
- Lima VD. Presentation to BC's First Nation Health Lead authority. Mathematical Modeling & Forecasting UN 90-90-90 Target. BC Cascade of Care. Vancouver, BC. February 24<sup>th</sup>, 2017.
- Lima VD, Rozada I. Presentation to Providence HealthCare Chair and Director. Statistical and Mathematical Modeling. Vancouver, BC. June 22<sup>nd</sup>, 2017.
- Lima VD. REACH Implementation Science Collaboration Meeting. BC Cascade of Care. Toronto, ON. June 26-27, 2017.
- Lima VD. Presentation to BC's PharmaCare. Fiscal Impact Forecast. Vancouver, BC. November 3<sup>rd</sup>, 2017.
- Lima VD. Presentation to BC Deputy Minister of Health and STOP HIV/AIDS Steering Committee. PrEP Modelling Study and The 90-90-90 Target Forecast. Victoria, BC. January 26, 2018.
- Lima VD. STOP HIV/AIDS in BC. Public Health Agency of Canada. National HIV Estimates Face to Face Meeting. Ottawa, Ontario. December 4-5, 2019.
- Lima VD. Drug Cost Impact Analysis. British Columbia Centre for Excellence in HIV/AIDS's Committee for Drug Evaluation and Therapy (former HIV Therapeutic Guidelines Committee). Vancouver, British Columbia. February 7, 2019.
- PrEP Indicators Webinar. In this webinar, I presented the proposed new indicators to monitor the progress of the Pre-Exposure Prophylaxis (PrEP) program in British Columbia. Target Audience: Health Authorities, Ministry of Health and Researchers. Vancouver, British Columbia, Canada. November 19, 2019.
- STOP HIV/AIDS Indicators Webinar. In this webinar, I presented the proposed new indicators to monitor the progress of the STOP HIV/AIDS program in British Columbia, which aims to expand "Treatment as Prevention" in BC. Target Audience: Health Authorities, Ministry of Health and Researchers. Vancouver, British Columbia, Canada. January 31, 2019.
- Lima VD. Current Research Areas. UBC Division of Infectious Diseases Retreat. Vancouver, Canada. January 18, 2020.
- Lima VD. Evolving Patterns of Brand and Generic Antiretroviral Drug Utilization Within a Universal Healthcare System in Canada. Virtual 30<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2021), May 6, 2021.
- Lima VD. The Use of Administrative Data in British Columbia. CAHR 2022 Virtual Epidemiology & Public Health Sciences Special Session – Using Administrative Data to Support the HIV Care Cascade in Key Populations. April 27, 2022

## **(e) Invited Participation**

### **Advisor for National/International Agencies**

#### **Current**

- Public Health Agency of Canada. National HIV Cascade Working Group (03/2014 - present).
  - In this collaboration, my role is to advise the Public Health Agency of Canada on the definitions for the 90-90-90 Target to end the AIDS epidemic in Canada. I also provide data from BC to use as input in their mathematical model to estimate the HIV incidence and prevalence in BC and Canada.
- Canadian Association for HIV Research. Board Member. Director of Epidemiology and Public Health (05/2021 – present)
  - In this collaboration, one of my roles is to advise on different issues raised as part of the management of the Canadian Association for HIV Research. In addition, I am responsible for expanding the Epidemiology and Public Health portfolio of the Association (e.g., suggesting/planning workshops). Last, I participate in the organization of the national HIV conference.

- International Association of Providers of AIDS Care (IAPAC)-Lancet HIV Commission on the Future of Urban HIV Responses. Commissioner, Modelling Subcommittee (05/2021 – present)
  - As a Commissioner, my role is to advise on and contribute to a report aimed at: (1) Reflecting on the calculus of political will, community engagement, and data-driven/equity-based HIV responses to close gaps across the HIV prevention/care continua and end HIV-related stigma; (2) Documenting experiences, lessons learned, and best practices in urban HIV responses; (3) Reinforcing the need to address HIV-associated co-morbidities and syndemic conditions; (4) Examining structural barriers to achieving SDGs 3.3 and 11 in urban settings (e.g., social and economic inequality, health and other disparities, and intersectional stigma; and (5) Addressing the threat posed by the COVID-19 pandemic and future pandemics.
  - I am also responsible for co-leading the mathematical modelling sub-group of the Commission in collaboration with Dr. Brian Williams (South Africa)

## Completed

**In these agencies, I served as an Advisor on mathematical modelling and the control of the HIV epidemic in Canada and internationally.**

- The International AIDS Society (IAS), in partnership with the International Center for AIDS Care and Treatment Programs (ICAP) and The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund): Bridging the Divide: Inter-Disciplinary Partnerships for HIV and Health Systems (07/2009).
- World Health Organization (WHO): WHO Meeting: ART for Prevention: modeling, evaluating and testing the impact on HIV and TB (11/2009).
- World Health Organization (WHO) & The Joint United Nations Programme on HIV/AIDS (UNAIDS): Preparing for PrEP: bridging from science to implementation (03/2010).
- The International AIDS Society (IAS), in partnership with the International Center for AIDS Care and Treatment Programs (ICAP) and The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund): Bridging the Divide: Inter-Disciplinary Partnerships for HIV and Health Systems (07/2010).
- HIV Modelling Consortium Meeting. The Potential Impact of Treatment on HIV Incidence (11/2011).
- UNAIDS. Modelling the impact and costs of introducing new prevention technologies to end the HIV pandemic (04/2012).
- UNAIDS. Modelling the impact and costs of introducing new prevention technologies to end the HIV pandemic (10/2012).
- UNAIDS/EGPAF/WHO/UNICEF consultation Moving to the Final Chapter of AIDS: A Final Set of Global Paediatric Treatment Targets (06/2014).
- Consultant - Brazilian Ministry of Health Department of STD, AIDS and Viral Hepatitis. August 25- 29, 2014
- Advisory Panel Member - IAPAC (International Association of Providers of AIDS Care) guidelines on optimizing the HIV treatment cascade (04/2013 – 09/2015).
- Advisory Panel Member - Joint United Nations Programme on HIV/AIDS (UNAIDS). Treatment 2015 Advisory Committee (04/2014 – 04/2015).
- Brazilian Ministry of Health Department of STD, AIDS and Viral Hepatitis. July 8-22, 2015
- Brazilian Ministry of Health Department of STD, AIDS and Viral Hepatitis. May 9-13, 2016
- Modelling Advisor - Medicines Patent Pool. (08/2015 – 12/2017)
- Public Health Agency of Canada. National HIV Estimates. Ottawa, Ontario. December 4-5, 2019.

## (f) Conference Participation

- Moderator - Abstract-Driven Session II – 3<sup>rd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 24, 2013. *A total of 235 delegates from 41 countries attended the Workshop, including 58 sponsored delegates from 28 countries, and a total of 28 sponsored delegates from resource-limited settings hardest hit by the HIV/AIDS epidemic worldwide.*
- Moderator - Session What Works and What Doesn't – 4<sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 4, 2014. *A total of 202 participants from 41 countries attended the Workshop, including 24 sponsored delegates from resource-limited settings hardest hit by the HIV/AIDS epidemic worldwide.*
- Mentor - 27<sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2018) HIV Researcher Workshop.

**(g) Other Presentations**

**(h) Other Scholarship of Education Activities**

**(i) Other Professional Contributions**

**10. SERVICE TO THE UNIVERSITY**

**(a) Areas of special interest and accomplishments**

As described in the next sections, I have been part of several committees at UBC.

**(b) Memberships on committees, including offices held and dates**

<b>Year &amp; Role</b>	<b>Description</b>	
08/2017-10/2020	Department of Medicine's Academic Appointments, Reappointments, Promotions and Tenure Committee University of British Columbia	
	<b>Duties</b>	The committee is comprised of members from the academic and clinical streams who discuss and vote on cases as a group.
02/2018-03/2018 Member	School of Population and Public Health MPH Admissions Committee University of British Columbia	
	<b>Duties</b>	To review MPH applications for the September 2018 intake
09/2018-present Executive Member	Experimental Medicine Program Executive Committee University of British Columbia	
	<b>Duties</b>	The committee is comprised of different faculty members that discuss topics ranging from graduate school scholarships to curriculum changes in the department.
09/2018-present Member	Experimental Medicine Program Awards Committee University of British Columbia	
	<b>Duties</b>	To review all awards (UBC, CIHR and others) that students from the Program apply to. Usually, there are 7 awards that the committee needs to review per year, with the number of applicants for most awards ranging 5 to over 20.
11/2018-present Member	Providence Health Care Research Ethics Board (REB) University of British Columbia	
	<b>Duties</b>	The Providence Health Care REB oversees all research involving human subjects at Providence Health Care to ensure that the research on our patients meets the highest scientific and ethical standards. I usually review 1-2 studies per month.
10/2019 Member	Department of Medicine Infectious Diseases Division Head Search Committee University of British Columbia	
	<b>Duties</b>	To identify the new Infectious Disease Division Head at the University of British Columbia's Faculty of Medicine.

*Also, see section 8(d)*

**(c) Faculty mentoring**

I received mentoring from Dr. Jacek Kopec through the Faculty Mentoring Program from the Department of Medicine, Faculty of Medicine, University of British Columbia – 04/2011 to 06/2016.

**(d) Other service, including dates**

<b>Year &amp; Role</b>	<b>Description</b>
------------------------	--------------------

04/2013 Internal Reviewer	Department of Medicine Merit and Performance Salary Adjustment Award committee member University of British Columbia	
	<b>Duties</b>	I reviewed CVs of assistant professors and made recommendations based on their academic performance. Applicant: Assistant Professor Antonio Aviña-Zubieta UBC, Faculty of Medicine, Department of Medicine, Division of Rheumatology
08/2013 Internal Reviewer	SPARC Internal Review for grants being submitted to the Canadian Institutes of Health Research University of British Columbia	
	<b>Duties</b>	To conduct a scholarly peer review and provide constructive written feedback (i.e. track changes, notes on hard copy, summary report) intended to improve the quality of the researcher's grant application. Applicant: Professor Jane Buxton UBC, School of Population and Public Health
02/2014 Internal Reviewer	SPARC Internal Review for grants being submitted to the Canadian Institutes of Health Research University of British Columbia	
	<b>Duties</b>	To conduct a scholarly peer review and provide constructive written feedback (i.e. track changes, notes on hard copy, summary report) intended to improve the quality of the researcher's grant application.

SPARC: Support Programs to Advance Research Capacity (<http://sparc.ubc.ca/sparc>)

## 11. SERVICE TO THE HEALTH PROFESSIONS/HEALTH AUTHORITIES

### (a) Areas of special interest and accomplishments

#### Service to Health Professionals

As the Scientist and Senior Methodologist at the British Columbia Centre for Excellence in HIV/AIDS, I have been the supervisor and mentor of a multidisciplinary research team since 2006 consisting of epidemiologists, biostatisticians and mathematical modellers. These individuals either work in my Research team or provide support to all research staff at the British Columbia Centre for Excellence in HIV/AIDS. As part of my mentorship role, I encourage these individuals to appraise the literature critically and apply advanced methods to address the research questions posed to them. I also invest in the professional development of these individuals by paying or raising funds for conferences they are interested in attending and courses to advance their analytical skills. At last, all of these individuals have been able to publish their own research questions, or have published with other researchers at the British Columbia Centre for Excellence in HIV/AIDS in high-impact peer-reviewed journals. Some individuals have gone on to pursue successful academic or medical careers. *It is important to mention that I also provide technical support to the Centre's Director, other researchers affiliated or collaborating with the Centre; this includes statistical, mathematical and epidemiological support and consultation.*

#### Current Members of my Research and Operational Team

- MSc level Biostatistician. Wendy Zhang (07/2007-present)
- MSc level Biostatistician. Erin Ding (11/2012-present)
- MSc level Biostatistician. Clara Wang (05/2015-present)
- MSc level Biostatistician. Monica Ye (01/2016-present)
- MSc level Biostatistician. Tian Shen (09/2020-present)
- MSc level Biostatistician. Neil Faught (01/2022-present)
- PhD level Mathematical Modeller. Jielin Zhu (01/2017-present)
- MSc level Epidemiologist. Lalani Munasinghe (10/2021-present)
- MPH level Epidemiologist. Bronhilda Takeh (05/2022-present)

#### Past Members of my Team

- (01/2012-04/2012) PhD level Mathematical Modeller. Miss Isabell Graf was a visiting PhD student in mathematics visiting from Germany. She was hired to work on the US Criminal Justice System HIV Modeling Project
- (2006-2014) MSc level Biostatistician. Mr. Keith Chan is now working as a statistician for Redwood Outcomes, Vancouver, British Columbia, Canada.
- (2007-2009) MSc level Biostatistician. Mrs. Kimberly Fernandes is now working as an analyst at the Institute for Clinical Evaluative Science, Toronto, Canada.
- (2009-2011) MSc level Biostatistician. Mr. Steve Kanters finished his PhD at the University of British Columbia. He is now the head of biostatistics at Doctor Evidence, LLC, ed Vancouver, British Columbia, Canada.
- (2007-2010) BSc level Epidemiologist. Mr. Eric Druyts has finished his PhD at the University of British Columbia. He is now the founding partner at Pharmalytics Group, Vancouver, British Columbia, Canada.
- (01/2009-04/2009) Visiting physician from Argentina. Mrs. Valeria Fink is now working for Fundación Huésped in Argentina.
- (11/2014-05/2015) Visiting physician from South Africa. Mrs. Anja Reuter is now in South Sudan working for Médecins Sans Frontières.
- (11/2011-03/2014) MSc level Biostatistician. Miss Jeong Min is now working for the Health Economic Unit at CHEOS.
- (09/2013-07/2015) MPH level Epidemiologist. Mrs. Lillian Lourenço is now working for the Canadian Centre for Addiction and Mental Health in Toronto, Canada.
- (05/2014-08/2015) MSc level Statistician. Mrs. Huiting Ma is now working for St-Michael’s Hospital in Toronto, Canada.
- (03/2014-11/2015) MSc level Statistician. Mrs. Adriana Nopal.
- (06/2015-09/2016) MSc level Mathematical Modeller. Mr. Keith Poore
- (09/2015-04/2017) MSc level Statistician. Mr. Conrado Franco Villalobos. Moved to Montreal.
- (08/2013-05/2018) PhD level Mathematical Modeller. Dr. Ignacio Rozada. Working in a tech company.
- (09/2017-09/2018) MSc level Biostatistician. Mr. Tian Li. Moved to Toronto.
- (09/2017-09/2018) MSc level Biostatistician. Mr. Roy Pan. Started PhD at UBC.
- (06/2013-03/2020) MSc level Biostatistician. Zinshan Cui. Started PhD at UBC
- MSc level Epidemiologist. Martin St. Jean (08/2015-10/2020). Working for Vancouver Coastal Health Authority.
- MSc level Epidemiologist. Sony Subedi (02/2019-10/2020). Working for First Nation Health Authority.
- MPH level Research Coordinator/Epidemiologist. Adrianna Paiero (02/2019-12/2020). Working for Fraser Health Authority.
- MSc level Biostatistician. Hiwot Tafessu (09/2018-05/2021). Working for an American company.
- PhD level Epidemiologist. Emmanuel Dankwah (01/2021-09/2021). Returned to his home country.
- MPH level Epidemiologist. Alejandra Fonseca (01/2021-05/2022). Returned to her home country.
- MSc level Biostatistician. Tom Park (07/2021-06/2022)

**Service to Health Authorities and the Provincial Government**

My first mathematical model, assessing the long-term impact of “Treatment as Prevention” (TasP) on the HIV epidemic, provided key evidence to the Provincial Government that TasP can be used to reduce HIV transmission and associated costs in British Columbia (Lima VD, et al. J Infect Dis. 2008; 198:59). I received an award for this model from the International AIDS Society in 2007, and my results were used as evidence by the Provincial Government to fund a multimillion-dollar TasP initiative called STOP HIV/AIDS (<http://stophiv aids.ca>). Additionally, I independently validated the IAS-USA ART guidelines by developing a non-compliance indicator to predict treatment outcomes (Lima VD, PLoS One. 2012; 7(11):e47859). The British Columbia Ministry of Health Services and physicians now use this indicator to monitor HIV-patients across the province (<http://stophiv aids.ca>).

**(b) Memberships on committees, including offices held and dates**

Year & Role	Description
10/2015 - present Member	Drug Evaluation and Therapy (former HIV Therapeutic Guidelines Committee) British Columbia Centre for Excellence in HIV/AIDS

	<b>Duties</b>	I provide feedback in the development of the Therapeutic Guidelines for The Antiretroviral Treatment (ARV) of Adult HIV Infection in British Columbia, Canada. I provide statistical support to address pressing issues that the committee identifies. Recently, I developed a Tier scheme to approve the dispensation of different antiretrovirals so it does not negatively affect the Pharmacare budget for HIV. <a href="http://bccfe.ca/therapeutic-guidelines/guidelines-antiretroviral-arv-treatment-adult-hiv-infection">http://bccfe.ca/therapeutic-guidelines/guidelines-antiretroviral-arv-treatment-adult-hiv-infection</a>
12/2010-present Member	Continuous Quality Improvement Committee British Columbia Centre for Excellence in HIV/AIDS	
	<b>Duties</b>	My role is to develop early warning indicators that will flag poor patient outcomes and structural issues that impact the quality of patient care.
11/2011-present Member	Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) Technical Monitoring Committee Government of British Columbia	
	<b>Duties</b>	I review requests for statistical analyses using the STOP HIV/AIDS dataset and I also conduct all complex statistical analyses requested by the Director of the British Columbia Centre for Excellence in HIV/AIDS.
11/2015-present Member	Healthy Aging with HIV Working Group British Columbia Centre for Excellence in HIV/AIDS	
	<b>Duties</b>	I help address issues related to the delivery of Antiretroviral Treatment and management of comorbid conditions among older individuals living with HIV
01/2018 – present Member	Pre-Exposure Prophylaxis (PrEP) Working Group Government of British Columbia	
	<b>Duties</b>	I support the evaluation of BC's PrEP program initiated in early 2018; this includes the creation and validation of a set of programmatic compliance indicators to evaluate the programs progress and prediction of the long-term impact on the HIV epidemic in BC.
01/2018 – present Member	Data Quality British Columbia Centre for Excellence in HIV/AIDS	
	<b>Duties</b>	I help address issues related to data quality of all data stored at the British Columbia Centre for Excellence in HIV/AIDS. The Committee develops standards for data entry and monitoring to minimize coding error and flag any issue that needs attention.
10/2019 – present Member	Scientific Review Group British Columbia Centre for Excellence in HIV/AIDS	
	<b>Duties</b>	I help evaluate the scientific merit of proposed research projects at the BC Centre for Excellence in HIV/AIDS .
12/2020 – present Member	Privacy Group British Columbia Centre for Excellence in HIV/AIDS	
	<b>Duties</b>	I help address issues related to privacy matters (e.g., policies, agreements, training) at the British Columbia Centre for Excellence in HIV/AIDS.

**(c) Other service, including dates**

**12. SERVICE TO THE COMMUNITY**

**(a) Areas of special interest and accomplishments**

Due to my productivity and the quality of my research outputs, I was invited to review numerous articles for several high-impact peer-reviewed journals. In 2015, due to my contribution history at PLoS One, I was invited to be one of its Academic Editors. Additionally, I have been selected to be a reviewer for the Canadian Institutes of Health Research at several instances and the scientific officer for scholar applications for the Michael Smith Foundation for Health Research, among other important recognitions.

**(b) Memberships on scholarly societies, including offices held and dates**

- International AIDS Society (07/2006-present)
- Canadian Association for HIV Research (04/2015-present)

**(c) Memberships on other societies, including offices held and dates**

**(d) Memberships on scholarly committees, including offices held and dates**

- Scientific Advisory Committee Member – 1st International HIV Treatment as Prevention Workshop. Vancouver, BC. April 2011.
- Scientific Advisory Committee Member – 2nd International HIV Treatment as Prevention Workshop. Vancouver, BC. April 2012.
- Scientific Advisory Committee Member – 3rd International HIV Treatment as Prevention Workshop. Vancouver, BC. April 2013.
- Scientific Advisory Committee Member – 4th International HIV Treatment as Prevention Workshop. Vancouver, BC. April 2014.
- Co-chair – Epidemiology and Population Health Sciences Track; 27<sup>th</sup> Conference of the Canadian Association for HIV Research. Vancouver, BC. April 2018.
  - Duties: meetings between co-chairs, contacting presenters, deciding which abstracts would be oral/poster presentations, introducing presenters and awardees at the conference.
- Abstract Judge – University of British Columbia Department of Medicine Research Expo. Vancouver, BC. November 7, 2018.

**(e) Memberships on other committees, including offices held and dates**

- Member – The Antiretroviral Therapy Cohort Collaboration (ART-CC) (07/2006-03/2019)
  - The ART Cohort Collaboration has established a multidisciplinary group of collaborations in epidemiology, clinical research, biostatistics, data and basic science. It includes 20 cohort studies from Europe and North America, was established to estimate prognosis of people living with HIV, treatment naïve patients initiating antiretroviral therapy. In this collaboration, I have performed statistical analyses, performed data quality checks for the cohort data from British Columbia, contributed as an author in different papers, and participated in grant/study planning meetings.
- Member – The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (05/2018-present)
  - The NA-ACCORD is the North American regional representative of the International epidemiologic Databases to Evaluate AIDS (IeDEA). It has established a multidisciplinary group of collaborations in epidemiology, clinical research, biostatistics, data and basic science. Comprised of over 20 collaborating cohorts, NA-ACCORD is widely representative of HIV care in the United States and Canada. In this collaboration, I have advised on statistical analyses, performed data quality checks for the cohort data from British Columbia, contributed as an author in different papers, and participated in grant/study planning meetings.
- Member – US Veterans Aging Cohort Study (VACS) Polypharmacy Research Group (05/2019-present)
  - In this collaboration, we discuss different projects related to the impact of aging and polypharmacy among those living with HIV. In this collaboration, I am leading a study, I have advised on statistical analyses and design of different studies.

**(f) Editorships (list journal and dates)**

- Academic Editor – PLoS One (02/2015 – present)
- Handling Editor – PLoS One; Call for Papers ‘Mathematical Modelling of Epidemiology’ (03/2019-09/2019)

**(g) Reviewer (journal, agency, etc. including dates)**

**Peer-Reviewed Journals**

- **International**
  - \* J Infect Dis (07/2006-present)
  - \* Clin Infect Dis (06/2008-present)
  - \* J Int AIDS Soc (03/2009-present)
  - \* BMJ (05/2009-present)
  - \* J Clin Virol (05/2009-present)

- \* J Acquir Immune Defic Syndr (05/2009-present)
- \* Therapy (05/2009-present)
- \* Soc Sci Med (07/2009-present)
- \* Antivir Therapy (07/2009-present)
- \* AIDS Care (01/2010)
- \* BMC-series journals (07/2010-present)
- \* JAMA (07/2010-present)
- \* PLoS One (11/2011-present)
- \* The Lancet (05/2012)
- \* Ann Hepatol (11/2012-present)
- \* Trop Med Int Health (1/2013)
- \* Hepatol (09/2015-present)
- \* Drug Alcohol Depend (01/2013-present)
- \* Lancet Infect Dis (06/2014-present)
- \* Sex Transm Infect (02/2015-present)
- \* Lancet HIV (02/2015-present)
- \* Ann Intern Med (02/2015-present)
- \* Applied Math Modelling (06/2017-present)
- \* American Journal of Epi (01/2019-present)

- **National**

- \* CMAJ (05/2011-present)

### Peer-Reviewed Conference Abstracts

- **International**

- \* 1<sup>st</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 2011.
- \* 2<sup>nd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 2012.
- \* 3<sup>rd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 2013.
- \* 4<sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia, Canada. April 2014.
- \* 8<sup>th</sup> Conference of the International AIDS Society. Vancouver, British Columbia, Canada. July 2015.
- \* 21<sup>st</sup> International AIDS Conference. Durban, South Africa. July 2016.
- \* 9<sup>th</sup> Conference of the International AIDS Society. Paris, France. July 2017.
- \* 22<sup>nd</sup> International AIDS Conference. Amsterdam, The Netherlands. July 2018.
- \* 10<sup>th</sup> International AIDS Society Conference on HIV Science (IAS 2019). Mexico City, Mexico. July 2019.
- \* 23<sup>rd</sup> International AIDS Conference (AIDS 2020). San Francisco & Oakland, United States. July 2020.
- \* 11<sup>th</sup> International AIDS Society Conference on HIV Science (IAS 2021). Virtual. July 2021.
- \* 24<sup>th</sup> International AIDS Conference (AIDS 2022). Montreal, Canada. July 2022.

- **National**

- \* 2015 Conference of the Canadian Association for HIV Research. Toronto, Ontario, Canada. April, 2015.
- \* 2016 Conference of the Canadian Association for HIV Research. Winnipeg, Manitoba, Canada. May, 2016.
- \* 2017 Conference of the Canadian Association for HIV Research. Montreal, Quebec, Canada. April, 2017.

### Peer-Reviewed Conference Participation

- \* Moderator for Oral Abstract Session. 24<sup>th</sup> International AIDS Conference (AIDS 2022). Montreal, Canada. July 2022.

### Grant Agencies

Declined invitations are not shown here.



- Grant Peer Reviewer - Public, Community & Population Health 2 Committee, 2010; Canadian Institutes of Health Research (05/2010-12/2010)
- Scientific Officer - Scholar program competition for the Population Health research theme, 2014; Michael Smith Foundation for Health Research (01/2014-07/2014)
- Grant Peer Reviewer - Planning and Dissemination Grants for the Institute Community Support, 2014; Canadian Institutes of Health Research (01/2014-12/2014)
- Reviewer - Doctoral Research Awards B Committee, 2015-2018 - Population Health Research Peer Review Panel; Canadian Institutes of Health Research (07/2015-present)
- Peer reviewer - Operating Grant Innovative Biomedical and Clinical HIV/AIDS Research, 2016; Canadian Institutes of Health Research (05/2016-12/2016)
- Member - College of Reviewers; Canadian Institutes of Health Research (07/2017-present)
- Reviewer - New Investigator Award competition, 2018; University of Washington/Fred Hutch Center for AIDS Research (CFAR) (07/2018)
- Panel Member - Research Trainee Competition, 2018 & 2019; Population Health Research Review Panel, Michael Smith Foundation for Health Research (05/2018-present)
- Peer reviewer – Analysis of CLSA Data Catalyst Grant; Canadian Institute of Health Research (12/2019)
- Peer reviewer for the Canada Research Chairs Program (2019; 2020)
- Peer reviewer - Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C competition; Canadian Institute of Health Research (07-08/2021)
- Scientific Officer - Catalyst Grant: STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C competition; Canadian Institute of Health Research (07-08/2021)

**(h) External examiner (indicate universities and dates)**

- Mr. Bewketu Teshale Bekele. PhD Thesis. Department of Mathematics, University of Stellenbosch, South Africa. (12/2015)

**(i) University examiner (indicate universities and dates)**

- Ms. Tingting Yu. PhD Thesis examiner. Department of Statistics, University of British Columbia, Vancouver, Canada. (12/2018)
- Ms. Amber R. Campbell. MSc Thesis Chair. Experimental Medicine Program, University of British Columbia, Vancouver, Canada. (03/2020)
- Ms. Shayda Swan. PhD Comprehensive Exam Chair. Experimental Medicine Program, University of British Columbia, Vancouver, Canada. (06/2022)

**(j) Consultant (indicate organization and dates)**

*To avoid repetition, please see item 9(e)*

**(k) Other service to the community**

**Interviews**

- Research Profile - Following your HAART - Canadian Institutes of Health Research. October 29, 2010.
- B.C. treatment as prevention strategy gains ground on HIV/AIDS by André Picard - Public Health Reporter of The Globe and Mail. Interview Tuesday, February 10, 2015, 2:00 PM PST. Published Thursday, February 12, 2015, 7:41 PM EST.
- Global News: BC 1 by Sonia Sunger. Interview Monday, February 16, 2015, 11:30 AM PST.

**Organization of Workshops and other Knowledge Translation Activities**

Year & Role	Description	
2011	Quality Improvement	
	Duties	Group/Organization/Business Serviced: British Columbia Ministry of Health Services

		<p><b>Target Stakeholder:</b> Healthcare Personnel</p> <p><b>Outcome / Deliverable:</b> Programmatic Indicator</p> <p><b>Evidence of Uptake/Impact:</b> The British Columbia Ministry of Health Services and physicians now use this indicator to monitor HIV-patients across the province</p> <p><b>References / Citations / Web Sites:</b> <b>Reference:</b> Lima VD, PLoS One. 2012;7(11):e47859;</p> <p><b>Website:</b> <a href="http://stophiv aids.ca">http://stophiv aids.ca</a></p> <p><b>Activity Description:</b> I independently validated the IAS-USA ART guidelines by developing a non-compliance indicator to predict HIV treatment outcomes.</p>
2018-present	Statistical Reviews	
	<b>Duties</b>	I created an informal 1-hour workshop that happens once per month at the British Columbia Centre for Excellence in HIV/AIDS. In this workshop, different presenters (including myself) present a topic related to Biostatistics and Epidemiology. This workshop is attended by ~20 employees and students from the British Columbia Center for Excellence in HIV AIDS.

### 13. AWARDS AND DISTINCTIONS

#### (a) Awards for Teaching

#### (b) Awards for Scholarship

#### Salary Support Award

#### Completed Funding

Year & Role	Description	
2012/07 - 2020/06 Principal Applicant	Operations research applied to assess different strategies to reduce the public health and economic burdens of HIV/AIDS in British Columbia.	
	<b>Funding Source</b>	2012 Career Investigator Scholar Award Michael Smith Foundation for Health Research Total Funding: 390,000 (Canadian dollar) The funding for this award was adjusted to top-up the CIHR award Funding Competitive? Yes
09/2005 – 02/2006 Principal Applicant	Computerized adaptive testing in back pain: validation of the CAT-5D-QOL.	
	<b>Funding Source</b>	Fellowship Arthritis Research Centre of Canada Total Funding: 50,000 (Canadian dollar) Funding Competitive? No
06/2007 – 05/2010 Principal Applicant	Longitudinal Impact of Adherence on HIV/AIDS Disease Progression: Implications for Treatment Interventions.	
	<b>Funding Source</b>	Fellowship Award Program Canadian Institutes of Health Research (CIHR) Total Funding: 135,000 (Canadian dollar) Funding Competitive? Yes
02/2008-12/2011 Principal Applicant	Examining the Interplay between Adherence and Antiretroviral Treatment on Disease Outcomes over Time in HIV/AIDS Infected Patients.	
	<b>Funding Source</b>	Research Fellowship: Salary Support (Top-up for CIHR Fellowship) Michael Smith Foundation for Health Research Total Funding: 38,667 (Canadian dollar) <i>The funding for this award was adjusted to top-up the CIHR award</i> Funding Competitive? Yes

2013/07 - 2018/06 Principal Applicant	Operations research applied to assess different strategies to reduce the individual and public health burdens of HIV and HCV in British Columbia.	
	<b>Funding Source</b>	New Investigator Salary Award Canadian Institutes of Health Research (CIHR) Total Funding: 300,000 (Canadian dollar) Funding Competitive? Yes

**(c) Awards for Service**

Year	Description
2017	This award is given to faculty members based on the review of academic activities for the calendar year of 2013. This award was given to me in 2017, but it is retroactive to 2013.
	<b>Award Name</b> Outstanding Academic Performance in the Department of Medicine, Faculty of Medicine, University of British Columbia.
2018	This award is given to faculty members based on the review of academic activities for the calendar year of 2017.
	<b>Award Name</b> Outstanding Academic Performance in the Department of Medicine, Faculty of Medicine, University of British Columbia.
2019	This award is given to faculty members based on the review of academic activities for the calendar year of 2018.
	<b>Award Name</b> Outstanding Academic Performance in the Department of Medicine, Faculty of Medicine, University of British Columbia.
2020	This award is given to faculty members based on the review of academic activities for the calendar year of 2019.
	<b>Award Name</b> Outstanding Academic Performance in the Department of Medicine, Faculty of Medicine, University of British Columbia.
2021	This award is given to faculty members based on the review of academic activities for the calendar year of 2020.
	<b>Award Name</b> Outstanding Academic Performance in the Department of Medicine, Faculty of Medicine, University of British Columbia.

**(d) Other Awards**

**Conference Awards**

Year	Description
07/2007	Peer-Reviewed Abstract "Expanded access to HAART: A powerful strategy to curb the growth of the HIV epidemic and costs"
	<b>Award Name</b> Young Investigator Award 4 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention.
02/2009	Peer-Reviewed Abstract "Drug resistance monitoring practices are strongly associated with mortality"
	<b>Award Name</b> Young Investigator Award 16 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections
02/2010	Peer-Reviewed Abstract "Similar immunologic responses to modern HAART among injection drug users (IDU) and non-IDUs in a populational setting"
	<b>Award Name</b> Young Investigator Award 17 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections
02/2011	Peer-Reviewed Abstract "Why the MSM-driven HIV epidemic is not slowing down even in the presence of HAART?"

	<b>Award Name</b>	Young Investigator Award 18 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections
--	-------------------	--

### University Awards

Year & Role	Description	
12/2000	Awarded to the student with the highest standing in the “Epidemiological Methods” course	
	<b>Award Name</b>	The John Snow Prize School of Population and Public Health (formerly known as Department of Health Care and Epidemiology) University of British Columbia

## 14. OTHER RELEVANT INFORMATION (Maximum One Page)

### Future Research Work

In my research program for the next five years, I will continue to carry out studies to assess the burden of aging among people living with HIV (PLWH). In BC, these studies will use linked data from various complex administrative databases in British Columbia to generate a representative population-based longitudinal cohort with fully characterized clinical and health utilization data on all diagnosed PLWH. In these studies, I aim to: (1) identify the significant gaps in the delivery of care to aging PLWH in British Columbia using advanced statistical methods and mathematical modelling; (2) assess the impact of different syndemics involving determinants of health that exacerbate the burden of HIV and comorbidities; (3) assess the impact of polypharmacy on patient outcomes and healthcare utilization; and (4) assess the impact of COVID-19 on different priority populations and the delivery of care to PLWH. I have already assembled a multidisciplinary team involving physicians, epidemiologists, pharmacists, policymakers, statisticians, and mathematical modellers for these studies.

Through my international cohort collaborations (i.e., the NA-ACCORD and US Veterans Study), I also plan to conduct studies that cannot be done using data from BC due to sample size limitations and lack of information on key determinants of health at the population level (e.g., alcohol abuse). Through my international modelling collaboration through the IAPAC-Lancet HIV Commission, we plan to build different mathematical models to compare the HIV epidemic of different cities that adopted the Fast-Track Cities partnership to accelerate the HIV response to end the AIDS epidemic by 2030. These models will, for example: (1) estimate the current impact of the HIV epidemic in these cities and predict the course of the epidemic in view of different interventions; (2) estimate the impact of specific syndemics that impact health outcomes; (3) assess how COVID-19 disruptions affected care for hard-to-reach populations; and (4) highlight cities that need help in improving data surveillance systems to estimate what will take in their HIV response to end the AIDS epidemic.

I believe that these studies have the potential to provide comprehensive information and evidence to stakeholders designing national/international prevention strategies and health policies. Additionally, my research program will create considerable research opportunities and collaborations, and it will provide a setting where trainees will be supported across varied disciplinary and methodological backgrounds, further enhancing Canada’s competitive advantage in clinical and population health research.

### Future Teaching Activities

I hope to teach other courses at UBC focusing on my mathematical modelling, statistical and HIV clinical epidemiology. Currently, I am developing another elective course entitled “Medical Statistics” for 3<sup>rd</sup> and 4<sup>th</sup> year medical students. At last, through the Experimental Medicine Program, Statistics department and the School of Population and Public Health, I expect to continue to fulfill my duties as a supervisor of MSc, MPH and PhD students.

**SURNAME:** Lima

**FIRST NAME:** Viviane  
**MIDDLE NAME(S):** Dias

**Initials:** VDL  
**Date:** June 6, 2022

**Key to my contribution**

**Bold** – to highlight my name in each publication

Statistical/Model Supervisor – supervised statistical or mathematical modelling analyses

Statistician – performed all statistical analyses

Modeller – designed and implemented model and interpreted results

Supervisor – supervised design, analysis and writing of manuscript

Co-author – provided critical review of manuscript

Collaborator – is an author through a data collaboration

Lead author – wrote the first draft of manuscript, compiled co-authors revisions and managed manuscript submission

*Note that it is part of the authorship rules at the British Columbia Centre of Excellence in HIV/AIDS to include the directors of the departments that contributed data. They are Drs. Robert Hogg (2017 onward Dr. Rolando Barrios) (Epidemiology and Public Health), Zabrina Brumme (Previously Dr. Richard Harrigan; Laboratory) and Julio Montaner (Main Director)*

**1. REFEREED PUBLICATIONS**


**(a) Journals**

**Total Number:** 226

**Web of Science h-index:** 51

**Google Scholar i10-index:** 137

**Average papers per year:** 13



**2005 (N=1)**

Statistician and lead author	<b>Lima VD</b> , Kopec JA. Quantifying the effect of health status on health care utilization using a preference-based health measure. <i>Soc Sci Med</i> . 2005; 60(3): 515-24.
------------------------------	--

**2006 (N=2)**

Statistician and lead author	<b>Lima VD</b> , Kretz P, Palepu A, Bonner S, Kerr T, Moore D, Daniel M, Montaner JS, Hogg RS. Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART. <i>AIDS Res Ther</i> . 2006; 3: 14.
Statistician and lead author	Hogg RS, Bangsberg DR, <b>Lima VD</b> , Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. <i>PLoS Med</i> . 2006; 3(9): e356.

**2007 (N=5)**

Statistician and co-author	Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, <b>Lima VD</b> , Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N3481 in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. <i>PLoS Med</i> . 2007; 4(12): e335.
Statistician and co-author	Phillips E, Gutiérrez S, Jahnke N, Yip B, <b>Lima VD</b> , Hogg RS, Harrigan PR, Montaner JSG. Determinants of Nevirapine Hypersensitivity and its Effect on the Association between Hepatitis C Status and Mortality in Naïve HIV Patients. <i>AIDS</i> . 2007; 21(12): 1561-1568.
Statistician and lead author	<b>Lima VD</b> , Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, Montaner JSG, Hogg RS. The Effect of Adherence on the Association between Depressive Symptoms and Mortality among HIV-Positive Individuals First Initiating HAART. <i>AIDS</i> . 2007; 21: 1175-1183.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JSG. Continued Improvement in Survival among HIV-Infected Individuals with newer forms of highly active antiretroviral therapy. <i>AIDS</i> . 2007; 21: 685-692.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Montaner JSG. Presenting plasma HIV RNA level and rate of CD4 T-cell decline. <i>JAMA</i> . 2007; 297: 805-806.

**2008 (N=10)**

Statistician and co-author	Harrigan PR, Sheen CW, Gill VS, Wynhoven B, Hudson E, <b>Lima VD</b> , Lecocq P, Aguirre R, Poon AF, Sluis-Cremer N. Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. <i>AIDS</i> . 2008; 22(18):2501-8.
Statistician and Co-author	Hogg R, <b>Lima V</b> , Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M; Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. <i>Lancet</i> . 2008; 372: 293-9.
Statistician and lead author	<b>Lima VD</b> , Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. <i>AIDS</i> . 2008; 22(17): 2371-80.
Statistician and co-author	Wood E, Hogg RS, <b>Lima VD</b> , Kerr T, Yip B, Marshall BD, Montaner JS. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. <i>JAMA</i> . 2008; 300: 550-4.
Collaborator	Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? <i>AIDS</i> . 2008; 22(18): 2481-92.

Modeller and lead author	<b>Lima VD</b> , Johnston K, Hogg RS, Levy AR, Harrigan PR, Montaner JSG. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. <i>J Infect Dis.</i> 2008; 198: 59-67.
Statistician and lead author	<b>Lima VD</b> , Gill V, Yip B, Hogg RS, Harrigan PR. Increased Resilience to the Development of Drug Resistance with Modern Boosted Protease Inhibitor-Based Highly Active Antiretroviral Therapy. <i>J Infect Dis.</i> 2008; 198(1): 51-8.
Statistician and co-author	Kopec JA, Badii M, McKenna M, <b>Lima VD</b> , Sayre EC, Dvorak M. Computerized adaptive testing in back pain: validation of the CAT-5D-QOL. <i>Spine (Phila Pa 1976).</i> 2008; 33(12): 1384-90.
Statistician and co-author	Phillips E, Hayden A, Gutiérrez S, Jahnke N, Yip B, <b>Lima VD</b> , Hogg RS, Harrigan PR, Montaner JS. Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply. <i>AIDS.</i> 2008; 22(3): 548-9.
Statistical Supervisor and co-author	Joy R, Druyts EF, Brandson EK, <b>Lima VD</b> , Rustad CA, Zhang W, Wood E, Montaner JS, Hogg RS. Impact of Neighborhood-Level Socioeconomic Status on HIV Disease Progression in a Universal Health Care Setting. <i>J Acquir Immune Defic Syndr.</i> 2008; 47(4): 500-505.

## 2009 (N=19)

Co-author	Hull MW, <b>Lima VD</b> , Hogg RS, Harrigan PR, Montaner JS. Epidemiology of treatment failure: a focus on recent trends. <i>Curr Opin HIV AIDS.</i> 2009; 4(6): 467-73.
Co-author	Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, <b>Lima VD</b> , Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Safety and efficacy of once-daily nevirapine dosing: a multicohort study. <i>Antivir Ther.</i> 2009; 14(7): 931-8.
Statistical Supervisor and co-author	Weiser SD, Fernandes KA, Brandson EK, <b>Lima VD</b> , Anema A, Bangsberg DR, Montaner JS, Hogg RS. The association between food insecurity and mortality among HIV-infected individuals on HAART. <i>J Acquir Immune Defic Syndr.</i> 2009; 52(3): 342-9.
Statistician and co-author	Moore DM, Harris R, <b>Lima V</b> , Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczar D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA. Antiretroviral Therapy Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. <i>J Acquir Immune Defic Syndr.</i> 2009; 52(3): 357-63.
Co-author	Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, <b>Lima VD</b> , Günthard HF, Gilks C, Pillay D. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. <i>Lancet Infect Dis.</i> 2009; 9(7): 409-17.
Co-author	Harrigan PR, <b>Lima VD</b> , Montaner JSG. Reconsidering First-Line Antiretroviral Therapy in Resource-Limited Settings: The need for Operational Research. <i>Journal of Infectious Diseases.</i> <i>J. Infect. Dis.</i> 2009; 199(9): 1407-8.
Statistical Supervisor and co-author	Palmer A, Tomkinson J, Phung C, Ford N, Joffres M, Fernandes KA, Zeng L, <b>Lima V</b> , Montaner JS, Guyatt GH, Mills EJ. Does ratification of human-rights treaties have effects on population health? <i>Lancet.</i> 2009; 373(9679): 1987-92.
Statistician and co-author	Kaida A, <b>Lima VD</b> , Andia I, Kabakyenga J, Mbabazi P, Emenyonu N, Patterson TL, Hogg RS, Bangsberg DR. The WHOMEN's scale (Women's HAART Optimism Monitoring and Evaluation Scale v.1) and the association with fertility intentions and sexual behaviours among HIV-positive women in Uganda. <i>AIDS Behav.</i> 2009; 13 Suppl 1: 72-81.
Statistician and co-author	Phillips P, Lee JK, Wang C, Yoshida E, <b>Lima VD</b> , Montaner J. Chylous ascites: a late complication of intra-abdominal Mycobacterium avium complex immune reconstitution syndrome in HIV-infected patients. <i>Int J STD AIDS.</i> 2009; 20(4):285-7.
Statistical Supervisor and co-author	McInnes CW, Druyts E, Harvard SS, Gilbert M, Tyndall MW, <b>Lima VD</b> , Wood E, Montaner JS, Hogg RS. HIV/AIDS in Vancouver, British Columbia: a growing epidemic. <i>Harm Reduct J.</i> 2009; 6: 5.
Statistician and lead author	<b>Lima V</b> , Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplior assay. <i>J Acquir Immune Defic Syndr.</i> 2009; 51(1): 3-6.

Statistician and lead author	<b>Lima VD</b> , Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. <i>J Acquir Immune Defic Syndr</i> . 2009; 50(5): 529-36.
Statistician and lead author	<b>Lima VD</b> , Fink V, Yip B, Hogg RS, Harrigan PR, Montaner JS. Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals. <i>Am J Public Health</i> . 2009; 99 Suppl 1: S193-6.
Statistician, Statistical Supervisor and co-author	Druyts EF, Rachlis BS, <b>Lima VD</b> , Harvard SS, Zhang W, Brandson EK, Strathdee SA, Montaner JS, Hogg RS. Mortality is influenced by locality in a major HIV/AIDS epidemic. <i>HIV Med</i> . 2009; 10(5): 274-81.
Statistician, Statistical Supervisor and co-author	Druyts EF, Yip B, <b>Lima VD</b> , Burke TA, Lesovski D, Fernandes KA, McInnes CW, Rustad CA, Montaner JS, Hogg RS. Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. <i>HIV Med</i> . 2009; 10(2): 88-93.
Statistician and co-author	Hull MW, Harris M, <b>Lima V</b> , Guillemi S, Harrigan PR, Montaner JS. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation. <i>J Clin Pharmacol</i> . 2009; 49(2): 155-61.
Statistician and lead author	<b>Lima V</b> , Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. <i>Soc Sci Med</i> . 2009; 68(6): 1044-9.
Statistician and co-author	Ntanda H, Olupot-Olupot P, Mugenyi P, Kityo C, Lowes R, Cooper C, <b>Lima V</b> , Mills E. Orphanhood predicts delayed access to care in Ugandan children. <i>Pediatr Infect Dis J</i> . 2009; 28(2): 153-5.
Statistician and co-author	Anema A, <b>Lima VD</b> , Johnston K, Levy A, Montaner JS. Expanded Highly Active Antiretroviral Therapy Coverage - A Powerful Strategy to Curb Progression to AIDS, Death and New Infections. <i>Eur Infect Dis</i> . 2009; 3(1): 41-43.

## 2010 (N=19)

Statistician and lead author	<b>Lima VD</b> , Lepik KJ, Zhang W, Muldoon KA, Hogg RS, Montaner JSG. Regional and Temporal Changes in HIV-related Mortality in British Columbia, 1987-2006. <i>Can J Public Health</i> . 2010; 101(5): 415-419.
Collaborator	Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS; CANOC Collaboration. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. <i>J Acquir Immune Defic Syndr</i> . 2010; 55(4): 451-9.
Co-author	Montaner JS, Wood E, Kerr T, <b>Lima VD</b> , Barrios R, Shannon K, Harrigan R, Hogg R. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. <i>J Acquir Immune Defic Syndr</i> . 2010; 55 Suppl 1: S5-9.
Statistician and lead author	<b>Lima VD</b> , Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. <i>J Acquir Immune Defic Syndr</i> . 2010; 55(4): 460-5.
Statistician and lead author	<b>Lima VD</b> , Harrigan PR, Sénécal M, Yip B, Druyts E, Hogg RS, Montaner JS. Epidemiology of antiretroviral multiclass resistance. <i>Am J Epidemiol</i> . 2010; 172(4): 460-8.
Statistical Supervisor and co-author	Guillemi S, Harris M, Bondy GP, Ng F, Zhang W, <b>Lima VD</b> , Michaels CE, Belzberg A, Montaner JS. Prevalence of Bone Mineral Density Abnormalities and Related Risk Factors in an Ambulatory HIV Clinic Population. <i>J Clin Densitom</i> . 2010; 13(4): 456-61.
Statistician and lead author	Montaner JS, <b>Lima VD</b> , Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. <i>Lancet</i> . 2010; 376(9740): 532-9.
Modeller and co-author	Johnston KM, Levy AR, <b>Lima VD</b> , Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JS. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. <i>AIDS</i> . 2010; 24(12): 1929-35.
Modeller and lead author	<b>Lima VD</b> , Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. <i>PLoS One</i> . 2010; 5(6): e10991.



Statistical Supervisor and co-author	Orchard TR, Druyts E, McInnes CW, Clement K, Ding E, Fernandes KA, Anema A, <b>Lima VD</b> , Hogg RS. Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. <i>AIDS Care</i> . 2010; 22(3): 324-31.
Statistician and lead author	<b>Lima VD</b> , Druyts E, Montaner JS, Hogg RS. Regional and temporal trends in migration among people living with HIV/AIDS in British Columbia, 1993-2005. <i>Can J Public Health</i> . 2010; 101(1): 44-9.
Collaborator	Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration. Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. <i>BMC Infect Dis</i> . 2010; 25 (10): 40.
Collaborator	Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, Machouf N, Montaner J, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS; CANOC Collaboration. Cohort profile: The Canadian Observational Cohort collaboration. <i>Int J Epidemiol</i> . 2011 Feb;40(1):25-32.
Statistician and co-author	Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, Juárez-Kasusky I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, <b>Lima VD</b> , Belaunzarán-Zamudio F, Crabtree-Ramírez B, Montaner J. A prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naïve subjects With CD4+<200 cell/mm3 in Mexico. <i>J Acquir Immune Defic Syndr</i> . 2010; 53 (5): 582-588.
Statistician and lead author	Montaner JS, <b>Lima VD</b> , Williams BG. Evaluating outcomes of the President's Emergency Plan for AIDS Relief in Africa. <i>Ann Intern Med</i> . 2010; 152(2): 131-2; author reply 132-3.
Statistical Supervisor and co-author	Moore DM, Zhang W, Yip B, Genebat M, <b>Lima VD</b> , Montaner JS, Hogg RS. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. <i>HIV Med</i> . 2010; 11(5): 299-307.
Statistical Supervisor and co-author	Gill VS, <b>Lima VD</b> , Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. <i>Clin Infect Dis</i> . 2010; 50(1): 98-105.
Co-author	Johnston KM, Levy AR, <b>Lima VD</b> , Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JSG. Reply to 'Evidence is still required for treatment as prevention for riskier routes of HIV transmission. <i>AIDS</i> . 2010; 24: 2892-3.
Co-author	Au-Yeng C, Wood E, Kerr T, <b>Lima VD</b> , Harrigan PR, Montaner JSG. A Made-in-Canada Strategy to STOP HIV and AIDS. <i>UBC Medical Journal</i> . 2010; 1 (2): 8-10.

## 2011 (N=8)

Collaborator	Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirschall G; ART in Prevention of HIV and TB Research Writing Group. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. <i>Curr HIV Res</i> . 2011; 9(6): 446-69.
Modeller and co-author	Williams BG, <b>Lima VD</b> , Gouws E. Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV. <i>Curr HIV Res</i> . 2011; 9(6): 367-82.
Statistical Supervisor and co-author	Jafari S, Chan K, Aboulhosn K, Yip B, <b>Lima VD</b> , Hogg RS, Montaner J, Moore DM. Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study. <i>AIDS Res Ther</i> . 2011; 8: 31.
Collaborator	Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, Machouf N, Montaner J, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS; CANOC Collaboration. "The way I see it": the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada. <i>AIDS Care</i> . 2011; 40(1): 25-32.
Statistical Supervisor and co-author	Eyawo O, Fernandes KA, Brandson EK, Palmer A, Chan K, <b>Lima VD</b> , Harrigan RP, Montaner JS, Hogg RS. Suboptimal use of HIV drug resistance testing in a universal health-care setting. <i>AIDS Care</i> . 2011; 23(1): 42-51.
Statistical Supervisor and co-author	Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, <b>Lima VD</b> , Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. <i>HIV Med</i> . 2011; 12(6): 352-360.

Statistician and co-author	Duncan KC, Reading C, Borwein AM, Murray MC, Palmer A, Michelow W, Samji H, <b>Lima VD</b> , Montaner JS, Hogg RS. HIV Incidence and Prevalence Among Aboriginal Peoples in Canada. <i>AIDS Behav.</i> 2011; 15(1): 214-27.
----------------------------	---

**2012 (N=15)**

Statistical Supervisor and co-author	Hogg RS, Heath K, <b>Lima VD</b> , Nosyk B, Kanters S, Wood E, Kerr T, Montaner JS. Disparities in the burden of HIV/AIDS in Canada. <i>PLoS One.</i> 2012; 7(11): e47260.
Co-author	Harris M, Nosyk B, Harrigan R, <b>Lima VD</b> , Cohen C, Montaner J. Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. <i>AIDS Res Treat.</i> 2012; 2012: 595762.
Statistician and lead author	<b>Lima VD</b> , Le A, Nosyk B, Barrios R, Yip B, Hogg RS, Harrigan PR, Montaner JS. Development and validation of a composite programmatic assessment tool for HIV therapy. <i>PLoS One.</i> 2012; 7(11): e47859.
Collaborator	May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaud R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>Int J Epidemiol.</i> 2012; 41(6): 1807-20.
Statistical Supervisor and co-author	Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, <b>Lima VD</b> , Montaner JS, Harrigan PR. Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay. <i>PLoS One.</i> 2012; 7(8): e43882.
Statistical Supervisor and co-author	Zhang W, O'Brien N, Forrest JI, Salters KA, Patterson TL, Montaner JS, Hogg RS, <b>Lima VD</b> . Validating a Shortened Depression Scale (10 Item CES-D) among HIV-Positive People in British Columbia, Canada. <i>PLoS One.</i> 2012; 7(7): e40793.
Co-author	The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV Treatment as Prevention: Models, Data, and Questions-Towards Evidence-Based Decision-Making. <i>PLoS Med.</i> 2012; 9(7): e1001259.
Co-author	Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, <b>Lima VD</b> , Leitch HA. Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era. <i>Adv Hematol.</i> 2012; 2012:910954.
Co-author	Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, <b>Lima VD</b> , Harris M, Leitch HA. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. <i>Leuk Lymphoma.</i> 2012; 53(12): 2390-6.
Statistical Supervisor and co-author	Wiseman SM, Forrest JI, Chan JE, Zhang W, Yip B, Hogg RS, <b>Lima VD</b> , Montaner JS. Factors Predictive of 30-Day Postoperative Mortality in HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy. <i>Ann Surg.</i> 2012; 256(1): 170-6.
Statistician and lead author	<b>Lima VD</b> , Nosyk B, Wood E, Kozai T, Zhang W, Chan K, Montaner JS. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. <i>AIDS.</i> 2012; 26(12): 1491-500.
Collaborator	Raboud J, Anema A, Su D, Klein MB, Zakaryan A, Swan T, Palmer A, Hosein S, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Hogg RS, Cooper C; Canadian Observational Cohort (CANOC) Collaboration. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. <i>HIV Clin Trials.</i> 2012; 13(2):90-102.
Collaborator	Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J; CANOC Collaboration. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. <i>J Infect Dis.</i> 2012; 205(8): 1230-8.
Statistical Supervisor and co-author	Mtambo A, Chan K, Shen A, <b>Lima V</b> , Hogg R, Montaner J, Moore D. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. <i>HIV Med.</i> 2012; 13(3): 141-7.
Statistician and co-author	Murray M, Hogg RS, <b>Lima VD</b> , May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease

	progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. <i>HIV Med.</i> 2012; 13(2): 89-97.
--	--

### 2013 (N=12)

Collaborator	Ndumbi P, Gillis J, Raboud JM, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas CM; Canadian Observational Cohort (CANOC) collaboration. Clinical impact of altered T-cell homeostasis in treated HIV patient enrolled in a large observational cohort. <i>AIDS.</i> 2013; Nov 28;27(18):2863-72.
Co-author	Anema A, Marshall BD, Stevenson B, Gurm J, Montaner G, Small W, Roth EA, <b>Lima VD</b> , Montaner JS, Moore D, Hogg RS. Intergenerational Sex as a Risk Factor for HIV Among Young Men Who Have Sex with Men: A Scoping Review. <i>Curr HIV/AIDS Rep.</i> 2013; 10(4): 398-407.
Collaborator	Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration. Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. <i>PLoS One.</i> 2013; 8(10): e77665;
Co-author	Nosyk B, Min J, <b>Lima VD</b> , Yip B, Hogg RS, Montaner JS; STOP HIV/AIDS Study Group. HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. <i>J Acquir Immune Defic Syndr.</i> 2013; 63(5): 653-9.
Statistical Supervisor and co-author	Hogg R, Nosyk B, Harrigan P, <b>Lima V</b> , Chan K, Heath K, Wood E, Kerr T, Montaner J. Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions. <i>HIV Med.</i> 2013; 14(9): 581-2.
Statistical Supervisor and co-author	Mtambo A, Harris M, Toy J, Guillemi S, Zhang W, <b>Lima VD</b> , Hogg R, Montaner JS, Hull M. Evaluation of Treatment Tolerability, Satisfaction and Laboratory Parameters in HIV+ Patients Switching from Ritonavir Capsule to Tablet Formulation. <i>Curr HIV Res.</i> 2013; 11(3): 231-7.
Statistician and lead author	<b>Lima VD</b> , Granich R, Phillips P, Williams B, Montaner JS. Potential Impact of the US President's Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries. <i>J Infect Dis.</i> 2013; 208(12): 2075-84.
Co-author	Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange J, <b>Lima VD</b> , Patterson T, Strathdee SA, Williams B, Montaner J. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. <i>AIDS.</i> 2013; 27(7): 1159-65.
Statistical Supervisor and co-author	Gonzalez-Serna A, <b>Lima VD</b> , Montaner JS, Harrigan PR, Brumme CJ. "Test-and-Treat" Strategy for Control of HIV and AIDS Can Lead to a Decrease, Not an Increase, of Multidrug-Resistant Viruses. <i>Clin Infect Dis.</i> 2013; 57(3): 478-9.
Co-author	Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, <b>Lima VD</b> , Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology.</i> 2013; 58(5): 1598-609.
Statistical Supervisor and co-author	Nosyk B, Colley G, Yip B, Chan K, Heath K, <b>Lima VD</b> , Gilbert M, Hogg RS, Harrigan PR, Montaner JS; STOP HIV/AIDS Study Group. Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. <i>PLoS One.</i> 2013; 8(1): e54416.
Co-author	Nosyk B, Anglin MD, Brecht ML, <b>Lima VD</b> , Hser YI. Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study. <i>Am J Epidemiol.</i> 2013; 177(7): 675-82.

### 2014 (N=22)

Statistician and lead author	Nguyen D, Stanek V, Guillemi S, Ding E, Colley G, Montaner JSG, <b>Lima VD</b> , Bondy G. High Prevalence of Carotid Plaque Identified Using Standard Carotid Ultrasound Techniques in HIV-Positive Patients with Low to Moderate Vascular Risk. <i>J AIDS Clin Res.</i> 2014; 5(9): 1000338.
Supervisor, Statistician and co-author	Lourenço L, Colley G, Nosyk B, Shopin D, Montaner JS, <b>Lima VD</b> ; STOP HIV/AIDS Study Group. High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. <i>PLoS One.</i> 2014; 9(12): e115277.
Statistician and co-author	Cheng MP, Hirji A, Roth DZ, Cook VJ, <b>Lima VD</b> , Montaner JS, Johnston JC. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. <i>Can J Public Health.</i> 2014; 105(4): e258-62.

Statistician, Supervisor and co-author	Lourenço L, <b>Lima VD</b> , Heath K, Nosyk B, Gilbert M, Colley G, Consolacion T, Barrios R, Robert H, Krajdén M, Konrad S, Murti M, Nelson J, May-Hadford J, Haggerstone J, Pick N, Gustafson R, Rusch M, Day I, Montaner JS. Process Monitoring of an HIV Treatment as Prevention Program in British Columbia, Canada. <i>J Acquir Immune Defic Syndr</i> . 2014; 67(3): e94-109.
Co-author	Jacka B, Applegate T, Krajdén M, Olmstead A, Harrigan R, Marshall BDL, Kora DeBeck, Milloy M-J, Lamoury F, Pybus O, <b>Lima V</b> , Magiorkinis G, Montoya V, Montaner J, Joy J, Woods C, Dobrer S, Dore GD, Poon AF, Grebely J. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. <i>Hepatology</i> . 2014; 60(5): 171-80.
Statistician and co-author	Nolan S, <b>Dias Lima V</b> , Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. <i>Addiction</i> . 2014; 109(12):2053-9
Lead author	<b>Lima VD</b> , Thirumurthy H, Kahn JG, Saavedra J, Carceres CF, Whiteside A. Modeling Scenarios for the End of AIDS. <i>Clin Infect Dis</i> . 2014; 59 Suppl 1: S16-20.
Statistician and co-author	Grebely J, <b>Lima VD</b> , Milloy MJ, DeBeck K, Marshall BDL, Montaner J, Simo A, Krajdén M, Dore GJ, Kerr T, Wood E. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. <i>PLoS One</i> 2014; 9(6): E97726.
Co-author	Nosyk B, Montaner JS, Yip B, <b>Lima VD</b> , Hogg RS; STOP HIV/AIDS Study Group. Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011. <i>Med Care</i> . 2014; 52(4): 362-9.
Statistician and lead author	<b>Lima VD</b> , Sierra-Madero J, Wu Z, Singer J, Wood E, Hull MW, Harrigan PR, Montaner JSG. Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years. <i>J Int AIDS Soc</i> . 2014. 17: 18617.
Co-author	Leung JM, Liu JC, Mtambo A, Ngan D, Nashta N, Guillemi S, Harris M, <b>Lima VD</b> , Mattman A, Shaipanich T, Raju R, Hague C, Leipsic JA, Sin DD, Montaner JS, Man SF. The Determinants of Poor Respiratory Health Status in Adults Living with Human Immunodeficiency Virus Infection. <i>AIDS Patient Care STDS</i> . 2014; 28(5): 240-7.
Statistical Supervisor and co-author	Gonzalez-Serna A, Chan K, Yip B, Chau W, McGovern R, Samji H, <b>Lima VD</b> , Hogg RS, Harrigan R. Temporal trends in the discontinuation of first-line antiretroviral therapy. <i>J Antimicrob Chemother</i> . 2014; 69(8): 2202-9
Collaborator	Heath K, Samji H, Nosyk B, Colley G, Gilbert M, Hogg RS, Montaner JS; STOP HIV/AIDS Study Group. Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). <i>Int J Epidemiol</i> . 2014; 43(4): 1073-81.
Statistical Supervisor and co-author	Carter A, Min J, Chau W, <b>Lima VD</b> , Kestler M, Pick N, Money D, Montaner JS, Hogg RS, Kaida A. Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). <i>PLoS One</i> . 2014; 9(3): e92334.
Supervisor, Statistical Supervisor and co-author	Cui Z, Grafstein E, Yip B, Hogg R, Montaner J, <b>Lima V</b> . Modelling clinical progression and health care utilization of HIV-positive patients in British Columbia prior to death. <i>HIV Med</i> . 2014; 15(9): 557-64.
Statistician and lead author	Montaner JS, <b>Lima VD</b> , Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajdén M, Gustafson R, Daly P, Kendall P. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. <i>PLoS One</i> . 2014; 9(2): e87872.
Statistical Supervisor and co-author	Gonzalez-Serna A, Min JE, Woods C, Chan D, <b>Lima V</b> , Montaner JS, Harrigan PR, Swenson LC. Performance of HIV-1 Drug Resistance Testing at Low Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals. <i>Clin Infect Dis</i> . 2014; 58 (8): 1165-73.
Collaborator	Ndumbi P, Gillis J, Raboud J, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas C; Canadian Observational Cohort (CANOC) Collaboration. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy. <i>HIV Med</i> . 2014; 15(3): 153-64.
Statistical Supervisor and co-author	Nosyk B, Montaner JS, Colley G, <b>Lima VD</b> , Chan K, Heath K, Yip B, Samji H, Gilbert M, Barrios R, Gustafson R, Hogg RS; for the STOP HIV/AIDS Study Group. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. <i>Lancet Infect Dis</i> . 2014; 14(1): 40-9.
Collaborator	Antoniou T, Gillis J, Loutfy MR, Cooper C, Hogg RS, Klein MB, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Raboud JM; Canadian Observational Cohort (CANOC) collaboration. Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. <i>J Int Assoc Provid AIDS Care</i> . 2014; 13(2): 153-9.

Statistician and lead author	<b>Lima VD</b> , Kerr T, Wood E, Kozai T, Salters KA, Hogg RS, Montaner JS. The effect of history of injection drug use and alcoholism on HIV disease progression. <i>AIDS Care</i> . 2014; 26(1): 123-9.
------------------------------	---

**2015 (N=24)**

Collaborator	Kaida A, Carter A, de Pokomandy A, Patterson S, Proulx-Boucher K, Nohpal A, Sereda P, Colley G, O'Brien N, Thomas-Pavanel J, Beaver K, Nicholson VJ, Tharao W, Fernet M, Otis J, Hogg RS, Loutfy M; CHIWOS Research Team. Sexual inactivity and sexual satisfaction among women living with HIV in Canada in the context of growing social, legal and public health surveillance. <i>J Int AIDS Soc</i> . 2015; 18(Suppl 5): 20284
Mathematical Modeller and lead author	<b>Lima VD</b> , Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, Kredjen M, Yoshida E, Wood E, Montaner JSG. Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs? <i>PLoS One</i> . 2015; 10(12): e0143836.
Co-author	Nolan S, Hayashi K, Milloy MJ, Kerr T, Dong H, <b>Lima VD</b> , Lappalainen L, Montaner J, Wood E. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. <i>Drug Alcohol Depend</i> . 2015; 156: 57-61.
Statistician and lead author	<b>Lima VD</b> , Eyawo O, Ma H, Lourenço L, Chau W, Hogg RS, Montaner JS. The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada. <i>J Int AIDS Soc</i> . 2015; 18(1): 20261.
Collaborator	Cescon A, Patterson S, Davey C, Ding E, Raboud JM, Chan K, Loutfy MR, Cooper C, Burchell AN, Palmer AK, Tsoukas C, Machouf N, Klein MB, Rourke SB, Rachlis A, Hogg RS, Montaner JS; CANOC Collaboration. Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. <i>J Int AIDS Soc</i> . 2015 Oct 5;18:20024.
Co-author	Nosyk B, Min JE, <b>Lima VD</b> , Hogg RS, Montaner JS; STOP HIV/AIDS study group. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. <i>Lancet HIV</i> . 2015; 2(9): e393-400.
Supervisor and co-author	Lourenço L, Hull M, Nosyk B, Montaner JS, <b>Lima VD</b> . The need for standardization of the HIV continuum of care. <i>Lancet HIV</i> . 2015; 2(6): e225-6.
Co-author	Nosyk B, Lourenço L, Min JE, Shopin D, <b>Lima VD</b> , Montaner JS; STOP HIV/AIDS Study Group. Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'. <i>AIDS</i> . 2015; 29(13): 1681-9.
Statistician and lead author	<b>Lima VD</b> , Goldberg N, Lourenço L, Chau W, Hogg RS, Guillemi S, Barrios R, Montaner JS. Virologic suppression and mortality of patients who migrate for HIV care in the province of British Columbia, Canada, from 2003 to 2012: a retrospective cohort study. <i>BMC Health Serv Res</i> . 2015; 15: 376.
Co-author	Nosyk B, Krebs E, Min JE, Ahamad K, Buxton J, Goldsmith C, Hull M, Joe R, Kraiden M, <b>Lima VD</b> , Olding M, Wood E, Montaner JS. The 'Expanded HIV care in opioid substitution treatment' (EHOST) cluster-randomized, stepped-wedge trial: A study protocol. <i>Contemp Clin Trials</i> 2015; 45(Pt B): 201-9.
Mathematical Modeller Supervisor and co-author	Caro-Vega Y, del Rio C, <b>Lima VD</b> , Lopez-Cervantes M, Crabtree-Ramirez B, Bautista-Arredondo S, Colchero MA, Sierra-Madero J. Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model. <i>PLoS One</i> . 2015; 10(8): e0136534.
Collaborator	Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS; CANOC collaboration. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. <i>BMC Infect Dis</i> . 2015; 15: 274.
Statistician and lead author	<b>Lima VD</b> , Reuter A, Harrigan PR, Lourenco L, Chau W, Hull M, Mackenzie L, Guillemi S, Hogg RS, Barrios R, Montaner JSG. Initiation of Antiretroviral Therapy at High CD4+ Cell Counts Is Associated with Positive Treatment Outcomes. <i>AIDS</i> 2015; 29(14): 1871-82
Co-author	Nosyk B, Min JE, Evans E, Li L, Liu L, <b>Lima VD</b> , Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clin Infect Dis</i> . 2015; 61(7): 1157-65.
Co-author	Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Kraiden M, Marshall BD, Montaner J, <b>Lima VD</b> , Olmstead AD, Milloy MJ, Wood E, Grebely J. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. <i>Drug Alcohol Depend</i> . 2015; 152: 272-6.

Statistical Supervisor and co-author	Nosyk B, Min JE, Colley G, <b>Lima VD</b> , Yip B, Milloy MJ, Wood E, Montaner JS. The causal effect of opioid substitution treatment on HAART medication refill adherence. <i>AIDS</i> . 2015; 29(8): 965-73.
Mathematical Modeller and lead author	<b>Lima VD</b> , Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JSG, Spaulding. The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. <i>PLoS One</i> . 2015; 10(4): e0123482.
Co-author	Liu JC, Leung JM, Ngan DA, Nashta NF, Guillemi S, Harris M, <b>Lima VD</b> , Um SJ, Li Y, Tam S, Shaipanich T, Raju R, Hague C, Leipsic JA, Bourbeau J, Tan WC, Harrigan PR, Sin DD, Montaner J, Man SF. Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease. <i>PLoS One</i> . 2015; 10 (4):e0124426.
Statistician and lead author	<b>Lima VD</b> , Lourenco L, Yip B, Hogg R, Phillips P, Montaner JSG. Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013. <i>Lancet HIV</i> . 2015; 2(3): e92-e97.
Statistical Supervisor and co-author	Lourenço L, Samji H, Nohpal A, Chau W, Colley G, Lepik K, Barrios R, <b>Lima V</b> , Hogg R, Montaner J, Kesselring S, Moore D. Declines in highly active antiretroviral therapy initiation at CD4 cell counts $\leq 200$ cells/ $\mu$ L and the contribution of diagnosis of HIV at CD4 cell counts $\leq 200$ cells/ $\mu$ L in British Columbia, Canada. <i>HIV Med</i> . 2015; 16(6): 337-45.
Co-author	Nosyk B, <b>Lima V</b> , Colley G, Yip B, Hogg RS, Montaner JS. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. <i>Pharmacoeconomics</i> . 2015; 33(3): 243-53.
Collaborator	Carter A, Greene S, Nicholson V, O'Brien N, Sanchez M, de Pokomandy A, Loutfy M, Kaida A; Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) Research Team. Breaking the Glass Ceiling: Increasing the Meaningful Involvement of Women Living With HIV/AIDS (MIWA) in the Design and Delivery of HIV/AIDS Services. <i>Health Care Women Int</i> . 2015; 36(8): 936-64.
Collaborator	Samji H, Taha T, Moore D, Burchell A, Cescon A, Cooper C, Raboud J, Klein M, Loutfy M, Machouf N, Tsoukas C, Montaner J, Hogg R; Canadian Observational Cohort (CANOC) Collaboration; Canadian Observational Cohort CANOC Collaboration. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. <i>HIV Med</i> . 2015; 16(2): 76-87.
Statistical Supervisor and co-author	Patterson S, Cescon A, Samji H, Cui Z, Yip B, Lepik KJ, Moore D, <b>Lima VD</b> , Nosyk B, Harrigan PR, Montaner JS, Shannon K, Wood E, Hogg RS. Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. <i>Int J Epidemiol</i> . 2015; 44(1): 58-67.

## 2016 (N=10)

Collaborator	Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, Patterson S, Chia J, Leslie A, Raboud J, Loutfy M, Cooper C, Klein M, Machouf N, Tsoukas C, Montaner J, Hogg RS; Canadian Observation Cohort (CANOC) Collaboration. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. <i>BMC Infect Dis</i> . 2016;16(1):590.
Co-author	Hogg RS, Lachowsky NJ, <b>Lima VD</b> , Montaner JSG. Heightened epidemic in men who have sex with men in Brazil. <i>Lancet HIV</i> . 2016; 3 (10): e454-e455
Statistical Supervisor and co-author	Guillemi SA, Ling SH, Dahlby, JS, Yip B, Zhang W, Hull MW, <b>Lima VD</b> , Hogg RS, Werb R, Montaner JSG, Marianne H. Effects of a switch from tenofovir-to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function. <i>J Int AIDS Soc</i> . 2016; 19(1): 20995
Collaborator	Loutfy M, Greene S, Kennedy VL, Lewis J, Thomas-Pavanel J, Conway T, de Pokomandy A, O'Brien N, Carter A, Tharao W, Nicholson V, Beaver K, Dubuc D, Gahagan J, Proulx-Boucher K, Hogg RS, Kaida A; CHIWOS Research Team. Establishing the Canadian HIV Women's Sexual and Reproductive Health Cohort study (CHIWOS): Operationalizing Community-based Research in a Large National Quantitative Study. <i>BMC Med Res Methodol</i> . 2016 Aug 19; 16(1):101.
Statistician and lead author	<b>Lima VD</b> , Hull M, McVea D, Chau W, Harrigan PR, Montaner JSG. Long-Term Effectiveness of Initiating on a Non-Nucleoside Reverse Transcriptase Inhibitor-versus Ritonavir Boosted Protease Inhibitor-Based Antiretroviral Therapy: Implications for First-Line Therapy Choice in Resource-Limited Settings. <i>J Int AIDS Soc</i> . 2016; 5(19): 20978
Co-author	Cheung CC, Ding E, Sereda P, Yip B, Lourenco L, Barrios R, Montaner J, Hogg RS, <b>Lima V</b> , Moore DM. Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012. <i>HIV Med</i> . 2016; 9:694-701.

Co-author and Statistical Supervisor	Lee GQ, Lachowski C, Cai E, <b>Lima VD</b> , Boum Y, Muzoora C, Mocello AR, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR. Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. <i>AIDS</i> . 2016; 30(11): 1781-8.
Co-author	Jacka B, Applegate T, Poon AF, Raghvani J, Harrigan PR, DeBeck K, Milloy MJ, Kraiden M, Olmstead A, Joy JB, Marshall BD, Hayashi K, Pybus OG, <b>Lima VD</b> , Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, Grebely J. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. <i>J Hepatol</i> . 2016; 64(6): 1247-55
Mathematical Modeller Supervisor and co-author	Rozada I, Coombs D, <b>Lima VD</b> . Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. <i>J Theor Biol</i> . 2016; 395: 31-9.
Supervisor, Statistical Supervisor and co-author	Lourenço L, Nohpal A, Shopin D, Colley G, Nosyk B, Montaner J, <b>Lima VD</b> ; Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) Study Group. Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. <i>HIV Med</i> . 2016; 17(4): 269-79.

## 2017 (N=19)

Co-author and Statistical Supervisor	Samad F, Harris M, Puskas CM, Ye M, Chia J, Chacko S, Bondy GP, <b>Lima VD</b> , Montaner JS, Guillemi SA. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50. <i>BMJ Open Diabetes Res Care</i> . 2017;5(1):e000457.
Lead author and Statistician	<b>Lima VD</b> , St-Jean M, Rozada I, Shoveller JA, Nosyk B, Hogg RS, Sereda P, Barrios R, Montaner JSG. Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada. <i>J Int AIDS Soc</i> . 2017; 20(3)
Co-author	Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD, Johnson M, <b>Lima VD</b> , Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC; Antiretroviral Therapy Cohort Collaboration (ART-CC). CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clin Infect Dis</i> ; 65(6):959-966.
Collaborator	O'Brien N, Greene S, Carter A, Lewis J, Nicholson V, Kwaramba G, Ménard B, Kaufman E, Ennabil N, Andersson N, Loutfy M, de Pokomandy A, Kaida A; CHIWOS Research Team. Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Womens Health Issues</i> . 2017;27(6):721-730.
Co-author	Lee GQ, Bangsberg DR, Mo T, Lachowski C, Brumme CJ, Zhang W, <b>Lima VD</b> , Boum Y 2nd, Mwebesa BB, Muzoora C, Andia I, Mbalibulha Y, Kembabazi A, Carroll R, Siedner MJ, Haberer JE, Mocello AR, Kigozi SH, Hunt PW, Martin JN, Harrigan PR. Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. <i>AIDS</i> . 2017 Nov 13;31(17):2345-2354.
Co-author	Ti L, <b>Lima V</b> , Hull M, Nosyk B, Joy J, Montaner J, Kraiden M, Harrigan R, Kerr T, Shannon K, Wood E, Shoveller J, Ramji A, Ko HH, Yoshida E, Hall D, Barrios R. Hepatitis C testing in Canada: don't leave baby boomers behind. <i>CMAJ</i> . 2017;189(25):E870-E871.
Statistician and co-author	Rocheleau G, Brumme CJ, Shoveller J, <b>Lima V</b> , Harrigan R. Longitudinal Trends of HIV Drug Resistance in a Large Canadian Cohort; 1996-2016. <i>Clin Microbiol Infect</i> . 2017; 24(2):185-191.
Co-author	MacKenzie LJ, Hull MW, Samji H, <b>Lima VD</b> , Yip B, Zhang W, Lourenço L, Colley G, Hogg RS, Montaner JSG. Is there a rural/urban gap in the quality of HIV care for treatment-naïve HIV-positive individuals initiating antiretroviral therapy in British Columbia? <i>AIDS Care</i> . 2017. 29(10):1218-1226
Collaborator	Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN, Cooper C, Hill T, Hull M, Klein MB, Loutfy M, Martin F, Machouf N, Montaner J, Nelson M, Raboud J, Rourke SB, Tsoukas C, Hogg RS, Sabin C; Canadian Observational Cohort (CANOC) - UK Collaborative HIV Cohort (UK CHIC) Collaboration. A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. <i>HIV Med</i> . 2017; 16(9):65-666.

Collaborator	Antoniou T, Szadkowski L, Walmsley S, Cooper C, Burchell AN, Bayoumi AM, Montaner JS, Loutfy M, Klein MB, Machouf N, Tsoukas C, Wong A, Hogg RS, Raboud J; Canadian Observational Cohort (CANOC) collaboration. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infect Dis.</i> 2017;17(1):266.
Collaborator	Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, Hull M, Chia J, Hogg RS, Moodie EE, Klein MB; Canadian Observational Cohort (CANOC) Collaboration. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infect Dis.</i> 2017 Apr 4;17(1):246.
Statistical Supervisor and co-author	Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, <b>Lima VD</b> , Guillemi S, Montaner JSG, Barrios R. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. <i>AIDS.</i> 2017;31(10):1425-1434.
Co-author	Nosy B, Zang X, Min JE, Krebs E, <b>Lima VD</b> , Milloy MJ, Shoveller J, Barrios R, Harrigan PR, Kerr T, Wood E, Montaner JSG. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study. <i>Lancet HIV.</i> 2017;4(7):e303-e310.
Collaborator	Carter A, de Pokomandy A, Loutfy M, Ding E, Sereda P, Webster K, Nicholson V, Beaver K, Hogg RS, Kaida A; CHIWOS Research Team. Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study. <i>BMC Res Notes.</i> 2017;10(1):138.
Supervising Statistician and co-author	Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, <b>Lima VD</b> , Ahmed T, Kendall CE, Althoff KN, Justice AC, Barrios R, Shoveller J, Montaner JS; Comparative Outcomes and Service Utilization Trends (COAST) study. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. <i>Lancet HIV.</i> 2017; 4(6):e270-e276
Supervising Statistician and co-author	Eyawo O, Franco-Villalobos C, Hull MW, Nohpal A, Samji H, Sereda P, <b>Lima VD</b> , Shoveller J, Moore D, Montaner JS, Hogg RS; Comparative Outcomes and Service Utilization Trends (COAST) study. Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. <i>BMC Infect Dis.</i> 2017;17(1):174.
Statistician and lead author	<b>Lima VD</b> , Wang L, Brumme C, Wu L, Montaner JS, Harrigan PR. Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification. <i>PLoS One.</i> 2017;12(2):e0171155
Supervisor, Statistician and co-author	St-Jean M, Harrigan PR, Sereda P, Montaner J, <b>Lima VD</b> . An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition. <i>HIV Med.</i> 2017;18(5):342-353.
Supervisor, Statistical Supervisor and co-author	Kesselring S, Cescon A, Colley G, Osborne C, Zhang W, Raboud JM, Hosein SR, Burchell AN, Cooper C, Klein MB, Loutfy M, Machouf N, Montaner J, Rachlis A, Tsoukas C, Hogg RS, <b>Lima VD</b> ; Canadian Observational Cohort Collaboration (CANOC). Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy. <i>HIV Med.</i> 2017 Mar;18(3):151-160.

## 2018 (N=11)

Supervisor, Statistical Supervisor and co-author	Amram O, Wang L, Sereda P, Shoveller J, Barrios B, Montaner J, <b>Lima VD</b> . Assessing the Relationship Between Physician Availability and Viral Load Suppression in British Columbia. <i>The Canadian Geographer.</i> 2018; 62(2):120-129.
Supervisor, Statistical Supervisor and co-author	Amram O, Shoveller J, Hogg R, Wang L, Sereda P, Barrios R, Montaner J, <b>Lima V</b> . Distance to HIV care and treatment adherence: Adjusting for socio-demographic and geographical heterogeneity. <i>Spat Spatiotemporal Epidemiol.</i> 2018; 27:29-35.
Co-author	Ingle SM, Crane HM, Glass TR, Yip B, <b>Lima VD</b> , Gill MJ, Hanhoff N, Ammassari A, Mugavero MJ, Tate JP, Guest J, Turner NL, May MT, Sterne JAC. Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. <i>J Clin Med.</i> 2018;7(10). pii: E328.
Co-author	Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, <b>Lima VD</b> , d'Arminio Monforte A, Smith C, Cavassini M, Saag M, Castilho JL, Sterne JAC. Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio. <i>AIDS.</i> 2018;32(10):1361-1367.



Supervisor, Statistical Supervisor and co-author	Ma H, Villalobos CF, St-Jean M, Eyawo O, Lavergne MR, Ti L, Hull MW, Yip B, Wu L, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, <b>Lima VD</b> . The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study. <i>BMC Health Serv Res</i> . 2018;18(1):319.
Statistical Supervisor and co-author	Lepik KJ, Yip B, Ulloa AC, Wang L, Toy J, Akagi L, <b>Lima VD</b> , Guillemi S, Montaner JSG, Barrios R. Adverse drug reactions to integrase strand transfer inhibitors. <i>AIDS</i> . 2018;32(7):903-912
Co-author and Statistical Supervisor	Kang H, Cui Z, Chia JTN, Khorsandi Zardoshti A, Barrios R, <b>Lima VD</b> , Guillemi S. Innovative Multimodal Training Program for Family Physicians Leads to Positive Outcomes Among Their HIV-Positive Patients. <i>J Contin Educ Health Prof</i> . 2018; 38(1):60-65.
Co-author	Eyawo O, Hull MW, Salters K, Samji H, Cescon A, Sereda P, <b>Lima VD</b> , Nosyk B, Whitehurst DGT, Lear SA, Montaner JSG, Hogg RS; Comparative Outcomes and Service Utilization Trends (COAST) Study. Cohort profile: The Comparative Outcomes and Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> . 2018; 8(1):e019115.
Co-author	Logie CH, Lacombe-Duncan A, Wang Y, Kaida A, Conway T, Webster K, de Pokomandy A, Loutfy MR, Anema A, Becker D, Brotto L, Carter A, Cardinal C, Colley G, Ding E, Duddy J, Gataric N, Hogg RS, Hosward T, Jabbari S, Jones E, Kestler M, Langlois A, <b>Lima V</b> , et al. Pathways From HIV-Related Stigma to Antiretroviral Therapy Measures in the HIV Care Cascade for Women Living with HIV in Canada. <i>J Acquir Immune Defic Syndr</i> . 2018;77(2):144-153.
Co-author	Jacka B, Bray B, Applegate TL, Marshall BD, <b>Lima VD</b> , Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Kraiden M, Montaner J, Grebely J. Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. <i>J Viral Hepat</i> . 2018; 25(1):28-36.
Statistician and co-author	Rocheleau G, Brumme CJ, Shoveller J, <b>Lima VD</b> , Harrigan PR. Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016. <i>Clin Microbiol Infect</i> . 2018;24(2):185-191.

## 2019 (N=16)

Co-author and Statistical Advisor	Van Ommen CE, Albert AYK, Piske M, Money DM, Cote HCF, <b>Lima VD</b> , Maan EJ, Alimenti A, van Schalkwyk J, Pick N, Murray MCM. Exploring the live birth rates of women living with HIV in British Columbia, Canada. <i>PLoS One</i> . 2019; 14(2): e0211434.
Co-author and Statistician	Kamelian K, Lepik KJ, Chau W, Yip B, Zhang WW, <b>Lima VD</b> , Robbins MA, Woods C, Olmstead A, Joy J, Barrios R, Harrigan PR. Prevalence of HIV-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis. <i>Open Forum Infectious Diseases</i> . 2019; 6(3):ofz060.
Co-author	Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, Thiebaut R, Guest J, Gill J, Crane H, <b>Dias Lima V</b> , d'Arminio Monforte A, Sterling TR, Miro J, Moreno S, Stephan C, Smith C, Tate J, Shepherd L, Saag M, Rieger A, Gillor D, Cavassini M, Montero M, Ingle SM, Reiss P, Costagliola D, Wit FWNM, Sterne J, de Wolf F, Gekus R. Antiretroviral Therapy Cohort Collaboration (ART-CC). Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals with Sustained Virological Suppression on Antiretroviral Therapy. <i>J Acquir Immune Defic Syndr</i> . 2019; 80(3):292-300.
Co-author	Allan B, Closson K, Collins AB, Kibel M, Pan S, Cui Z, McLinden T, Parashar S, <b>Lima VD</b> , Chia J, Yip B, Barrios R, Montaner JSG, Hogg RS. Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting. <i>BMJ open</i> . 2019; 9(3):e023957.
Supervisor and co-author	Nanditha NGA, St-Jean M, Tafessu H, Guillemi SA, Hull MW, Lu M, Henry B, Barrios R, Montaner JSG, <b>Lima VD</b> . Missed opportunities for earlier diagnosis of HIV in British Columbia, Canada: A retrospective cohort study. <i>PLoS One</i> . 2019; 14(3): e0214012.
Co-author	Beaulieu T, Krishnamoorthy A, <b>Lima VD</b> , Li T, Wu A, Montaner J, Barrios R, Ti L, on behalf of the STOP HIV/AIDS study group. Impact of personality disorders on leaving hospital against medical advice among people living with HIV in British Columbia, Canada. <i>Social Psychiatry and Psychiatric Epidemiology</i> . 2019; 54(9):1153-1159.
Co-author	Ulloa A, Puskas C, Yip B, Zhang W, Stanley C, Stone S, Pedromingo M, <b>Lima VD</b> , Montaner JSG, Guillemi S, Barrios R. Retention in care and mortality trends among patients receiving comprehensive care for HIV infection: a retrospective cohort study. <i>CMAJ Open</i> . 2019; 7(2):E236-E245.

Co-author	Allan B, Closson K, Collins AB, Kibel M, Pan S, Cui Z, McLinden T, Parashar S, <b>Lima VD</b> , Chia J, Yip B, Barrios R, Montaner JSG, Hogg RS. Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting. <i>BMJ Open</i> . 2019; 9(3):e023957.
Statistical Advisor	Han J, Wu Z, McGoogan JM, Mao Y, Tang H, Li J, Zhao Y, Jin C, Detels R, Brookmeyer R, <b>Lima VD</b> , Montaner JSG. Overrepresentation of Injection Drug Use Route of Infection Among Human Immunodeficiency Virus Long-term Nonprogressors: A Nationwide, Retrospective Cohort Study in China, 1989–2016, <i>Open Forum Infectious Diseases</i> . 2019; 6(5):ofz182.
Co-author	Closson K, McLinden T, Patterson TL, Eyawo O, Gard KG, Salters K, Chau W, Ye M, Hull MW, <b>Lima VD</b> , Montaner JSG, Hogg RS, for the Comparative Outcomes and Service Utilization Trends (COAST) study. HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. <i>Schizophrenia Research</i> . 2019; 209:198-205.
Co-author	Moore D, Ye M, Wong J, Barrios R, Hull M, Li J, Sereda P, Grennan T, <b>Lima V</b> , Toy J, Montaner J. P162 Unsuppressed viral load (VL) by HIV exposure category among people living with HIV in British Columbia (BC), Canada: 2005-2015. <i>Sexually Transmitted Infections</i> . 2019; 95(1):A128-A128
Collaborator	Logie CH, Marcus N, Wang Y, Kaida A, O'Campo P, Ahmed U, O'Brien N, Nicholson V, Conway T, de Pokomandy A, Fernet M, Loutfy M; on the CHIWOS Research Team. A longitudinal study of associations between HIV-related stigma, recent violence and depression among women living with HIV in a Canadian cohort study. <i>J Int AIDS Soc</i> . 2019; 22(7):e25341.
Supervisor	Zhu J, Rozada I, David J, Moore DM, Guillemi SA, Barrios R, Montaner JSG, <b>Lima VD</b> . The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada. <i>Lancet E Clinical Medicine</i> . 2019; 13:101-111.
Co-author	Gali B, Eyawo O, Hull MW, Samji H, Zhang W, Sereda P, <b>Lima VD</b> , McGrail K, Montaner JSG, Hogg RS, Moore D; on behalf of the COAST study team. Incidence of select chronic co-morbidities among a population-based cohort of HIV-positive individuals receiving highly active antiretroviral therapy. <i>Current Medical Research and Opinion</i> . 2019; 25(11):1955-1963.
Co-author and supervisor	St-Jean M, Tafessu H, Closson K, Patterson TL, Lavergne MR, Elefante J, Ti L, Hull MW, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, <b>Lima VD</b> . The syndemic effect of HIV/HCV co-infection and mental health disorders on acute care hospitalization rate among people living with HIV/AIDS: a population-based retrospective cohort study. <i>Canadian Journal of Public Health</i> . 2019; 110(6):779-791.
Collaborator	Shokoohi M, Bauer GR, Kaida A, Logie CH, Carter A, Lacombe-Duncan A, Loutfy M; CHIWOS Research Team. A Latent Class Analysis of the Social Determinants of Health Impacting Heavy Alcohol Consumption Among Women Living with HIV in Canada: The Canadian HIV Women's Sexual and Reproductive Health Cohort Study. <i>AIDS Behav</i> . 2019;23(12):3226-3236.

## 2020 (N=6)

Co-supervisor	David JF, <b>Lima VD</b> , Zhu J, Brauer F. A co-interaction model of HIV and syphilis infection among gay, bisexual and other men who have sex with men. <i>Infect Dis Model</i> . 2020 [Epub ahead of print].
Co-author	Jones AA, Gicas KM, Seyedin S, Willi TS, Leonova O, Vila-Rodriguez F, Procyshyn RM, Smith GN, Schmitt TA, A VertinskyT, Buchanan T, Rauscher A, Lang DJ, MacEwan GW, <b>Lima VD</b> , Montaner JSG, Panenka WJ, Barr AM, Thornton WE, Honer WG. (2020) Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. <i>PLoS Medicine</i> , 17(7): e1003172.
Collaborator	O'Brien N, Godard-Sebillotte C, Skerritt L, Dayle J, Carter A, Law S, Cox J, Andersson N, Kaida A, Loutfy M, de Pokomandy A; CHIWOS Research Team. Assessing Gaps in Comprehensive HIV Care Across Settings of Care for Women Living with HIV in Canada (2020). <i>J Womens Health (Larchmt)</i> . [Epub ahead of print]
Co-author	Bourgi K, Jenkins CA, Rebeiro PF, Sheperd BE, Palella F, Moor RD, Althoff KN, Gill J, Rabkin CS, Gange SJ, Horberg MA, Margolick J, Li J, Wong C, Willig A, <b>Lima VD</b> , Crane H, Thorne J, Silverberg M, Kirk G, Mathews WC, Sterling TR, Lake J, Koethe JR, North American AIDs Cohort Collaboration on Research and Design (NA-ACCORD). (2020) Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. <i>J Int AIDS Soc</i> 23(4): e25484.

Lead author	<b>Lima VD</b> , Brumme ZL, Brumme C, Sereda P, Krajdén M, Wong J, Guillemi SA, Henry B, Hogg RS, Barrios R, Montaner JSG; for the STOP HIV/AIDS Study Group. (2020) The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. <i>Curr HIV/AIDS Rep.</i> 2020;17(2):77-87.
Collaborator	Gormley R, Lin SY, Carter A, Nicholson V, Webster K, Martin RE, Milloy MJ, Pick N, Howard T, Wang L, de Pokomandy A, Loutfy M, Kaida A; CHIWOS Research Team. Social Determinants of Health and Retention in HIV Care Among Recently Incarcerated Women Living with HIV in Canada. <i>AIDS Behav.</i> 2020;24(4):1212-1225.

## 2021 (N=16)

Supervisor	Nanditha NGA, Zheng G, Tafessu HM, McLinden T, Bratu A, Kopec J, Hogg RS, Montaner JSG, <b>Lima VD</b> . Disparities in multimorbidity and mortality among people living with and without HIV across British Columbia's health regions: A population-based cohort study. <i>Can J Public Health.</i> 2021;112(6):1030-1041
Co-author	Thompson KA, Blank G, Toy J, Moore DM, Lachowsky N, Bacani N, Zhang W, Sereda P, <b>Lima VD</b> , Barrios R, Montaner JSG, Hull MW. Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. <i>Open Forum Infect Dis.</i> 2021 Oct 6;8(11):ofab492.
Co-author	McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, <b>Lima VD</b> , Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo K, Mayor A, Tate JP; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA; Veterans Aging Cohort Study. Discrimination And Calibration Of The Vacs Index 2.0 For Predicting Mortality Among People With HIV In North America. <i>Clin Infect Dis.</i> 2021 Oct 5:ciab883. Epub ahead of print.
Co-author	Lee JS, Humes EA, Hogan BC, Buchacz K, Eron JJ, Gill MJ, Sterling TR, Rebeiro PF, <b>Lima VD</b> , Mayor A, Silverberg MJ, Horberg MA, Moore RD, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018. <i>Clin Infect Dis.</i> 2021;73(7):e2334-e2337
Co-author	Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, Horberg MA, Matthews WC, Silverberg MJ, Thorne J, Mayor AM, <b>Lima VD</b> , Palella FJ, Saag MS, Althoff KN, Gill MJ, Wong C, Klein MB, Crane HM, Marconi VC, Shepherd BE, Sterling TR, Koethe JR. Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada. <i>Clin Infect Dis.</i> 2021;73(7):e2234-e2242
Co-author	Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, <b>Lima VD</b> , Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Clinical effectiveness of integrase strand transfer inhibitor-based antiretroviral regimens among adults with human immunodeficiency virus: a collaboration of cohort studies in the United States and Canada. <i>Clin Infect Dis.</i> 2021;73(7):e1408-e1414
Supervisor	St-Jean M, Dong X, Tafessu H, Moore D, Honer WG, Vila-Rodriguez F, Sereda P, Hogg RS, Patterson TL, Salters K, Barrios R, Montaner SG, <b>Lima VD</b> . Overdose mortality is reducing the gains in life expectancy of antiretroviral-treated people living with HIV in British Columbia, Canada. <i>Int J Drug Policy.</i> 2021: 103195.
Co-author	Edwards JK, Cole SR, Breger TL, Rudolph JE, Filiatreau LM, Buchacz K, Humes E, Rebeiro PF, D'Souza G, Gill MJ, Silverberg MJ, Mathews WC, Horberg MA, Thorne J, Hall HI, Justice A, Marconi VC, <b>Lima VD</b> , Bosch RJ, Sterling TR, Althoff KN, Moore RD, Saag M, Eron JJ. Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study. <i>Ann Intern Med.</i> 2021; 174(9):1197-1206.
Collaborator	Davy-Mendez T, Napravnik S, Eron JJ, Cole SR, van Duin D, Wohl DA, Hogan BC, Althoff KN, Gebo KA, Moore RD, Silverberg MJ, Horberg MA, Gill MJ, Mathews WC, Klein MB, Colasanti JA, Sterling TR, Mayor AM, Rebeiro PF, Buchacz K, Li J, Nanditha NGA, Thorne JE, Nijhawan A, Berry SA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA). Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>J Infect Dis.</i> 2021;224(4):657-666.
Lead author	<b>Lima VD</b> , Zhu J, Card KG, Lachowsky NJ, Chowell-Puente G, Wu Z, Montaner JSG. Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada? <i>Epidemics.</i> 2021;35:100461.

Co-author	Bratu A, McLinden T, Kooij K, Ye M, Li J, Trigg J, Sereda P, Nanditha NGA, <b>Lima V</b> , Guillemi S, Salters K, Hogg R. Incidence of diabetes mellitus among people living with and without HIV in British Columbia, Canada between 2001 and 2013: a longitudinal population-based cohort study. <i>BMJ Open</i> . 2021 May 11;11(5):e048744.
Co-author	Marziali ME, McLinden T, Card KG, Closson K, Wang L, Trigg J, Salters K, <b>Lima VD</b> , Parashar S, Hogg RS. Social Isolation and Mortality Among People Living with HIV in British Columbia, Canada. <i>AIDS Behav</i> . 2021 Feb;25(2):377-388.
Lead author	<b>Lima VD</b> , Wang L, Sereda P, McLinden T, Barrios R, Montaner JSG. Estimation of time of HIV seroconversion using a modified CD4 depletion model. <i>Plos One</i> . 2021;16(2):e0246135
Collaborator	Zhabokritsky A, Szadkowski L, Cooper C, Loutfy M, Wong A, McClean A, Hogg RS, Walmsley SL; Canadian Observational Cohort (CANOC) Collaboration. Increased CD4:CD8 ratio normalization with implementation of current ART management guidelines. <i>J Antimicrob Chemother</i> . 2021 Feb 11;76(3):729-737.
Co-author	Marziali ME, McLinden T, Card KG, Closson K, Wang L, Trigg J, Salters K, <b>Lima VD</b> , Parashar S, Hogg RS. Social Isolation and Mortality Among People Living with HIV in British Columbia, Canada. <i>AIDS Behav</i> . 2021 Feb;25(2):377-388.
Supervisor	Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J, Montaner JSG, Hogg RS, <b>Lima VD</b> . Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. <i>BMJ Open</i> . 2021;11(1):e041734.


## 2022 (N=11)

Statistical Supervisor and co-author	Yazdani K, Salters K, Shen T, Dolguikh K, Trigg J, White RF, Closson K, Nanditha NGA, Honer WG, Vila-Rodriguez F, <b>Lima VD</b> , Montaner JSG, Barrios R. A twenty-year population-based study of all-cause and cause-specific mortality among people with concurrent HIV and psychotic disorders. <i>AIDS</i> . 2022. Epub ahead of print.
Supervisor	Fonseca-Cuevas A*, Nanditha NGA*, Shen T, Moore DM, Lachowsky NL, Card KG, Sang JM, Wang L, Chia J, Duailibe F, Hogg RS, <b>Lima VD</b> . Use of Gay chatlines and online dating platforms as potential mediators or moderators in the relationship between loneliness, self-rated attractiveness and HIV acquisition risk among gbMSM in Vancouver, Canada. <i>Sexually Transmitted Diseases</i> . 2022. Epub ahead of print. * Shared 1st authorship
Supervisor	Nehumba D, Paiero A, Tafessu H, Salters K, Moore D, <b>Lima VD</b> . Household food insecurity, sense of community belonging, and access to a regular medical doctor as mediators in the relationship between mood and/or anxiety disorders and self-rated general health in Canada between 2011-2016: A serial cross-sectional analysis. <i>Can J Public Health</i> . 2022. Epub ahead of print.
Co-author	Lepik KJ, Wang L, Harris M, McLinden T, Guliani S, Akagi L, Toy J, Sereda P, <b>Lima VD</b> , Montaner JSG, Barrios R. Evolving patterns of antiretroviral drug interactions in people living with HIV in British Columbia, Canada. <i>AIDS</i> . 2022; 36(8):1105-15
Co-author	Thompson KA, Blank G, Toy J, Moore DM, Lachowsky N, Bacani N, Zhang W, Sereda P, <b>Lima V</b> , Barrios R, Montaner JSG, Hull MW. Prevalence and Incidence of Hepatitis C Infection Amongst Men Who Have Sex with Men in a Population-Based PrEP Program in British Columbia, Canada. <i>Liver Int</i> . 2022; 42(7): 1528-35
Co-author	Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, <b>Lima VD</b> , Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD; North American AIDS Cohort Collaboration on Research, Design of the International Epidemiologic Databases to Evaluate AIDS. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>AIDS</i> . 2022;36(2):277-286.
Supervisor	Nanditha NGA, Dong X, Tafessu HM, Wang L, Lu M, Barrios R, Montaner JSG, <b>Lima VD</b> . The impact of a province-wide HIV Treatment-as-Prevention-based initiative in accelerating treatment initiation and virologic suppression: A population-based cohort study in British Columbia, Canada. <i>CMAJ Open</i> . 2022;10(1):E27-E34.
Collaborator	Gormley R, Nicholson V, Parry R, Lee M, Webster K, Sanchez M, Cardinal C, Li J, Wang L, Balleny R, de Pokomandy A, Loutfy M, Kaida A; CHIWOS Research Team. Help-Seeking to Cope With Experiences of Violence Among Women Living With HIV in Canada. <i>Violence Against Women</i> . 2022;28(3-4):823-850.

Supervisor	Nanditha NGA, Dong X, McLinden T, Sereda P, Kopek J, Hogg R, Montaner JSG, <b>Lima VD</b> . The impact of lookback windows on the prevalence and incidence of chronic diseases among people living with HIV: An exploration in administrative health data in Canada. <i>BMC Med Res Methodol.</i> 2022;22(1):1.
Co-author	Kasaie P, Stewart C, Humes E, Gerace L, Zhang J, Silverberg MJ, Horberg MA, Rebeiro PF, Hyle EP, <b>Lima VD</b> , Wong C, Gill MJ, Gebo K, Moore R, Kitahata MM, Althoff KN. Projecting the age-distribution of men who have sex with men receiving HIV treatment in the United States. <i>Ann Epidemiol.</i> 2022;65:46-55
Supervisor	St-Jean M, Closson K, Salway T, Card K, Patterson TL, Hogg RS, <b>Lima VD</b> . Sexual minority status modifies the association between HIV risk behavior and prevalent mood or anxiety disorders in British Columbia, Canada. <i>Soc Psychiatry Psychiatr Epidemiol. Soc Psychiatry Psychiatr Epidemiol.</i> 2022;57(1):207-218.

**(b) Conference Proceedings**

**Total Number: 214**



**2007 (N=20)**

Statistician and lead author	<b>Lima V</b> , Yip B, Druyts E, Kumar R, Rustad C, Hogg R. Time to and Factors Associated with Triple Class Failure with ARVs in Canada. 11 <sup>th</sup> European AIDS Conference/EACS. Madrid, Spain. October 24-27, 2007.
Statistical Supervisor and co-author	Yip B, <b>Lima V</b> , Burke T, Druyts E, Hogg R. Non-Drug Resource Use and Costs of Managing HIV/AIDS: Evidence from a Contemporary HIV Practice in Canada. 11 <sup>th</sup> European AIDS Conference/EACS. Madrid, Spain. October 24-27, 2007.
Statistician and lead author	<b>Lima VD</b> , Johnson K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JSG. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. 2 <sup>nd</sup> International Workshop on HIV Transmission. Principles of Intervention, Washington DC, District of Columbia, United States, August 26-28, 2007.
Statistician and lead author	<b>Lima VD</b> , Yip B, Wood E, Montaner JSG, Hogg RS. The impact of migration on longitudinal adherence patterns among HIV-infected individuals initiating HAART. 4 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, July 22-25, 2007.
Statistician and lead author	<b>Lima VD</b> , Yip B, Hogg RS, Harrigan PR, Sherlock CH, Montaner JSG. Plasma HIV-1 RNA Levels as a Predictor of CD4 Cell Count Decline among Untreated HIV Infected Individuals. 4 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, July 22-25, 2007.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Harrigan PR, Wood E, Yip B, Montaner JSG. The impact of HAART on HIV transmission: the interplay of HIV-1 RNA plasma viral load, adherence and drug resistance over time. 4 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, July 22-25, 2007.
Modeller and lead author	<b>Lima VD</b> , Johnson K, Hogg RS, Levy AR, Harrigan PR, Montaner JSG. Expanded access to HAART: A powerful strategy to curb the growth of the HIV epidemic and costs. 4 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, July 22-25, 2007.
Statistician and co-author	Gill VS, Low AJ, Joy R, Harrigan PR, <b>Lima VD</b> . Accumulation of Class Drug-Resistance among Survivors and Non-Survivors in a Large Cohort of Antiretroviral-Naïve Individuals. XVI International HIV Drug Resistance Workshop. Bridgetown, Barbados, June 12-16, 2007.
Statistician and co-author	Low A, Chan D, Dong W, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, <b>Lima VD</b> , Harrigan PR. Current Implementations of HIV Genotyping Algorithms are Inadequate for the Prediction of X4 Co-Receptor Usage in Clinical Isolates from Population-Based V3 Sequences: Approaches to improvement. XVI International HIV Drug Resistance Workshop. Bridgetown, Barbados, June 12-16, 2007.
Modeller and lead author	<b>Lima VD</b> , Johnson K, Hogg RS, Levy AR, Harrigan PR, Montaner JSG. Predicting the future of the HIV epidemic: The dynamic between high HAART usage and prevalence of drug-resistant strains of HIV. 16 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research. Toronto, April 26-29, 2007.
Statistician and lead author	<b>Lima VD</b> , Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, Montaner JSG, Hogg RS. The Effect of Adherence on the Association between Depressive Symptoms and Mortality among Individuals Living with

	HIV/AIDS First Initiating HAART. 16 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research. Toronto, April 26-29, 2007.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Harrigan PR, Wood E, Yip B, Montaner JSG. Longitudinal Effect of HAART on HIV RNA Plasma Viral Load: Implications for Transmission. 16 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research. Toronto, April 26-29, 2007.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Gross R, Bangsberg DR, Yip B, Wood E, Harrigan PR, Montaner JSG. The Interplay of Initial Highly Active Antiretroviral Therapy (HAART) Regimen and Intravenous Drug Use on the Association of Adherence and Mortality over Time. Statistical and Epidemiology Issues in HIV Research. Vail, April 11-13, 2007.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Harrigan PR, Wood E, Yip B, Montaner JSG. The impact of HAART on HIV Transmission: The Interplay of HIV-1 RNA Plasma Viral Load, Adherence and Drug Resistance over Time. Statistical and Epidemiology Issues in HIV Research. Vail, April 11-13, 2007.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Gross R, Bangsberg D, Yip B, Wood E, Harrigan PR, Montaner JSG. Marginal Structural Models for Estimating the Impact of Longitudinal Adherence on Survival. 11 <sup>th</sup> International Workshop on HIV Observational Databases. Monte Carlo, Monaco. March 22-25, 2007.
Statistician and lead author	<b>Lima V</b> , Johnson K, Hogg R, Levy A, Harrigan R, Montaner J. Modeling the Impact of Increasing Utilization of HAART on HIV Incidence in Settings with Multiple Sources of Infection. 14 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2007). Los Angeles, CA. February 25-28, 2007.
Statistician and co-author	Gross R, Yip B, <b>Lima V</b> , Montaner J, Hogg R. Benefit of continued high level adherence for maintaining HIV suppression for subjects with low baseline CD4 count on boosted or single protease inhibitor (PI)-based regimens. 2 <sup>nd</sup> International Conference on HIV Treatment Adherence (IAPAC 2007). Jersey City, NJ, United States. March 28-30, 2007.
Statistician and co-author	Hogg RS, for the Antiretroviral Cohort Collaboration. Continued increases in life expectancy among persons initiating HAART in high income countries. 14 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2007). Los Angeles, CA. February 25-28, 2007.
Statistician and lead author	Moore DM, for the Antiretroviral Cohort Collaboration. Regimen dependent variations in the occurrence of reduced immunologic responses to HAART in the presence of virologic suppression. 14 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2007). Los Angeles, CA. February 25-28, 2007.
Statistical Supervisor and co-author	Gill V, Harrigan R, Hogg R, <b>Lima V</b> . A Statistical Model to Predict the Development of HIV Drug Resistance in Drug Naïve Individuals Incorporating the Effects of Boosted PI regimens and Adherence. 14 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2007). Los Angeles, CA. February 25-28, 2007.

## 2008 (N=21)

Statistician and lead author	<b>Lima VD</b> , Harrigan PR, Hogg RS, Montaner JSG. Untangling the impact of adherence on long-term treatment response among HIV-infected individuals first initiating HAART – greater resilience of contemporary HAART regimens. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistician and lead author	<b>Lima VD</b> , Druyts EF, Fernandes KA, Rachlis B, Montaner JSG, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patient. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistician and lead author	<b>Lima VD</b> , Hogg R, Harrigan PR, Bangsberg D, Gross R, Yip B, Montaner JSG. The combined effect of modern HAART regimens and adherence on mortality over time. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistician and co-author	Jahnke NA, Yip B, <b>Lima VD</b> , Montaner JSG, Hogg RS. The effect of HCV genotype on mortality among HIV-co-infected individuals receiving antiretroviral treatment within a populational cohort. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Brandson EK, Fernandes KA, McInnes CW, Druyts EF, Tyndall M, <b>Lima VD</b> , Montaner JSG, Hogg RS. Clinical outcomes and quality of life: a preliminary look at HIV+ participants enrolled in a DOT program. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Brandson EK, Palmer A, Zhang W, Rustad CA, <b>Lima VD</b> , Montaner JSG, Hogg RS. Better body image, better health among HIV+ persons on HAART: addressing the roles of stigma and depression. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.

Statistical Supervisor and co-author	Lepik KJ, Barrios R, Yip B, Zhang W, Fernandes KA, Levy AR, Moore D, <b>Lima VD</b> , Hogg RS, Montaner JS. Monitoring clinical laboratory records and antiretroviral regimen changes: two complementary methods for signal detection in surveillance of adverse drug reactions. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Lepik KJ, Barrios R, Yip B, Zhang W, Fernandes KA, Hogg RS, Levy A, Moore D, Akagi L, Ferris E, <b>Lima VD</b> , Montaner JS. Developing a population-based surveillance system for monitoring antiretroviral-related adverse drug reactions in British Columbia, Canada. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	McInnes CW, Druyts EF, Tyndall M, <b>Lima VD</b> , Johnston K, Gilbert M, Wood E, Montaner JSG, Hogg RS. HIV prevalence in Vancouver, British Columbia: a growing epidemic. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Brandson EK, Fernandes KA, Palmer A, Clement K, Olson B, <b>Lima VD</b> , Montaner JSG, Hogg RS. HAART-full of life: variations in quality of life among Aboriginal and non-Aboriginal peoples ever on antiretroviral therapy in BC. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Modeller and co-author	Johnston K, Levy A, <b>Lima VD</b> , Hogg R, Tyndall M, Briggs A, Gustafson P, Montaner JS. Dynamic cost-effectiveness of increased use of HAART in British Columbia, Canada. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Anema A, Druyts EF, Palmer A, Yip B, <b>Lima VD</b> , Patterson TL, Morrow M, Strathdee SA, Montaner JSG, Hogg RS. The impact of hepatitis C virus and schizophrenia on survival of HIV-positive individuals on HAART. AIDS 2008 - XVII International AIDS Conference. Mexico City, Mexico. August 3-8, 2008.
Statistical Supervisor and co-author	Gill VS, <b>Lima VD</b> , Fernandes KA, Harrigan PR. Injection drug users have a higher probability of developing resistance than non-injection drug users regardless of adherence or initial treatment regimen. XVII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications. Sitges, Spain. June 10-14, 2008.
Statistician and lead author	<b>Lima VD</b> , Fernandes KA, Rachlis B, Druyts EF, Montaner JSG, Hogg RS. The Strong Influence of Migration on Antiretroviral Adherence in a Population-Based Cohort of HIV/AIDS Patients. 17th Annual Canadian Conference on HIV/AIDS Research (CAHR 2008). Montreal, Canada. April 24-27, 2008.
Statistical Supervisor and co-author	McInnes CW, Druyts EF, Tyndall M, <b>Lima VD</b> , Johnston K, Gilbert M, Wood E, Montaner JSG, Hogg RS. Estimated numbers of men and women infected with HIV/AIDS in Vancouver, British Columbia. 17th Annual Canadian Conference on HIV/AIDS Research (CAHR 2008). Montreal, Canada. April 24-27, 2008.
Statistical Supervisor and co-author	Druyts EF, Rachlis B, Zhang W, Brandson EK, <b>Lima VD</b> , Rustad CA, Strathdee SA, Wood E, Montaner JSG, Hogg RS. Survival amongst HIV positive individuals prescribed HAART: A comparison of Vancouver's West End and Downtown Eastside neighbourhoods. 17th Annual Canadian Conference on HIV/AIDS Research (CAHR 2008). Montreal, Canada. April 24-27, 2008.
Statistical Supervisor and co-author	Rustad CA, <b>Lima VD</b> , Yip B, Druyts EF, Senecal M, Montaner JSG, Hogg RS. Time to and risk factors associated with triple class failure amongst patients prescribed antiretroviral therapy for the treatment of HIV. 12 <sup>th</sup> International Workshop on HIV Observational Databases. Malaga, Spain. March 27-30, 2008.
Statistician and lead author	<b>Lima VD</b> , Hogg RS, Harrigan PR, Bangsberg DR, Gross R, Yip B, Montaner JSG. The Combined Effect of Modern HAART Regimens and Adherence on Mortality over Time. 12 <sup>th</sup> International Workshop on HIV Observational Databases. Malaga, Spain. March 27-30, 2008.
Statistician and lead author	<b>Lima V</b> , Hudson E, Wynhoven B, Yip B, Hogg R, Montaner J, Harrigan R. Drastically Declining Incidence of HIV Drug Resistance: The End of the Beginning? 15 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, United States. February 3-6, 2008.
Statistical Supervisor and co-author	Gill V, Fernandes K, Wynhoven B, Low A, <b>Lima V</b> , Hogg R, Harrigan R. Causes of Death and Accumulation of Class Drug-resistance among Survivors and Non-survivors in a Large Cohort of ARV-naïve Individuals. 15 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, United States. February 3-6, 2008.
Statistical Supervisor and co-author	Guillemi S, Ng F, Zhang W, <b>Lima V</b> , Rocha C, Harris M, Bondy G, Belzberg A, Montaner J. Risk Factors for Reduced Bone Mineral Density in HIV-infected Individuals in the Modern HAART Era. 15 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, United States. February 3-6, 2008.



2009 (N=7)

Statistical Supervisor and co-author	Hull M, Moore D, Harris M, Ding E, Shen A, Yip B, <b>Lima V</b> , Harrigan PR, Hogg R, Montaner JS. A lamivudine (3TC)-based backbone in conjunction with a boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the presence of M184V mutations. The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, California. September 12-15, 2009. Poster #H-916.
Statistician and lead author	<b>Lima V</b> , Anema A, Wood R, Moore D, Harrigan R, Mills E, Hogg R, Montaner J. The combined impact of male circumcision, condom use and HAART coverage on the HIV HIV-1 epidemic in South Africa: A mathematical model. 5 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
Statistician and lead author	<b>Lima V</b> , Harrigan R, Rosenblum M, Deeks S, Hogg R, Yip B, Montaner J, Bangsberg D. Duration of viral suppression strongly modifies the adherence-viral rebound relationship. 5 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
Statistician and lead author	<b>Lima VD</b> , Druyts EF, Hogg RS, Montaner JSG. The impact of the 2008 IAS-USA guidelines on HIV transmission in British Columbia (Canada) and direct treatment cost: A mathematical transmission model. 5 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
Statistician and lead author	<b>Lima VD</b> , Harrigan PR, Montaner JSG. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies/mL with the Taqman Assay in comparison to the Amplicor Assay. 16 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2009). Montreal, Canada. February 8-11, 2009.
Statistical Supervisor and co-author	Mtambo A, Moore D, Chan K, Harrigan PR, Yip B, Montaner JS, <b>Lima V</b> , Hogg R. Treatment limitations imposed by ARV resistance mutations: a comparison of initial regimens containing boosted PI with those containing NNRTI. The 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Quebec. February 8-11, 2009. Poster #647.
Statistician and lead author	<b>Lima V</b> , Eyawo O, Swenson L, Hogg R, Montaner J, Harrigan R. Drug resistance monitoring practices are strongly associated with mortality. 16 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2009). Montreal, Canada. February 8-11, 2009.

2010 (N=11)

Co-author	Harrigan PR, Sherlock C, Hogg R, Barrios R, <b>Dias Lima V</b> , Montaner JS. What should be the Primary Virological Endpoint in Clinical Trials of Antiretroviral Efficacy? HIV DART 2010, Hilton Los Cabos, Mexico. December 7-10, 2010.
Statistician and lead author	<b>Lima V</b> , Harrigan R, Yip B, Hogg S, Montaner J. Enhanced adherence to HAART is associated with further decrease in HIV drug resistance within a population-based HAART expansion initiative in British Columbia (BC). XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.
Statistician and lead author	<b>Lima V</b> , Hull M, Guillemi S, Barrios R, Millan D, Yip B, Montaner JSG. Clinical outcomes associated with the use of modern salvage therapy. XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.
Statistician and lead author	<b>Lima V</b> , Moore D, Harrigan R, Hogg R, Montaner J. Comparison of long-term efficacy of boosted PIs and NNRTIs. XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.
Statistical Supervisor and co-author	Chan K, Harrigan R, Moore D, Wynhoven B, Lontaner J, Hogg R, <b>Lima V</b> . Limited future regimen options for those starting on NNRTI-based triple combinations due to antiretroviral drug resistance mutations. XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.
Statistical Supervisor and co-author	Kanters S, Montaner J, Hogg R, Yip B, Moore D, <b>Lima V</b> . The combined effect of adherence and CD4 cell count on mortality. XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.
Statistical Supervisor and co-author	Guillemi S, Hull M, Kanters S, Harris M, Milan D, <b>Dias Lima V</b> , Harrigan PR, Montaner JS. Does smoking tobacco affect atazanavir exposure in HIV-infected individuals? The 18th International AIDS Conference, Vienna, Austria. July 18-23, 2010.
Statistician and co-author	Shen A, <b>Lima V</b> , Heung C, Palmer A, Au-Yeung C, Montaner J, Hogg R, Mills E. Assessment of PEPFAR's impact on health system improvement in Sub-Saharan African countries. XVIII International AIDS Conference (AIDS 2010). Vienna, Austria. July 18-23, 2010.

Statistician and lead author	<b>Lima V</b> , Barrios R, Harrigan R, Hull M, Guillemi S, Hogg R, Milan D, Yip B, Ding E, Montaner J. Programmatic non-compliance with HIV treatment guidelines is strongly associated with mortality. 14 <sup>th</sup> International Workshop on HIV Observational Databases. Sitges, Spain. March 25-27, 2010.
Statistician and lead author	<b>Lima V</b> , Hull M, Guillemi S, Barrios R, Milan D, Yip B, Ding E, Hogg R, Montaner J. Similar immunologic responses to modern HAART among injection drug users (IDU) and non-IDUs in a populational setting. 17 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2010). San Francisco, USA. February 16-19, 2010.
Statistician and co-author	Montaner J, Wood E, Kerr T, Yip B, <b>Lima V</b> , Shannon K, Harrigan R, Hogg R. Association of Expanded HAART Coverage with a Decrease in New HIV Diagnoses, Particularly among Injection Drug Users in British Columbia, Canada. 17 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2010). San Francisco, USA. February 16-19, 2010.

## 2011 (N=8)

Statistician and lead author	<b>Lima VD</b> , Sierra-Madero J, Wu Z, Singer J, Milan D, Montaner JSG. Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels. 6 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy. 17-20 July, 2011. Abstract MOAC0303.
Statistician and lead author	<b>Lima VD</b> , Sierra-Madero J, Wu Z, Singer J, Milan D, Montaner JSG. Cumulative viremia under HAART predicts long-term clinical outcomes. 6 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy. 17-20 July, 2011. Abstract CDB029.
Modeller and co-author	Baguley S, Codere G, Wallace L, Alexander J, <b>Lima VD</b> . HIV in Scotland: Modelling the impact of treatment as prevention and adherence to IAS guidelines. 6 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy. 17-20 July, 2011. Abstract CDB130.
Statistical Supervisor and co-author	Zhang W, O'Brien N, Forrest JI, Palmer AK, Montaner JSG, Hogg RS, <b>Lima VD</b> . Validating a shortened depression scale (10 item CES-D) amongst HIV-positive patients in British Columbia, Canada. 6 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy. 17-20 July, 2011. Abstract CDB507.
Statistical Supervisor and co-author	Mtambo A, Shaipanich T, Guillemi SA, Chan K, Tan W, Harris M, <b>Lima VD</b> , Montaner JSG, Sin D, Man P. Demographic and clinical predictors of chronic airflow limitation (CAL) among HIV+ patients attending an urban HIV clinic in Vancouver, BC. 6 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy. 17-20 July, 2011. Abstract CDB128.
Modeller and lead author	<b>Lima V</b> , Williams B, Hogg R, Montaner J. Why the MSM-driven HIV epidemic is not slowing down even in the presence of HAART? 18 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, USA. February 26-March 2, 2011. Abstract 486.
Modeller and co-author	Vasarhelyi K, Ramadanovic B, Adams A, Kok S, Gustafson R, Montaner J, Wittenberg R, Hogg R, <b>Lima V</b> , Rutherford A. Estimating the Rate of HIV Transmission in British Columbia, Canada. 18 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, USA. February 26-March 2, 2011. Abstract 1026.
Co-author	Harrigan PR, Sherlock C, Hogg R, Wynhoven B, Chui C, Swenson L, <b>Lima V</b> , Montaner J. What should be the Primary Virological Endpoint in Clinical Trials of Antiretroviral Efficacy? 18 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, USA. February 26-March 2, 2011. Abstract 661.

## 2012 (N=10)

Statistician and lead author	Montaner J, <b>Lima VD</b> , Yip B, Day I, Gustafson R, Barrios R, Kerr T, Wood E, Harrigan R, Bruham R, Krajden M, Gilbert M, Oglivie G, Hogg R, Nakagawa B, Daly P, Kendall P. Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses: an update on the 'treatment as prevention' experience in British Columbia, Canada. XIX International AIDS Conference (AIDS 2012). Washington, USA. July 22-27, 2012. Abstract THPE103.
Modeller and lead author	<b>Lima V</b> , Spaulding A, Kim B, Stein M, Messina L, et al. Modeling the impact of implementing a seek, test, treat and retain (STTR) strategy to halt the HIV epidemic within the criminal justice system (CJS) in

	different regions in the U.S. XIX International AIDS Conference (AIDS 2012). Washington, USA. July 22-27, 2012. Abstract THPE105.
Co-author	Samji H, Wang H, Chau W, Colley G, Lepik K, Barrios R, <b>Lima V</b> , Lourenco L, Hogg RS, Montaner, Moore D. Trends in late initiation of antiretroviral therapy (ART) in British Columbia, Canada and the contribution of late diagnosis. XIX International AIDS Conference (AIDS 2012). Washington, USA. July 22-27, 2012. Abstract MOPE186.
Statistician and co-author	Hogg R, <b>Lima V</b> , Wood E, Kerr T, Harrigan R, et al. HAART-related Decrease in the Rate of New HIV Diagnoses - a Unique Trend: British Columbia, Canada. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) Seattle, USA. March 5-8, 2012.
Statistical Supervisor, Supervisor, and co-author	Lourenco L, Chan K, Samji H, Hogg R, Montaner J, et al. Declines in Community Viral Load Are Uniformly Distributed across Geographic Areas: British Columbia, Canada. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) Seattle, USA. March 5-8, 2012.
Statistical Supervisor and co-author	Hull M, Zhang W, Yip B, Chen Y, Milan D, <b>Lima V</b> , Hogg R, and Montaner J. Initiation of ART in the Modern Era is Associated with Decreased Risk of Hepatotoxicity in HIV/HCV Co-infected Patients. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) Seattle, USA. March 5-8, 2012.
Statistician and lead author	<b>Lima VD</b> , Le A, Barrios R, Hogg RS, Montaner JSG, Harrigan PR. Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, USA. March 5-8, 2012.
Statistician and lead author	<b>Lima V</b> , Guillemi S, Werb R, Humphreys S, Montaner J. Microalbuminuria (albumin to creatinine ratio >30mg/g) is associated with increased all-cause mortality in a large cohort of antiretroviral-naïve HIV-infected patients. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, USA. March 5-8, 2012.
Modeller and lead author	<b>Lima VD</b> on behalf of the US Criminal Justice Modeling Collaboration. Modeling the Impact of Implementing a Test-and-Treat Strategy within the US Criminal Justice System. 2nd International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2012.
Statistician and lead author	<b>Lima V</b> , Yip B, Day, I, Gustafson R, Barrios R, Kerr T, Wood E, Harrigan R, Brunham R, Krajden M, Gilbert M, Ogilvie G, Hogg B, Nakagawa B, Daly P, Kendall P, Montaner J. Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses – An update on the “Treatment as Prevention” experience in British Columbia. 2nd International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2012.

## 2013 (N= 25)

Statistician and lead author	<b>Lima V</b> , Nosyk B, Krajden M, Hull M, Kerr T, Wood E, Yoshida E, Wu Z, Montaner JSG. A Test, Treat and Retain Combination Strategy for Elimination of HCV Transmission among Injection Drug Users: A Mathematical Model. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) Atlanta, USA. March 3-6, 2012. Abstract 714.
Statistician and lead author	<b>Lima VD</b> , DeBeck K, Milloy MJ, Grebely J, Lourenco L, Dobrer S, Montaner J, Kerr T, Wood E. The Role of Gender in the Risk of Hepatitis C (HCV) Infection. HEP DART. Big Island, Hawaii. December 8-12, 2013. Abstract 78.
Statistician and lead author	<b>Lima VD</b> , DeBeck K, Milloy MJ, Grebely J, Lourenco L, Dobrer S, Montaner J, Kerr T, Wood E. Polysubstance Injection Drug Use Dramatically Increases the Risk of HCV Infection. HEP DART. Big Island, Hawaii. December 8-12, 2013. Abstract 79.
Statistician and co-author	Grebely J, <b>Lima VD</b> , Milloy MJ, DeBeck K, Marshall BDL, Montaner J, Simo A, Krajden M, Dore GJ, Kerr T, Wood E. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. Big Island, Hawaii. December 8-12, 2013. Abstract 80.
Statistician and lead author	<b>Lima VD</b> , Nosyk B, Colley G, Heath K, Yip B, Samiji H, Hogg R, Montaner J. The Cascade of Care: A Promising Tool in HIV Surveillance. 7 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract TUPE338.
Statistician and lead author	<b>Lima VD</b> , Chen Y, Kozai T, Hogg R, Montaner J. The choice of first-line regimen influences the likelihood of therapy switches and disease progression. 7 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract TUPE304.

Statistical Supervisor and co-author	Nosky B, Montaner J, Colley C, Chan K, Heath K, Yip B, Samji H, Gilbert M, Barrios R, Gustafson R, <b>Lima V</b> , Hogg R. Linked data systems for longitudinal monitoring and evaluation of the continuum of HIV care in British Columbia. Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract WEPE651.
Statistician and lead author	<b>Lima VD</b> , Granich R, Phillips P, Williams B, Montaner JS. Potential impact of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis (TB)/HIV co-epidemic in selected Sub-Sahara African countries. Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract WEPE469.
Statistical Supervisor and co-author	Hogg RS, Chan K, Cescon A, Samji H, Yip B, Colley G, <b>Lima VD</b> , Monater JSG. Considerable gaps in life expectancy among HIV-positive individuals initiating HAART in British Columbia, Canada. Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract TUPE256.
Co-author	Nosyk B, <b>Lima V</b> , Colley G, Yip B, Heath K, Hogg R, Montaner J. Estimating dynamics of direct medical costs among individuals with HIV/AIDS. Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract TUPE329.
Statistical Supervisor and co-author	Carter AJ, Min JE, Chau W, <b>Lima VD</b> , Pick N, Montaner JSG, Kaida A. Gender inequities in IAS-USA HIV clinical care outcomes among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). Kuala Lumpur, Malaysia. 30 June-03 July, 2013. Abstract MOPE183.
Statistician and lead author	<b>Lima VD</b> , Chen Y, Kozai T, Hogg R, Montaner J. The choice of first-line regimen influences the likelihood of therapy switches and disease progression. 17 <sup>th</sup> International Workshop on HIV Observational Databases. Cavtat, Croatia. April 11-13, 2013.
Statistician and lead author	<b>Lima VD</b> , Granich R, Phillips P, Williams B, Montaner JS. Potential Impact of the US President's Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African Countries. 3 <sup>rd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2013.
Statistician and lead author	<b>Lima VD</b> , Nosyk B, Colley G, Heath K, Yip B, Samji H, Hogg R, Montaner J. The Cascade of Care: A Promising Tool in HIV Surveillance. 3 <sup>rd</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2013.
Statistical Supervisor and co-author	Hogg RS, Chan K, Cescon A, Samji H, Colley G, Yip B, <b>Lima VD</b> , Montaner JS. Inequities in life expectancy among people initiating HAART in British Columbia. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract O007
Statistical Supervisor and co-author	Carter SJ, Min JE, <b>Lima VD</b> , Pick N, Montaner JS, Hogg R, Kaida A. Gender inequities in Quality of initial HIV Care (QOC) among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract O003
Statistical Supervisor and co-author	Nosyk B, <b>Lima VD</b> , Yip B, Min J, Hogg R, Montaner J. The Cost-effectiveness of population-level HAART Expansion in British Columbia: 1996-2010. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract O074
Statistical Supervisor and co-author	Nosyk B, Montaner J, Colley G, Chan K, Heath K, Yip B, Samji H, Gilbert G, Barrios R, Gustafson R, <b>Lima VD</b> , Hogg R. Evaluating longitudinal patterns in the continuum of HIV care in British Columbia: 1996-2009. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract O100
Statistical Supervisor, Supervisor and co-author	Cescon A, Min J, Colley G, Hosein SR, Machouf N, Samji H, Burchell AN, Cooper C, Klein MB, Loufty MR, Montaner JS, Raboud JM, Rachlis A, Tsoukas C, Hogg RS, <b>Lima VD</b> . Compliance to treatment guidelines at the programmatic level in Canada: extension of a composite assessment metric for HIV therapy. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract O102
Statistical Supervisor and co-author	Lourenco L, Ding E, Shurgold S, Colley G, Yip B, <b>Lima V</b> , Samji H, Barrios R, Montaner JS, Hogg RS, Moore D. Factors Associated with Varying Levels of HAART Prescription Refill Adherence in British Columbia, Canada. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P031
Statistician, Supervisor and co-author	Kozai T, Zhang W, Salters K, Hogg R, Montaner J, <b>Lima V</b> . Association of Smoking and Injection Drug Use on Highly Active Antiretroviral Therapy (HAART) Outcomes in the Longitudinal Investigations into Supportive and Ancillary Health Services (LISA) Study. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P108
Statistical Supervisor and co-author	Nosyk B, Min J, <b>Lima VD</b> , Yip B, Hogg RS, Montaner JS. HIV-1 disease progression during Highly Active Antiretroviral Therapy: An application using populationlevel data in British Columbia: 1996-2011. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P193

Statistician, Supervisor and co-author	Kozai T, Harris M, Shurgold S, Werb R, Guillemi S, Montaner J, <b>Lima V</b> . Microalbuminuria is strongly associated with increased mortality. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P061
Statistical Supervisor and co-author	Moore D, Chan K, Nosyk B, Colley G, Lepik K, Barrios R, Lourenco L, Montaner J, <b>Lima V</b> , Heath K, Gustafson R, Hogg R. Use of non-recommended regimens as initial ART in British Columbia is associated with a reduced likelihood of virologic suppression. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P168
Co-author	Nosyk B, <b>Lima V</b> , Colley G, Yip B, Heath K, Hogg R, Montaner J. Regional variation in non-HAART direct medical costs among HIV-positive individuals in British Columbia. 22nd Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 11-14, 2013. Abstract P170

#### 2014 (N=8)

Co-author	Lee GQ, Lachowski C, Cai E, <b>Lima VD</b> , Boum Y, A. Mocello R, Hunt PW, Martin JN, Harrigan PR, Bangsberg DR. Non-R5-tropic HIV-1 in Subtype A and D Infections Were Associated with Lower Pre-therapy CD4 Count but not with Therapy Outcomes. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 5 -9, 2014.
Modeller, Supervisor and co-author	Rozada I, Lourenço L, Nosyk B, Montaner J, <b>Lima V</b> . Modelling the effect of a test and treat strategy for HCV prevention using highly effective DAAs in people who inject drugs in British Columbia. 20th International AIDS Conference, Australia, Melbourne, July 20-25, 2014. Abstract TUPE055
Statistician and lead author	Montaner JS, <b>Lima VD</b> , Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P, Rozada I. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. 20th International AIDS Conference, Australia, Melbourne, July 20-25, 2014. Abstract TUPE203.
Modeller, Supervisor and co-author	Rozada I, Lourenço L, Nosyk B, Montaner J, <b>Lima V</b> . Modelling the effect of a test and treat strategy for HCV prevention using highly effective DAAs in people who inject drugs in British Columbia. 4 <sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2014.
Model Supervisor and co-author	Caro-Vega Y, del Rio C, <b>Lima V</b> , Lopez-Cervantes M, Crabtree Ramirez B, Bautista-Arredondo S, Colchero MA, Sierra-Madero J. Estimating the Impact of Late HAART Initiation among MSM on HIV transmission in Mexico. 4 <sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2014.
Statistician, Supervisor and co-author	Lourenço L, Nohpal A, Shopin D, Colley G, Nosyk B, Heath K, Montaner J, Lima VD; on behalf of the STOP HIV/AIDS Study Group. Time to Retention Among Persons Linked to HIV Care in BC, Canada from 2000-2010. 9th International Conference on HIV Treatment and Prevention Adherence. Miami, Florida. June 8-10, 2014.
Supervisor and co-author	Lourenco L, Heath K, Barrios R, Gilbert G, Consolation T, Colley G, Nosyk B, Lima V, Nakagawa J, Hogg R, Montaner J; on behalf of the STOP HIV/AIDS Study Group. Process Monitoring of a Province-wide Treatment as Prevention Program Using Linked Administrative and Surveillance Data in British Columbia, Canada. 4 <sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2014.
Statistician and lead author	Montaner JS, <b>Lima VD</b> , Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P, Rozada I. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. 4 <sup>th</sup> International HIV Treatment as Prevention Workshop. Vancouver, British Columbia. April 22 to 25, 2014.

#### 2015 (N=17)

Co-author	Jacka B, Applegate T, Poon AF, Raghwanji J, Harrigan PR, DeBeck K, Milloy M-J, Krajden M, Olmstead A, Joy JB, Marshall BDL, Hayashi K, Pybus O, <b>Lima VD</b> , Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, and Grebely J. 'Onward Transmission of Hepatitis C Virus Infection among Younger and Older People who Inject Drugs in Vancouver, Canada' presented at 4th International Symposium on Hepatitis Care in Substance Users, Sydney, Australia, 7-9 October, 2015.
-----------	---

Statistical Supervisor and co-author	Lee GQ, Lachowski C, Cai E, <b>Lima VD</b> , Boum Y, A. Mocello R, Hunt PW, Martin JN, Harrigan PR, Bangsberg DR. Non-R5-tropic HIV-1 in Subtype A and D Infections Were Associated with Lower Pre-therapy CD4 Count but not with Therapy Outcomes. 54 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 17-21 September, 2015.
Statistician and lead author	<b>Lima VD</b> , Reuter A, Harrigan R, Lourenco L, Chau W, Hull M, MacKenzie L, Guillemi S, Hogg R, Barrios R, Montaner J. Initiation of Antiretroviral Therapy at high CD4 cell counts is associated with Increased Adherence, Viral Suppression, and Decreased HIV Drug Resistance in British Columbia, Canada. IAS 2015 Towards an HIV Cure Symposium, Vancouver, Canada. July 18-19, 2015
Statistician and lead author	<b>Lima VD</b> , Lourenco L, Yip B, Hogg R, Phillips P, Montaner JSG. Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013. WEPEC596
Supervisor and co-author	Lourenco L, Hull M, Montaner J, Nosyk B, <b>Lima VD</b> . Monitoring achievement of the latest UNAIDS HIV 90-90-90 Target: A need for harmonization of the HIV cascade of care. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, July 19-22, 2015. WEPEB379
Supervisor, Statistical Supervisor and co-author	Lourenço L, Ma H, Harrigan R, Sereda P, Montaner J, <b>Lima VD</b> . Validation of the World Health Organization HIV Drug Resistance Early Warning Indicators. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, July 19-22, 2015 TUPEB230
Co-author	Nosyk B, Min J, Evans E, Li L, Liu L, <b>Lima V</b> , Wood E, Montaner J. The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among injection drug using people living with HIV/AIDS. 8 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, Canada. July19-22, 2015. MOPDD0102
Co-author	Nosyk B, Lourenco L, Min J, Shopin D, <b>Lima V</b> , Montaner J. Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'. 8 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, Canada. July19-22, 2015. MOPED753
Co-author	Nosyk B, Min J, <b>Lima V</b> , Hogg R, Montaner. The cost-effectiveness of population-level HAART expansion in British Columbia. 8 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, Canada. July19-22, 2015. MOPED754
Co-author and Statistical Supervisor	Gali B, Chau W, Zhang W, Eyawo O, Samji H, <b>Lima V</b> , McGrail K, Hogg R, Moore D. Trends of non-HIV chronic comorbidities among HIV-positive individuals on highly active antiretroviral therapy in British Columbia from 2000-2009. 8 <sup>th</sup> IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, Canada. July19-22, 2015. WEPEB355
Statistical Supervisor and co-author	Brumme CJ, <b>Lima VD</b> , Gonzalez-Serna A, Swenson L, Lynch T, Gill J, Harrigan PR. Many low level viral load values are likely assay false positive results rather than genuine “blips” in viremia. 24th Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 30 - May 3, 2015. Abstract CS62.
Statistical Supervisor and co-author	Mackenzie LJ, Hull M, Samji H, <b>Lima VD</b> , Yip B, Zhang W, Lourenco L, Colley G, Hogg RS, Montaner JS. Assessing the effect of rurality on the programmatic compliance score, a metric predictive for all-cause mortality among treatment-naïve HIV-positive individuals starting antiretroviral therapy in British Columbia – is there a rural/urban gap? 24th Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 30 - May 3, 2015. Abstract CS53.
Statistical Supervisor and co-author	Gartner K, Wong H, Chau W, Zhang W, <b>Lima VD</b> , Moore D, Guillemi S. Latent tuberculosis infection (LTBI) screening and factors related to tuberculin skin testing (TST) in an HIV outpatient clinic in Vancouver, Canada. 24th Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 30 - May 3, 2015. Abstract CS21.
Statistical Supervisor and co-author	Eyawo O, Nohpal A, Sereda P, Samji H, Hull M, <b>Lima V</b> , Colley G, Moore D, Montaner J, Hogg RS. Shifting mortality rates and cause of death in the combination antiretroviral therapy (ART) era among HIV positive individuals: a comparison with the general population. 24th Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 30 - May 3, 2015. Abstract O104.
Statistical Supervisor and co-author	Hull M, Zhang W, Sereda P, Colley G, <b>Lima V</b> , Hogg R; Montaner J, Harrigan PR. Advanced fibrosis in HIV/hepatitis C (HCV) co-infected patients is associated with increased prevalence of HIV drug resistance in British Columbia, Canada. 24th Annual Canadian Conference on HIV/AIDS Research. Vancouver, British Columbia, Canada. April 30- May3, 2015. Abstract O035.
Supervisor, Statistical Supervisor and co-	Lourenço L, Ma H, Harrigan R, Sereda P, Montaner J, <b>Lima VD</b> . Validation of the World Health Organization HIV Drug Resistance Early Warning Indicators. 19th International Workshop on HIV Observational Databases. Catania, Sicily. March 26-28, 2015.

author	
Statistical Supervisor and co-author	Eyawo O, Nohpal A, Sereda P, Samji H, Hull M, <b>Lima V</b> , Colley G, Moore D, Montaner JS, Hogg R. Shifting mortality rates and cause of death in the HAART era (1996-2010) among HIV-positive individuals: a comparison with the general population. 19th International Workshop on HIV Observational Databases. Catania, Sicily. March 26-28, 2015.

**2016 (N=12)**

Statistician and lead author	<b>Lima V</b> , Hull M, McVera D, Harrigan PR, Chau W, Montaner JSG. Should NNRTIs Remain as the First-Line Therapy Choice in Resource-Limited Settings?. 23 <sup>rd</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2016). Boston, MA, USA. 22-25 February, 2016.
Statistical Supervisor and co-author	Lee GQ, Lachowski C, <b>Lima VD</b> , Zhang W, Boum Y, Mocello AR, Hunt PW, Martin JN, Bangsberg DR. HIV-1 Stop Codon Usage and Its Clinical Impacts in Rural Ugandan Patients. 23 <sup>rd</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2016). Boston, MA, USA. 22-25 February, 2016.
Mathematical Modeller Supervisor and co-author	Rozada I, Hull M, Montaner J, <b>Lima V</b> . Devising a Strategy to Control the HCV Epidemic in British Columbia, Canada. 23 <sup>rd</sup> Conference on Retroviruses and Opportunistic Infections (CROI 2016). Boston, MA, USA. 22-25 February, 2016.
Statistical Supervisor and co-author	Lepik KJ, Harrigan PR, Yip B, Woods CK, Robbins MA, Ulloa A, McGovern RA, <b>Lima VD</b> , Zhang W, Toy KJ, Akagi LA, Guillemi S, Montaner JSG, Barrios R. Incidence of emergent drug resistance mutations during clinical use of integrase inhibitor-containing antiretroviral regimens in British Columbia. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CS1.2.
Statistical Supervisor and co-author	Jaworsky D, Shumilak G, MacKenzie LJ, Jabbari S, Chau W, Zhang W, <b>Lima VD</b> , Hogg RS, Montaner JSG, Harrigan PR, Hull M. Antiretroviral drug resistance among people experiencing treatment interruption in rural regions of British Columbia. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract MD2.1.
Statistical Supervisor and co-author	Hogg RS, Montaner JSG, Eyawo O, Collins A, Zhang W, Chau W, Hull MW, <b>Lima VD</b> , Shoveller J, Barrios R. The State of Health: The Impact of Select Co-morbidities on Life Expectancy. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CS3.5.
Statistical Supervisor and co-author	Hogg RS, Cui Z, Ti L, Patterson S, Parashar S, <b>Lima VD</b> , Chia J, Yip B, Barrios R, Montaner JSG. The Impact of the Composition of Physicians' Practices on Mortality. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CSP2.05.
Statistical Supervisor and co-author	Lepik KJ, Franco-Villalobos C, Jabbari S, Paterson RF, Hull MW, Eyawo O, Hogg RS, <b>Lima VD</b> , Montaner JSG, Barrios R. Incidence of renal stones in persons treated with atazanavir versus other antiretrovirals: A population-based study. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CSP4.02.
Statistical Supervisor and co-author	Gali BJ, Jabbari S, Ma H, Eyawo O, <b>Lima VD</b> , McGrail K, Hogg RS, Moore D. Impact of Expanded Access to Highly Active Antiretroviral Therapy on Chronic Comorbidities among HIV-Positive individuals in British Columbia. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CSP5.07
Statistical Supervisor and co-author	Guillemi SA, Harris M, Chacko SA, Ma H, Chia J, Bondy G, Montaner JSG, <b>Lima VD</b> . Factors Associated with Incidence of Diabetes Mellitus (DM) in Older HIV Positive Patients. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract CSP5.08
Statistical Supervisor and co-author	Shumilak G, Jaworsky D, MacKenzie LJ, Chau W, Zhang W, <b>Lima VD</b> , Hogg RS, Montaner JSG, Hull M. Comparison of Antiretroviral Treatment Interruptions Between Urban and Rural Populations with HIV Infection in British Columbia. 25 <sup>th</sup> Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, MB, Canada. 12-15 May, 2016. Abstract EPHP14.08.
Statistical Supervisor, Main Supervisor and co-author	Amram O, Wang L, Jabbari S, Barrios B, Hogg R, Shoveller J, Montaner J, <b>Lima V</b> . The impact of distance to HIV care on adherence to treatment: adjusting for population and geographical heterogeneity using advanced spatial analysis. AIDS 2016. Durban, South Africa. 18-22 July, 2016. WEPEC276

2017 (N=17)

Co-author	Jacka B, Bray B, Applegate TL, Marshall BD, <b>Lima VD</b> , Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Kraiden M, Montaner J, Grebely J. Hepatitis C virus phylogenetic clustering and latent class analysis of drug use among people who use drugs in Vancouver Canada. 6th International Symposium on Hepatitis Care in Substance Users (INHSU). September 6-8, 2017. New York, US
Main Supervisor and co-author	Rozada I, Lu M, Montaner JSG, <b>Lima VD</b> . The potential effect of initiating combination antiretroviral therapy with Integrase Inhibitors on HIV transmission risk in British Columbia, Canada. 9 <sup>th</sup> International AIDS Society (IAS) Conference. Paris, France. July 23-26, 2017. Abstract 3046.
Mathematical Modeller Supervisor and lead author	<b>Lima VD</b> , Rozada I, Lachowsky NJ, Moore DM, Hull MW, Hogg RS, Shoveller JA, Montaner JSG. Impact of TasP, PrEP and condoms on the HIV epidemic among MSM in British Columbia. 9 <sup>th</sup> International AIDS Society (IAS) Conference. Paris, France. July 23-26, 2017. Abstract 4532
Co-author and Advisor.	Pati Pascom AR, Habckost Dutra de Barros C, <b>Lima VD</b> , de Araujo Freitas M, Montaner JSG, Meireles M, Mesquita F, Schwartz Benzaken A. The HIV care continuum in Brazil, from 2009 to 2015. 9 <sup>th</sup> International AIDS Society (IAS) Conference. Paris, France. July 23-26, 2017. Abstract 5031
Statistical Supervisor and co-author	Ulloa Baez AC, Pedromingo M, Stanley C, Stone S, Guillemi S, Yip B, Zhang W, <b>Lima VD</b> , Gataric N, Dutta R, Barrios R, Montaner JSG. Determination of AIDS- and Non-AIDS-Related Causes of Death Reported in Death Certificates as Compared to Physicians' Reviews in a Tertiary Referral Hospital in Vancouver, British Columbia. 9 <sup>th</sup> International AIDS Society (IAS) Conference. Paris, France. July 23-26, 2017. Abstract 2200.
Statistical Supervisor and co-author	Ulloa Baez AC, Pedromingo M, Stanley C, Stone S, Guillemi S, Yip B, Zhang W, <b>Lima VD</b> , Gataric N, Dutta R, Barrios R, Montaner JSG. Examining Differences in Cause-Specific Mortality among Patients Enrolled in a Hospital-Based HIV Care Clinic in a Canadian Setting. 9 <sup>th</sup> International AIDS Society (IAS) Conference. Paris, France. July 23-26, 2017. Abstract 2205.
Statistical Supervisor and co-author	Ling SH, Harris M, Zhang W, Yip B, Samad FA, Ganase BF, Kozai T, <b>Lima VD</b> , Shoveller JA, Montaner JSG, Guillemi SA, Hull MW. The association of HIV-related factors and severity of liver fibrosis measured by transient elastography (FibroSan®) in an HIV/HCV co-infected population. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CS2.01.
Statistical Supervisor and co-author	Harris M, Hull MW, Ling SH, Samad FA, Zhang W, Yip B, <b>Lima VD</b> , Shoveller JA, Montaner JSG. Predictive Value of AST to Platelet Ratio Index (APRI) for Hepatic Fibrosis Stage by Transient Elastography (TE) in HIV/HCV Co-infection. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CSP3.05.
Statistical Supervisor and co-author	Hull MW, Cui Z, Chia J, Zhang W, <b>Lima VD</b> , Hogg RS, Shoveller JA, Montaner JSG. Can ALT rise serve as a useful marker of hepatitis C (HCV) seroconversion in HIV/HCV co-infected patients? 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CSP3.07
Co-author	Van Ommen CE, Albert AY, Nesbitt A, Gordon S, Maan EJ, Cote HC, <b>Lima VD</b> , Money DM, Pick N, Murray MC, CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA). Exploring the Live Birth Rates of Women Living with HIV (WLWH) in British Columbia and the CARMA Cohort. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CSP9.06
Statistician and co-author	Rocheleau GL, Brumme C, <b>Lima VD</b> , Harrigan PR. Longitudinal Trends of HIV Drug Resistance in a large British Columbia Cohort; 1996-2015. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CSP14.01
Statistical Supervisor and co-author	Ulloa AC, Pedromingo M, Stanley C, Stone S, Guillemi S, Yip B, Zhang W, <b>Lima VD</b> , Gataric N, Dutta R, Barrios R, Montaner JSG. Examining Cause-Specific Mortality for Patients Enrolled in an Outpatient HIV Primary Care Clinic in a Tertiary Referral Hospital in a Canadian Setting. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract CSP16.04
Statistical Supervisor and co-author	Kang H, Chia J, Cui Z, Khorsandi A, <b>Lima VD</b> , Guillemi S. An Innovative HIV Preceptorship Training Program for Family Physicians and Its Impact On Patient Outcomes. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract EPHP3.04
Statistical Supervisor and co-author	Ulloa AC, Pedromingo M, Stanley C, Stone S, Guillemi S, Yip B, Zhang W, <b>Lima VD</b> , Gataric N, Dutta R, Barrios R, Montaner JSG. Impact of Health Care Utilization on Survival Rates in a Hospital-Based Outpatient HIV Clinic. 26 <sup>th</sup> Canadian Conference on HIV/AIDS Research (CAHR 2017). Montreal, Québec. April 6-9 2017. Abstract EPHP3.10



Statistical Supervisor, Main Supervisor and co- author	Ma H, Villalobos CF, St-Jean M, Eyawo O, Lavergne R, Hull M, Yip B, Wu L, Hogg R, Barrios R, Shoveller J, Montaner J, <b>Lima VD</b> . The impact of HCV co-infection on healthcare-related utilization among HIV-positive individuals in British Columbia, Canada. 21st International Workshop on HIV and Hepatitis Observational Databases. 30 March-1st April, 2017. Lisbon, Portugal.
Lead author and Statistical Supervisor	<b>Lima VD</b> , Wang L, Brumme C, Wu L, Montaner J, Harrigan PR. Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification. 21st International Workshop on HIV and Hepatitis Observational Databases. 30 March-1st April, 2017. Lisbon, Portugal.
Lead author and Statistical Supervisor	<b>Lima VD</b> , St-Jean M, Shoveller JA, Harrigan PR, Nosyk B, Hogg RS, Sereda P, Barrios R, Montaner JSG. Achieving the 90-90-90 Target by 2020: The Experience in British Columbia, Canada. 2017 Conference on Retroviruses and Opportunistic Infections (CROI 2017). February 13-16, 2017. Seattle, US.

## 2018 (N=15)

Lead author	<b>Lima VD</b> , Tafessu HM, St-Jean M, Closson K, Patterson T, Lavergne MR, Hogg RS, Barrios R, Shoveller JA, Montaner JSG. High Healthcare-Associated Direct Costs Associated with Mental Health Illness among People Living with HIV in British Columbia, Canada. The 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	Tafessu HM, St-Jean M, Lu M, Salters K, Eyawo O, Card KG, Hogg RS, Montaner JSG, <b>Lima VD</b> . The Compounding Impact of Comorbidities on Mortality among People Living with HIV: A Marginal Structural Model Analysis in the COAST Study. The 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	Rozada I, Lu M, Montaner JSG, <b>Lima VD</b> . The potential to avert HIV incidence in MSM initiating ART with Integrase Inhibitors. 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, BC, Canada.
Supervisor	Rozada I, Zhu J, Moore DM, Lachowsky N, Hull, MW, Shoveller JA, Roth EA, Card KG, Hogg RS, Montaner JSG, <b>Lima VD</b> . Determining the conditions necessary to eliminate the HIV epidemic among MSM in British Columbia. 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, BC, Canada.
Supervisor	Zhu J, Rozada I, Montaner JSG, <b>Lima VD</b> . Comparing Estimates for HIV Prevalence, Incident Cases and Percent of People Living with HIV (PLWH) Undiagnosed Utilizing Three Estimation Methods. 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	Zhu J, Rozada I, Grebely J, Ti L, Hull MW, Montaner JSG, <b>Lima VD</b> . The Need for Targeting People Who Inject Drugs and Baby Boomer Populations Independently in the Fight against the HCV Epidemic in British Columbia, Canada. 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	St-Jean M, Zhang W, Lu M, Guillemi SA, Barrios R, Montaner JSG, <b>Lima VD</b> . The Prognostic Role of the CD4/CD8, Neutrophil/Lymphocyte, Platelet/Lymphocyte Ratios in Cardiovascular Disease Risk among People Living with HIV. 27th Annual Canadian Conference on HIV/AIDS Research, on April 26-29, 2018. Vancouver, Canada.
Supervisor	St-Jean M, Tafessu HM, Closson K, Patterson TL, Lavergne MR, Hull MW, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, <b>Lima VD</b> . The Syndemic of HCV Infection and Mental Health Disorders among People Living with HIV: The Impact on Acute Care Hospitalizations. The 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	Nehumba D, St-Jean M, Closson K, Patterson TL, Shoveller JA, Card KG, Hogg RS, Barrios R, Montaner JS, <b>Lima VD</b> . Higher Prevalence of Mood and/or Anxiety Disorders among Individuals Vulnerable to Acquire HIV in Canada. 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Supervisor	Nanditha NGA, St-Jean M, Tafessu HM, Lu M, Guillemi S, Barrios R, Montaner JSG, <b>Lima VD</b> . Missed Opportunities for Earlier Diagnosis of HIV in British Columbia, Canada: A Retrospective Cohort Study. The 27th Annual Canadian Conference on HIV/AIDS Research. April 26-29, 2018. Vancouver, Canada.
Lead author	<b>Lima VD</b> , Rozada I, Zhu J, Moore DM, Lachowsky NJ, Hull MW, Shoveller JA, Roth EA, Hogg RS, Montaner JSG. Can the Combination of TasP and PrEP Eliminate HIV among Gay, Bisexual and Other Men Who Have Sex with Men in British Columbia, Canada? 22nd International Workshop on HIV and Hepatitis Observational Databases. March 22-24, 2018. Fuengirola, Spain.

Lead author	<b>Lima VD</b> , Tafessu HM, St-Jean M, Closson K, Patterson TL, Lavergne MR, Hogg RS, Barrios R, Shoveller JA, Montaner JSG; for the Seek and Treat for Optimal Prevention of HIV/AIDS Study Group. High Healthcare-Associated Direct Costs Associated with Mental Health Illness among People Living with HIV in British Columbia, Canada. 22nd International Workshop on HIV and Hepatitis Observational Databases. March 22-24, 2018. Fuengirola, Spain.
Supervisor	St-Jean M, Zhang W, Lu M, Guillemi SA, Barrios R, Montaner JSG, <b>Lima VD</b> . The Prognostic Role of the CD4/CD8, Neutrophil/Lymphocyte, Platelet/Lymphocyte Ratios in Cardiovascular Disease Risk among People Living with HIV. 22 <sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases. March 22-24, 2018. Fuengirola, Spain.
Supervisor	St-Jean M, Tafessu HM, Closson K, Patterson TL, Lavergne MR, Hull MW, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, <b>Lima VD</b> . The Syndemic of HCV Infection and Mental Health Disorders among People Living with HIV: The Impact on Acute Care Hospitalizations. 22 <sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases. March 22-24, 2018. Fuengirola, Spain.
Supervisor	Rozada I, Lu M, Montaner JSG, <b>Lima VD</b> . The potential to avert HIV incidence in individuals initiating ART with Integrase Inhibitors. 22nd International Workshop on HIV and Hepatitis Observational Databases. March 22-24, 2018. Fuengirola, Spain.

## 2019 (N=16)

Co-author	Marziali ME, Card K, McLinden T, Salters K, Closson K, Wang L, Trigg J, Lima V, Allan B, Hogg R. Relationship Between Social Isolation and Mortality Among People Living with HIV in British Columbia, Canada. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020. (Oral Abstract)
Co-author	Marziali ME, McLinden T, Card K, Salters K, Closson K, Wang L, Trigg J, Lima V, Allan B, Hogg R. Predictors of Social Isolation Among People Living with HIV in British Columbia, Canada. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020. (Oral Abstract)
Co-author	Toy J, Hull MW, Trigg J, Sereda P, Lima V, Lepik K, Guillemi S, Moore D, Hall D, Barrios R, Montaner JS. One Year of Population-based HIV Pre-exposure Prophylaxis (PrEP) in British Columbia (BC): Program Uptake and Participant Characteristics. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020.
Co-author	Toy J, Hull MW, Trigg J, Sereda P, Lima V, Lepik K, Guillemi S, Moore D, Hall D, Barrios R, Montaner JS. Prescribers of HIV Pre-Exposure Prophylaxis (PrEP) in British Columbia (BC) in the First Year of the Provincial Program. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020.
Co-author	Choi JH, McLinden T, Card K, Li J, Ma Y, Puskas C, Lima V, Jaworsky D, Loutfy M, Allan B, Brown J, Hogg R. The Impact of Geographic Location on HIV Viral Suppression and Mortality among People Who Use Injection Drugs. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020.
Co-author	Kibel MD, Wu A, Closson K, St-Jean M, Marziali M, NGA Nanditha, Salters K, McLinden T, Eyawo O, Patterson T, Moore D, Elefante J, Joe R, Barrios R, Lima V, Hogg RS. Mental Health Diagnoses in a Population-based Cohort of People Living with HIV. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020.
Co-author	Koehn K, Salters KA, Zhang W, Lu M, Lima VD, St-Jean M, Nanditha NGA, Grieve S, Wesseling T, Hogg RS, Barrios R. Aging with HIV vs Aged with HIV: Profiling Adults Diagnosed with HIV After Age 50 in British Columbia. 28th Annual Canadian Conference on HIV/AIDS Research. May 9-12, 2020.
Co-author	Toy KJ, Trigg J, Zhang WW, Sereda P, <b>Lima VD</b> , Lepik K, Hull M, Espinoza RM, Guillemi S, Hall D, Moore DM, Barrios R, Montaner JS. Rapid PrEP uptake in a publicly funded population-based program in British Columbia. 2019 Conference on Retroviruses and Opportunistic Infections (CROI 2019). Mar 4-7, 2019. Seattle, US.
Co-author	Barletta JA, Ye M, Lu M, Kibel M, <b>Lima VD</b> , Eyawo O, Montaner JS, Hogg RS, Guillemi S. HAART is associated with reduced risk of osteoporosis-related fractures. 2019 Conference on Retroviruses and Opportunistic Infections (CROI 2019). Mar 4-7, 2019. Seattle, US.
Supervisor	Nanditha NGA, St-Jean M, Tafessu HM, Lu M, Salters K, Montaner JS, Guillemi S, Hogg RS, <b>Lima VD</b> . Earlier age of onset and higher prevalence of comorbidities in people living with HIV. 2019 Conference on Retroviruses and Opportunistic Infections (CROI 2019). Mar 4-7, 2019. Seattle, US.
Lead author	<b>Lima VD</b> , Toy J, Sereda P, Lachowsky N, Moore DM, Hull MW, Trigg J, Montaner JSG, Barrios R. PrEP Uptake among Gay, Bisexual and Other Men Who Have Sex with Men (gbMSM) and Other Risk Groups

	in British Columbia (BC), Canada. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). March 28-30, 2019. Athens, Greece.
Supervisor	Tafessu HM, St-Jean M, Lu M, Salters K, Eyawo O, Hogg RS, Montaner JSG, <b>Lima VD</b> , for the COAST Study Team. Health Disparities Among People Living with HIV and the General Population in British Columbia, Canada. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). March 28-30, 2019. Athens, Greece.
Supervisor	St-Jean M, Yue M, Salters K, Moore D, Hogg RS, Patterson TL, Barrios R, Montaner SG, <b>Lima VD</b> . Overdose Cause-Deleted Life Expectancy and Factors Associated with Fatal Overdoses among People Living with HIV (PLWH) in British Columbia, Canada: A Competing Risk Modeling Approach. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). March 28-30, 2019. Athens, Greece.
Supervisor	Kibel, Wu, Closson, St-Jean, Marziali, Ni Gusti Ayu, Salters, McLinden, Eyawo, Patterson, Moore, Elefante, Joe, Barrios, Hogg, <b>Lima</b> . Mental Health Diagnoses in a Population-Based Cohort of People Living with HIV. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). March 28-30, 2019. Athens, Greece.
Supervisor	Nanditha NGA, St-Jean M, Tafessu HM, Lu M, Montaner JSG, Barrios R, <b>Lima VD</b> for the Seek and Treat for Optimal Prevention of HIV/AIDS Study Group. The impact of the STOP HIV/AIDS Program on the Optimization of the Continuum of Care in British Columbia, Canada. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). March 28-30, 2019. Athens, Greece.
Co-author	Lee J, Humes E, Gange SJ, Eron Jr JJ, Rebeiro P, Justice A, Klein M, Jacobson L, Gill J, <b>Lima VD</b> , Horberg M, Tate J, Mayor A, Moore RD, Althoff KN, for the North American AIDS Cohort Collaboration on Research and Design. CD4 response trajectories after ART initiation. 23 <sup>rd</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2019). Mar 28-30, 2019. Athens, Greece.

#### 2020 (n=14)

I did not list abstracts accepted to the 24<sup>th</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2020) since the conference was cancelled due to COVID-19.

Co-author	Bratu AG, McLinden T, Ye M, Li, J, Sereda P, Nanditha NGA, Lima VD, Guillemi S, Hogg RS. Incidence of Diabetes Mellitus Among People Living with HIV Compared with HIV Negative Individuals in British Columbia Between 2001-2013. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020. (Oral Abstract)
Co-author	Lepik KJ, Guliani S, Wang L, Harris M, Akagi L, Toy J, Sereda P, <b>Lima VD</b> , Montaner JS, Barrios R. Declining Prevalence of Drug Interactions Between Antiretroviral and Other Drugs in Antiretroviral Therapy (ART)-Treated Persons in British Columbia (BC), 2010-2016. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020. (Oral Abstract)
Co-author	Le A, Woods C, Kalyniak T, Hollebakk R, Cobarrubias K, Choi J, Dong W, Louie H, Lima VD, Harris M, Guillemi S, Phillips P, Montaner JSG, Brumme ZL, Brumme CJ. Utility of HIV Drug Resistance Testing in Low Viral Load Samples. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020. (Oral Abstract)
Co-author	Keeney CL, Toy J, Trigg J, Hull M, Sereda P, Lima V, St-jean M, Ready E, Lepik K, Moore D, Hall D, Guillemi S, Barrios R, Montaner J. Population-Based HIV Pre-Exposure Prophylaxis (PrEP) in British Columbia (BC): an 18-Month Update on Client Enrollment and Prescriber Participation. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020. (Oral Abstract)
Co-author	Clarke Q, Ye M, Li J, Lepik K, Guillemi S, Toy J, Montaner J, Barrios R, Hull M, Sereda P, Harris M, <b>Lima V</b> , Yu N, Moore D. Dolutegravir-containing ART Regimens are Not Independently Associated with Weight Changes among British Columbians Living with HIV. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020.
Co-author	Bratu AG, McLinden T, Ye M, Li J, Sereda P, Nanditha NGA, <b>Lima VD</b> , Guillemi S, Hogg RS. Relationship Between Hypertension and Incidence of Diabetes Mellitus Among People Living with HIV in British Columbia Between 2001-2013. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020.

Co-author	McLinden T, Nanditha AGY, Bratu A, St-jean M, Sereda P, Lima VD, Hogg RS, Barrios R. Context is Everything: a Recommendation for Selecting Case Definitions when Using Linked Administrative Health Data in HIV Research. 29th Annual Canadian Conference on HIV/AIDS Research. May 1-2, 2020.
Supervisor	Nanditha NGA, Zheng G, Tafessu HM, McLinden T, Bratu A, Hogg RS, Montaner JSG, Lima VD. Excess Mortality among PLWH with Multimorbidity Compared to HIV-Negative Controls. Conference on Retroviruses and Opportunistic Infections (CROI) 2020. March 8-11, 2020. Boston, USA.
Co-author	Davy-Mendex, Napravnik S, Gebo K, Althoff KN, Gill MJ, Horberg MA, Mathews WC, Eron JJ, Martin JN, Lau B, Buchacz K, Lima VD, Klein M, Berry S. Cause-specific Hospitalization Trends Among North American Persons with HIV 2005-2015. Conference on Retroviruses and Opportunistic Infections (CROI) 2020. March 8-11, 2020. Boston, USA.
Co-author	Toy J, Keeney Cora L, Trigg J, Zhange WW, Sereda P, Lima VD, Hull M, Lepik K, St-Jean M, Moore DM, Guillemi S, Barrios R, Yu N, Montaner JS. Publicly funded HIV PrEP in British Columbia: Program Retention and New HIV Diagnoses. Conference on Retroviruses and Opportunistic Infections (CROI) 2020. March 8-11, 2020. Boston, USA.
Co-author	Lee JS, Lau B, Eron JJ, Bosch R, Kitahata MM, Fleming J, Gill JM, Mathews WC, Sterling TR, Lima VD, Silberberg MJ, Horberg MA, Althoff KN, Moore RD. High probability of survival in patients who maintain viral loads <200 copies/mL. Conference on Retroviruses and Opportunistic Infections (CROI) 2020. March 8-11, 2020. Boston, USA.
Co-author	Marziali ME, McLinden T, Card K, Closson K, Wang L, Trigg J, Salters K, Lima V, Parashar S, Hogg RS. The Relationship Between Social Isolation and All-Cause Mortality Among People Living with HIV in British Columbia, Canada. American Psychopathological Association (APPA) Annual Meeting. March 5-7, 2020. New York, NY, United States.
Co-author	Koethe J, Bian A, Rebeiro P, Jenkins C, Bourgi K, Moore RD, Saag M, Anastos K, Fleming J, Klein M, <b>Lima VD</b> , Margolick, JB, Sterling TR, Lake JE. Greater Weight Gain After Switch to INSTI-based Regimen from NNRTI vs PI Regimens. Conference on Retroviruses and Opportunistic Infections (CROI) 2020. March 8-11, 2020. Boston, USA.
Supervisor	St-Jean M, Dong X, Moore DM, Sereda P, Salters K, Hogg RS, Patterson TL, Barrios R, Montaner SG, <b>Lima VD</b> . Drug overdoses are reducing the gains in life expectancy of people living with HIV (PLWH) in British Columbia, Canada. 23rd International AIDS Conference (AIDS 2020: Virtual). July 6-10, 2020. (Oral Abstract)

## 2021 (n=10)

Supervisor	Nanditha NGA, Mushfiquiee M, Zhu J, Kopec J, Hogg RS, Montaner JSG, <b>Lima VD</b> . Burden of age-associated chronic comorbidities among people living with and without HIV: Years of life lost to premature mortality in British Columbia, Canada. The International Workshop on HIV & Aging. Virtual meeting, September 23-24, 2021.
Supervisor	Nanditha NGA, Dong X, Tafessu HM, Lu M, Barrios R, Montaner JSG, <b>Lima VD</b> . Accelerating progress towards the United Nations' 90-90-90 target: The impact of a province-wide HIV Treatment-as-Prevention-based initiative in British Columbia, Canada. Virtual 11th IAS Conference on HIV Science (IAS 2021), Berlin, Germany. July 18-21, 2021
Lead Author	<b>Lima VD</b> , Sereda P, Toy J, Guillemi S, Barrios R, Montaner JSG. Evolving Patterns of Brand and Generic Antiretroviral Drug Utilization Within a Universal Healthcare System in Canada. Virtual 30th Annual Canadian Conference on HIV/AIDS Research (CAHR 2021), May 5 – 7, 2021. (oral)
Co-author	Grennan T, Hull M, Mohammed S, Tattersall T, Edward J, Gupta A, Dennehy MK, Romney M, Morshed M, Zhang W, Guliani S, Trigg J, Lima VD, Montaner JS, Gustafson R. Daily Doxycycline in MSM on PrEP for Prevention of Sexually Transmitted Infections. Virtual 2021 Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021). March 6-10, 2021.
Supervisor	Subedi S, Nanditha NGA, Tafessu HM, St-Jean M, Elefante J, Patterson TL, Honer W, Montaner JSG, <b>Lima VD</b> . Health disparities due to non-adherence to antipsychotics in PLWH with schizophrenia. Virtual 2021 Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021). March 6-10, 2021.
Co-author	Dhillon N, Tung AG, Trigg J, St-Jean M, <b>Lima VD</b> , Nanditha NGA, Montaner JS, Barrios R, Laird K, Ye M, Stanley C, McLinden T, Salters K. Opioid Use Disorder, Agonist Therapy, and Mortality Among People

	Living with HIV. Virtual 2021 Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021). March 6-10, 2021.
Co-author	McGinnis KA, Justice A, Moore R, Silverberg MJ, Althoff KN, Karris M, <b>Lima VD</b> , Crane H, Horberg MA, Klein MB, Gange S, Gebo K, Mayor A, Tate JP. Calibration of the VACS Index 2.0 For Estimating Mortality among PWH in North America. Virtual 2021 Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021). March 6-10, 2021.
Co-author	Kasaie P, Stewart C, Humes E, Gerace L, Gebo K, Boyd C, Justice A, Zandi P, Moore R, Buchacz K, <b>Lima VD</b> , Willig A, Wong C, Althoff KN. Multimorbidity in People With HIV Using ART in the US: Projections to 2030. Virtual 2021 Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021). March 6-10, 2021. (Oral)
Supervisor	Nanditha NGA, Zheng G, Tafessu HM, McLinder T, Bratu A, Kopec J, Montaner JSG, Hogg RS, <b>Lima VD</b> . Disparities in multimorbidity and mortality among people living with and without HIV across British Columbia's health regions: A population-based cohort study. CIHR's Student Research Health Forum (CSRHF), Manitoba, Canada [Virtual]. 2021
Supervisor	Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J, Montaner JSG, Hogg RS, <b>Lima VD</b> . Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: A population-based cohort study. UBC Faculty of Medicine Research Day, Vancouver, Canada [Virtual]. 2021

## 2022 (N=5)

Lead Author	Lima VD, Zhu J, Takeh B, David JF, Toy J, Sereda P, Hull M, Grennan T, Barrios R, Montaner JSG. What Will It Take to Control the Syphilis Epidemic among Gay, Bisexual and Other Men Who Have Sex with Men (MSM) in British Columbia (BC), Canada? The 24th International AIDS Conference (AIDS 2022). Montreal, July 29-August 2, 2022. (hybrid)
Supervisor	Nanditha NGA, Zhu J, Wang L, Kopec J, Hogg RS, Montaner JSG, Lima VD. Burden of chronic comorbidities among people living with and without HIV: Disability-adjusted life years in British Columbia, Canada. The 24th International AIDS Conference (AIDS 2022). Montreal, July 29-August 2, 2022. (hybrid)
Supervisor	Nanditha NGA, Zhu J, Wang L, Kopec J, Hogg RS, Montaner JSG, Lima VD. Estimates and projections of disability-adjusted life years associated with non-AIDS-defining cancers among people living with HIV in British Columbia, Canada between 2002-2020. 23rd International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2022). March 24-26, 2022. Seville, Spain.
Co-author	Lang R, Zhu J, McArthur K, Horberg MA, Grelotti DJ, Closson K, Lima VD, Parcesepe A, Nestadt PS, Camoens R, Loutfy M, Cook J, Goulet J, Althoff KN. Mental Health Disorders in People with HIV and the Effects on the HIV Care Continuum. Conference on Retroviruses and Opportunistic Infections (CROI) 2022. February 12-16, 2022. (virtual)
Co-author	Toy J, Keeney C, Espinoza RM, Zhang W, Kao D, ready E, Trigg J, Lepik KJ, Hull M, McLinden T, Lima VD, Sereda P, Moore D, Barrios R, Montaner JS. COVID-19 Pandemic Impact on HIV Prep Program Engagement in British Columbia. Conference on Retroviruses and Opportunistic Infections (CROI) 2022. February 12-16, 2022. (virtual)

## (c) Other

## 2. NON-REFEREED PUBLICATIONS

### (a) Journals

Supervisor and co-author	Lourenco L, Hull M, Nosyk B, Montaner JSG, <b>Lima VD</b> . The need for standardization of the HIV continuum of care. Comment. Lancet HIV 2015. 2(6): e225-e226.
--------------------------	---

### (b) Conference Proceedings

### (c) Other

- 3. BOOKS
- 4. PATENTS
- 5. SPECIAL COPYRIGHTS
- 6. ARTISTIC WORKS, PERFORMANCES, DESIGNS
- 7. OTHER WORKS

## Appendix 1. Syllabus for the Elective Clinical and Population Health Research

<b>UBC Department:</b>	Medicine (Division of Infectious Diseases)
<b>Specialty:</b>	Infectious Diseases
<b>Type:</b>	Research Elective
<b>Course Hours:</b>	4 weeks or 2 weeks
<b>Days &amp; Times:</b>	TBD by medical student
<b>Location:</b>	British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), St. Paul's Hospital, 6 <sup>th</sup> Floor Burrard Building, Vancouver, BC, Canada, V6Z 1Y6
<b>Preceptor:</b>	Dr. Viviane Dias Lima (vlima@bccfe.ca)
<b>Telephone:</b>	604-806-8796
<b>Student Capacity:</b>	One student at the time.

**Course Overview:** This elective will introduce medical students to different areas in Clinical and Population Health Research focused on HIV. Students will be given the opportunity to experience how different methodologies, including Spatial Analysis, Statistics, Mathematical Modeling and Epidemiology, are applied to project how epidemics progress, to develop preventative public health interventions and to help inform different stakeholders in our healthcare system on the best set of interventions to prevent the spread of HIV. In addition, students will have a chance to observe how these previous methodologies are being applied in a modern clinical and research setting aimed at designing recommendations to optimize HIV treatment outcomes, and monitoring all patients in care throughout the regions in British Columbia.

### Readings

- Course Notes
- Gordis L. Epidemiology, 6th Edition. Elsevier Canada, 2018.
- Zeiger M. Essentials of Writing Biomedical Research Papers, 2<sup>nd</sup> edition. New York, The McGraw-Hill Company, 2000.
- Peer-Reviewed Papers (chosen by preceptor).
- STROBE Guidelines.

**Learning Objectives:** The student will become acquainted with basic techniques in Epidemiology, Statistics, Mathematical Modeling and Spatial Analysis. He/she will receive beginner-level training in SAS, Berkeley Madonna and GIS. Furthermore, the student may be expected to participate in clinical and research activities of the BC-CfE and its affiliates, to participate in program evaluation and clinical monitoring activities of the BC-CfE and its affiliates, and to interact with other colleagues in the public health system who are involved in HIV and HCV monitoring and control.

**Academic Activities:** Students will have an opportunity to become involved in one of several ongoing research projects in the Epidemiology and Population Health Group at the BC-CfE and at The John Ruedy Immunodeficiency Clinic (IDC) at St. Paul's Hospital; and in the discussion and writing of peer-reviewed articles. The research group that the student will be working with meets on a regular basis to discuss current and future projects in the areas of Clinical and Population Health Research.

**Special Features:** This elective is closely linked to the BC-CfE and IDC, and the student will have opportunity to pursue new research and clinical endeavors and he/she will be able to participate, when needed, in the development and evaluation of clinical tools to monitor patient outcomes.

## Appendix 2. FLEX Activity

<b>UBC Department:</b>	Medicine (Division of Infectious Diseases)
<b>Specialty:</b>	Infectious Diseases
<b>Title:</b>	Aging with HIV (ID: 04669)
<b>Type:</b>	Flex Activity – 1 <sup>st</sup> , 2 <sup>nd</sup> and 4 <sup>th</sup> year medical students (MEDD 419, 429 and 449)
<b>Location:</b>	British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), St. Paul’s Hospital, 6 <sup>th</sup> Floor Burrard Building, Vancouver, BC, Canada, V6Z 1Y6
<b>Student Capacity:</b>	One student at the time.

**Activity Description:** People living with HIV/AIDS (PLWH) in Canada and other high-income settings, now have a similar life expectancy to the general population. However, premature morbidity and mortality from non-AIDS related causes are on the rise. Information that enables healthcare providers to identify the best interventions and strategies to address future healthcare needs of this aging population are urgently needed. The overall study goal is to model the complex interaction between HIV and comorbidities to forecast the future health of aging PLWH in British Columbia (BC), and the resulting economic impact. Our results will inform recommendations regarding the most promising interventions to continuously improve a number of important outcomes, including HIV treatment retention and long-term viral suppression; mortality, disability-adjusted life years, (planned/unplanned) healthcare utilization and associated costs.



### Appendix 3. MEDI 548, Directed Studies

<b>UBC Department:</b>	Medicine (Division of Infectious Diseases)
<b>Specialty:</b>	Infectious Diseases
<b>Type:</b>	Directed Studies
<b>Course Hours:</b>	36 (May – August)
<b>Days &amp; Times:</b>	TBD by medical student
<b>Location:</b>	British Columbia Centre for Excellence in HIV/AIDS (BC-CfE), St. Paul’s Hospital, 6 <sup>th</sup> Floor Burrard Building, Vancouver, BC, Canada, V6Z 1Y6
<b>Preceptor:</b>	Dr. Viviane Dias Lima (vlima@bccfe.ca)
<b>Telephone:</b>	604-806-8796

#### Course Description

Epidemiology is the study of the distribution and determinants of health-related states or events (including disease), and the application of this study to the control of diseases and other health problems.<sup>1</sup> Various methods can be used to carry out epidemiological investigations: surveillance and descriptive studies can be used to study distribution; analytical studies are used to study determinants.

In this directed study, students will explore working knowledge of the basic concepts and methods of epidemiology, with a focus on approaches for the acquisition, analysis and interpretation of information about disease. The knowledge provides the basis for describing and explaining disease occurrence, and introduces methods for developing, prioritizing and evaluating public health programs.

By the end of the course students should be able to:

- Use epidemiological concepts to describe the distribution and determinants of disease;
- Apply different measures of disease occurrence to examine exposure-disease associations;
- Calculate rates and risks to describe the health status of populations;
- Assess the relevance, and understand the limitations, of various study designs for the analysis of disease causation, the assessment of effectiveness of clinical interventions, and the distribution and general impact of health services;
- Formulate and apply logical statements of causation based on a firm understanding of the criteria for drawing causal inferences from data;
- Address threats to the validity of study design, including bias, misclassification, confounding, and effect modification;
- Evaluate the validity of screening and diagnostic tests;
- Understand issues related to measurement of prognosis of disease;
- Critically appraise published research;
- Identify, discuss and illustrate the basic principles, objectives, and elements of public health surveillance;
- Demonstrate a working knowledge of sources of population data;
- Describe standard approaches to investigations of disease outbreak;
- Formulate an approach, based on sound epidemiological principles and methods, to etiologic and health services questions of public health importance.

#### Text book and Course Materials

Gordis L. Epidemiology, 6th Edition. Elsevier Canada, 2018.

#### Course Schedule

Week	Dates	#Meeting Hours	Description
1	Monday, day 1	1.5	Course overview: The epidemiologic approach; Measures of disease frequency: Incidence and prevalence
	Wednesday, day 2	1.5	Measures of disease risk: Comparison and standardization of rates, risk, absolute and relative measures of effect
2	Monday, day 3	1.5	Design of experimental studies

	Wednesday, day 4	1.5	Design of observational studies Part 1
3	Monday, day 5	1.5	Design of observational studies Part 2; Threats to the validity of studies Part
	Wednesday, day 6	1.5	Evaluation of screening tests
4	Monday, day 7	1.5	Causation, evidence-based medicine and critical appraisal; sources of data
	Wednesday, day 8	1.5	Review of core concepts and discussion of new directions
5	Monday, day 9	4	STROBE guidelines
6	Monday, day 10	4	Perform literature review and develop research question based on gaps in literature
7	Monday, day 11	2	Finalize three papers for approval for critical appraisal
8	Monday, day 12	2	Compose Data Access Request (DAR), which includes a concept sheet
9	Monday, day 13	2	Compose DAR
10	Monday, day 14	2	DAR due
11	Monday, day 15	2	Work on critical appraisal
12	Monday, day 16	2	Work on critical appraisal
13	Monday, day 17	2	Work on critical appraisal
14	Monday, day 18	2	Critical appraisal due

### Assignments

- 1. Self-Assessment (10%)** – Students to finish the assessments in the end of each chapter of the textbook.
- 2. Critical Appraisal (40%)** – Students to identify a problem of their interest and 3 relevant peer-reviewed scientific papers to answer their question. Students to critically appraise the papers using epidemiological concepts learned in the course, and consider the application of the evidence to practice—i.e., what knowledge gained could be passed to relevant stakeholders (e.g., clinical leads, public health officials or policy makers).
- 3. Data Access Request [DAR] (30%)** - Student to prepare a DAR, including concept sheet, which serve as a technical proposal of student’s investigation of their epidemiological research question. The DAR outlines, among others, background, aims and hypotheses, explanatory variables, outcomes, potential confounders, and statistical methodology.

## Appendix 4. (Virtual) Annual Principles of STI/HIV Research and Public Health Practice Course

<b>University:</b>	University of Washington (USA)
<b>Specialty:</b>	Infectious Diseases
<b>Type:</b>	Summer Course
<b>Course Hours:</b>	2 or 3 weeks (July or August)
<b>Days &amp; Times:</b>	TBD every year (1 hour lecture)
<b>Location:</b>	Virtual
<b>Preceptor:</b>	Dr. Viviane Dias Lima (vlima@bccfe.ca)
<b>Telephone:</b>	604-806-8796

### Course Description

This course is intended for pre-doctoral and post-doctoral (PhD and MD) trainees and other individuals with interest and experience in STI and HIV research. In 2020, we held the first virtual addition of the course. We had over 140 participants across 14 time zones. In the virtual setting again in 2021, we expected about 150-200 attendees and a substantial number from locations outside of the US. The students will bring a broad range of backgrounds and interests and all participants are expected to be familiar with the basic vocabulary of STI & HIV-related research and/or practice. Most participants have substantial experience in one discipline or area relevant to HIV/STI research (e.g., operations research, bacterial pathogenesis, etc.), but lack a comprehensive skill set. Thus, they are enrolled in the course to gain a more complete set of fundamental skills necessary for research and practice in the field.

### Lecture Title

Introduction to Mathematical Modelling

### Learning objectives

- . To describe the basic difference between statistical and mathematical modelling
- . To introduce the basic concepts of mathematical modelling
- . To illustrate how to build a simple mathematical model
- . To work with students on a basic model

Date	Start Time	End Time	Lecture Title	Lecturer
7/19/2021 (Monday)	7:00 AM	7:30 AM	Welcome and Orientation	Renee Heffron, Christine Khosropour
	7:30 AM	8:00 AM	Introductory Lecture	Matt Golden, King Holmes
	8:00 AM	8:05 AM	BREAK	
	8:05 AM	9:05 AM	Essentials of Epidemiology	Kenneth Mugwanya
	9:05 AM	9:10 AM	BREAK	
	9:10 AM	10:10 AM	HIV Immunology and Pathogenesis	Jen Balkus
	10:10 AM	10:15 AM	BREAK	
	10:15 AM	11:15 AM	Networking Event	N/A
7/20/2021 (Tuesday)	7:00 AM	8:00 AM	Essentials of Biostatistics	Holly Janes
	8:00 AM	8:05 AM	BREAK	
	8:05 AM	9:05 AM	Gonorrhoea: Epidemiology, Pathogenesis, and Clinical Aspects	Lindley Barbee
	9:05 AM	9:10 AM	BREAK	
	9:10 AM	10:10 AM	Implementation Science Basics	Kenneth Sherr
	10:10 AM	10:15 AM	BREAK	
7/21/2021 (Wednesday)	10:15 AM	11:15 AM	Syphilis: Clinical aspects and Pathogenesis	Lorenzo Giacani
	7:00 AM	8:00 AM	HIV Epidemiology, Treatment, and the Care Continuum	Julie Dombrowski
	8:00 AM	8:05 AM	BREAK	
	8:05 AM	9:05 AM	HIV testing technologies	Joanne Stekler
	9:05 AM	9:10 AM	BREAK	
	9:10 AM	10:10 AM	HIV testing strategies	Cheryl Johnson
	10:10 AM	10:15 AM	BREAK	
7/22/2021 (Thursday)	10:15 AM	11:15 AM	Clinic/Research Roundtable/Panel	Stephanie Cohen; Leandro Mena; Stephanie Taylor
	7:00 AM	8:00 AM	HPV: Epidemiology, Pathogenesis, and Clinical Aspects	Rachel Winer
	8:00 AM	8:05 AM	BREAK	
	8:05 AM	9:05 AM	Survey Design in STI/HIV Research and Evaluation	Patrick Sullivan
	9:05 AM	9:10 AM	BREAK	
	9:10 AM	10:10 AM	Track 1: Advanced study design	Deborah Donnell
	9:10 AM	10:10 AM	Track 2: Implementation Science Frameworks	Arianna Means
	10:10 AM	10:15 AM	BREAK	
	10:15 AM	11:15 AM	Tracked Journal Club	Alison Drake, Jen Velloza, Rodney Perkins
	10:15 AM	11:15 AM	Tracked Journal Club	Claire Gwayi-Chore, Katrina Ortblad, Elizabeth Irungu

7/23/2021 (Friday)	7:00 AM	7:30 AM	Population-led Health Services	Nittaya Phanphak
	7:30 AM	8:00 AM	Global Community Advisory Groups	Jacque Wambui
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	8:35 AM	Fundamental Methods for Conducting Community-based Participatory Research	Bonnie Duran
	8:35 AM	9:05 AM	Behavioral and Social Science Research in the Design and Implementation of HIV Prevention Trials	Michele Andrasik
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Community Engagement Panel	Nittaya Phanphak; Bonnie Duran, Michele Andrasik, Jacque Wambui
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	MTE	Patrick Sullivan; Cheryl Johnson; Kenneth Sherr
7/26/2021 (Monday)	10:15 AM	11:15 AM	1:1 Consults	Arianna Means
	7:00 AM	8:00 AM	Chlamydia: Epidemiology, Pathogenesis, and Clinical Aspects	Will Geisler
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Cervical cancer control in low and middle income countries	Nelly Mugo
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Track 1: Animal Models and in vitro studies	Dorothy Patton; Kevin Hybiske
	9:10 AM	10:10 AM	Track 2: Analytic designs in Implementation Science	Nancy Puttkammer
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	Tracked Journal Club	Katrin Fabian
7/27/2021 (Tuesday)	10:15 AM	11:15 AM	Tracked Journal Club	S.O., Bhavna Chohan, Lucia Vojtech
	7:00 AM	8:00 AM	Ending the HIV Epidemic in the US: Perspective from a Local Health Department	Kathleen Brady
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Racial Disparities on HIV/STI in the US	Greg Millett
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Ending the HIV Epidemic in the US: the CDC Perspective	Demetre Daskalakis
7/28/2021 (Wednesday)	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	EHE Panel Discussion	Kathleen Brady; Greg Millett; Demetre Daskalakis
	7:00 AM	8:00 AM	PrEP	Renee Heffron
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Topical HIV Prevention	Sharon Hillier
7/29/2021 (Thursday)	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	The vaginal environment as a modifier of HIV/STI risk	Jeanne Marazzo
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	State of the Science on HIV Vaccines and Cure Research	Thumbi Ndung'u
	7:00 AM	7:30 AM	Men Who Have Sex with Men	Susan Graham
	7:30 AM	8:00 AM	Key Populations in STI/HIV: People who inject drugs	Sara Glick
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	8:35 AM	Realities and Controversies in HIV and STI Research with Adolescents	Alison Roxby
	8:35 AM	9:05 AM	Transgender Health and HIV/STI Prevention	Tonia Poteat
7/30/2021 (Friday)	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Panel Discussion	Susan Graham, Sara Glick, Alison Roxby, Tonia Poteat
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	Networking Event	N/A
	7:00 AM	8:00 AM	MTE	Matt Golden; Tonia Poteat; Nelly Mugo
			1:1 Consults	Kenneth Sherr; Scott McClelland
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	8:35 AM	Hepatitis: Epidemiology, Pathogenesis, and Clinical Aspects	Nina Kim
	8:35 AM	9:05 AM	Genital Herpes: Epidemiology, Pathogenesis, and Clinical Aspects	Anna Wald
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	9:40 AM	Tuberculosis and co-infection with HIV	David Home
9:40 AM	10:10 AM	HIV-Associated Cancers: Epidemiology and Pathogenesis	Corey Casper	
10:10 AM	10:15 AM	<b>BREAK</b>		
10:15 AM	11:15 AM	Adherence & Mental Health	Jane Simoni	

8/02/2021 (Monday)	7:00 AM	8:00 AM	Antimicrobial Resistant Gonorrhea Panel	Helen Fifer, Remco Peters, Martina Escher, Lindley Barbee
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	8:35 AM	STI Diagnostics	Damon Getman
	8:35 AM	9:05 AM	The role of pharmaceutical companies to advance HIV/STI prevention and treatment	Jared Baeten
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Mycoplasma genitalium and Trichomonas vaginalis: Epidemiology, Pathogenesis, and Clinical Aspects	Lisa Manhart
	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	10:45 AM	Extragenital Infections	Christine Khosropour
8/03/2021 (Tuesday)	10:45 AM	11:15 AM	Syphilis	Kyle Bernstein
	7:00 AM	8:30 AM	Journal Club: Responsible Conduct in Research	Carey Farquhar, Elizabeth Anne Bukusi, Adrienne Shaprio, Alison Roxby, Keshet Ronen
	8:30 AM	8:35 AM	<b>BREAK</b>	
	8:35 AM	9:35 AM	Professional Development: Manuscripts	Anna Wald
	9:35 AM	9:40 AM	<b>BREAK</b>	
	9:40 AM	10:25 AM	Professional Development- Mentor/Mentee	Ned Hook
	9:40 AM	10:25 AM	Professional Development- Mentor/Mentee	Julie Dombrowski
	10:25 AM	10:30 AM	<b>BREAK</b>	
8/04/2021 (Wednesday)	10:30 AM	11:15 AM	Track 1 - Career Panel	Ruane Barnabas, Lisa Manhart, Kenneth Mugwanya, Grace John-Stewart
	10:30 AM	11:15 AM	Track 2 - Career Panel	Julie Dombrowski, Kyle Bernstein, Cheryl Johnson, Stephanie Taylor
	7:00 AM	8:00 AM	Policy/Resource Allocation	Ruth Laibon-Masha
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Health economics in STI/HIV	Ruane Barnabas
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Community Partners "Field Trips"	NA
8/05/2021 (Thursday)	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	Community Partners Panel	Linda Chastine, Margaret Green
	7:00 AM	8:00 AM	Prevention of Mother to Child HIV Transmission	Grace John-Stewart
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Qualitative Research	Kristin Beima-Sofie
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Track 1: Mathematical Modeling	Viviane Lima
9:10 AM	10:10 AM	Track 2: Molecular HIV	Roxanne Kerani and Joshua Herbeck	
8/06/2021 (Friday)	10:10 AM	10:15 AM	<b>BREAK</b>	
	10:15 AM	11:15 AM	MTE	Grace John-Stewart, Ruane Barnabas, Damon Getman, Jared Baeten
	7:00 AM	8:00 AM	Future possibilities in HIV Prevention and Treatment	Connie Celum
	8:00 AM	8:05 AM	<b>BREAK</b>	
	8:05 AM	9:05 AM	Future Possibilities in STI Research and Control	Carolyn Deal
	9:05 AM	9:10 AM	<b>BREAK</b>	
	9:10 AM	10:10 AM	Historical Perspectives on HIV Prevention Interventions	Tom Quinn
10:10 AM	10:15 AM	<b>BREAK</b>		
10:15 AM	11:15 AM	Summary/Wrap Up	Renee Heffron, Christine Khosropour	